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Abstract
Efforts in managing diabetes, including the medical advances in novel therapies and
public health policies of disease control and prevention, have not reduced the disease
prevalence since 1990s. I analyze this phenomenon from the technology and policy
viewpoints underlying diabetes treatment and prevention, in order to control and manage the
disease in a cost-benefit balanced manner.
The innovative performance of the antidiabetic drug therapy is investigated by
analyzing the fifteen New Drug Applications (NDAs) of the antidiabetics approved by the
US Food and Drug Administration since the early 1990s. I examine the characteristics of the
clinical trials supporting NDAs and observe how the complexity of clinical trials has changed
over time. Nine out of the twenty-five selected indicators are found to exhibit an increasing
trend of complexity. The trend is more pronounced in the oral antiglycemics group (seven
indicators) than the subcutaneous group (two indicators). Interestingly, this trend in
increasing complexity in clinical trials is generally consistent with that of the increasing
R&D costs in the pharmaceutical industry, possibly account for the declining innovative
performance of the industry over the time period under investigation.
A system dynamics approach is applied to assess current public health policies in
diabetes control and prevention. The benefit of system thinking is to avoid potential policy
resistance by identifying the problematic characteristics of the system, such as time-delays,
feedback, and structure of stocks and flows. For diabetes management, the public health
system can be considered a "dynamic-complex" system in terms of current policy made by
the National Diabetes Control and Prevention Program. Despite providing earlier and
expanded screening as well as improved availability and accessibility of treatment for
diabetes, the policy results in the increase of prevalence. More undiagnosed people are
diagnosed, thus increasing the incidence, whereas people already diagnosed prolong their
lifespan due to the better and more accessible medical care. A future successful chronic
disease management program should systematically integrate the efforts from both the
treatment and prevention perspectives.
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Thesis Reader: Fred Moavenzadeh
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Glossary
Acarbose: generic name of Precose T, an antidiabetic drug in the chemical class of AGI
ActosTM: brand name of pioglitazone, an antidiabetic drug in the chemical class of TZD
Alpha-glucosidase Inhibitor (AGI): a chemical class of oral antidiabetic agents acting
by delaying gastrointestinal absorption of carbohydrates
Amary T M : brand name of glimepiride, an antidiabetic drug in the chemical class of SU
American Diabetes Association (ADA): an American health organization providing
research, information and advocacy in diabetes.
ApidraT M : brand name of Glulisine, a short-acting insulin drug by injection
Aspart: generic name of NovologTM, a short-acting insulin drug by injection
AvandiaTM: brand name of rosiglitazone, an antidiabetic drug in the chemical class of
TZD
Beta-cell: a type of cell in the pancreas, producing and releasing insulin
Biguanide: a chemical class of oral antidiabetic agents acting by decreasing hepatic
glucose production
Blood glucose: blood sugar
Detemir: generic name of Levemir m , a long-acting insulin drug by injection
Diabetes Mellitus: a disorder that blood sugar levels are abnormally high because the
body does not produce sufficient insulin or is resistant to the insulin that is produced
Diabetes: refers to diabetes mellitus specifically in this thesis
Dipeptidyl Peptidase-4 Inhibitor (DPP4i): a chemical class of oral antidiabetic agents
acting by enhancing a natural body system that lowers blood sugar, called the incretin
system
ExuberaTM: brand name of insulin inhaled, a recombinant insulin drug
Fasting Plasma Glucose (FPG): a measurement of blood sugar levels
Glargine: generic name of LantusTM, a long-acting insulin drug by injection
Glimepiride: generic name of AmaryTM, an antidiabetic drug in the chemical class of
SU
Glucagon: a 29-amino acid polypeptide acting as an important hormone in carbohydrate
metabolism
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Glucophage T M : brand name of metformin, an antidiabetic drug in the chemical class of
biguanide
Sulfonylurea (SU): a chemical class of oral antidiabetic agents acting by stimulating
insulin secretion
Glulisine: generic name of ApidraTM, a short-acting insulin drug by injection
Glycemia: the concentration of glucose in the blood
Glyset TM : brand name of meglitol, an antidiabetic drug in the chemical class of AGI
High Density Lipoprotein (HDL): used to indicate the level of "good cholesterol" in
blood
HumalogTM : brand name of lispro, a short-acting insulin drug by injection
Insulin Inhaled: generic name of Exuberarm, a recombinant insulin drug
Insulin Secretagogues: agents that can promote insulin secretion
Insulin: a hormone released from the pancreas, controlling the amount of sugar in the
blood
JanuviaTM: brand name of sitagliptin, an antidiabetic drug in the chemical class of DPP4i
LantusTM: brand name of glargine, a long-acting insulin drug by injection
Levemir M: brand name of detemir, a long-acting insulin drug by injection
Low Density Lipoprotein (LDL): used to indicate the level of "good cholesterol" in
blood
Meglitinide: a chemical class of oral antidiabetic agents acting by stimulating insulin
secretion from the pancreas
Meglitol: generic name of GlysetTM, an antidiabetic drug in the chemical class of AGI
Metformin: generic name of Glucophage T, an antidiabetic drug in the chemical class of
biguanide
Nateglinide: generic name of Starlix TM, an antidiabetic drug in the chemical class of
Meglitinide
National Diabetes Data Group (NDDG): a research group in NIH, focusing on
collection, analysis, and dissemination of data on diabetes and complications
National Institute of Diabetes Digestive and Kidney Diseases (NIDDK): part of the
NIH, conducting and supporting research on diabetes, digestive and kidney diseases
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National Institute of Health (NIH): an agency of the US Department of Health and
Human Services; the primary agency of the US government responsible for biomedical
research
Nephropathy: a disease or medical disorder of the kidney
New Drug Application (NDA): an application submitted by the manufacturer of a "new
drug" to the FDA
NovologTM: brand name of aspart, a short-acting insulin drug by injection
Oral Glucose Tolerance Test (OGTT): a diagnostic test for diabetes
Pancreas: an organ that can secret insulin
Phase I trials: studies in the first research phase during the clinical stage, focusing on the
clinical pharmacology and toxicity
Phase II trials: studies in the second research phase during the clinical stage, focusing on
an initial clinical investigation for treatment effect
Phase III trials: studies in the third research phase during the clinical stage, focusing on
a full-scale evaluation of treatment
Phase IV trials: studies in the fourth research phase during the clinical stage, focusing on
the post-marketing surveillance
Pioglitazone: generic name of ActosTM , an antidiabetic drug in the chemical class of
TZD
Pramlinitide: generic name of SymlinTM, a glucagon-lowering drug by injection
PrandinTM: brand name of repaglinide, an antidiabetic drug in the chemical class of
meglitinide
PrecoseTM: brand name of Acarbose, an antidiabetic drug in the chemical class of AGI
Prescription Drug User Fees Act (PDUFA): a program authorizing FDA to collect user
fees from prescription drugs for the purpose of expanding staffs and resources in drug
evaluation
Repaglinide: generic name of Prandin TM, an antidiabetic drug in the chemical class of
meglitinide
Retinopathy: a disease of the retina, especially one that is noninflammatory and
associated with damage to the blood vessels of the retina
9
Rosiglitazone: generic name of Avandia TM, an antidiabetic drug in the chemical class of
TZD
Sitagliptin: generic name of Januvia m, an antidiabetic drug in the chemical class of
DPP4i
StarlixTM: brand name of nateglinide, an antidiabetic drug in the chemical class of
meglitinide
Sulfonylurea (SU): a chemical class of oral antidiabetic agents acting by stimulating
insulin secretion
Symlin TM: brand name of pramlinitide, a glucagon-lowering drug by injection
Thiazolidinedione: a chemical class of oral antidiabetic agents that can reduce insulin
resistance by increasing insulin sensitivity in the peripheral tissue
Triglyceride: an important lipid (fat) in the blood, constrained in fat cells, and can be
broken down and used to provide energy for the body's metabolic processes
Type 1 Diabetes: juvenile-onset; insulin-dependent-diabetes mellitus (IDDM)
Type 2 Diabetes: adult-onset; non-insulin-dependent-diabetes mellitus (NIDDM)
World Health Organization (WHO): a specialized agency of the United Nations that
acts as a coordinating authority on international public health, headquartered in Geneva,
Switzerland
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ABSTRACT
Diabetes mellitus (diabetes) creates a heavy burden on the current healthcare
system due to the high morbidity and mortality rate from. Efforts in managing diabetes,
including the medical advances in novel therapies and public health policies of disease
control and prevention, have not reduced the disease prevalence since 1990s, and indeed
prevalence has increased. I analyze this phenomenon from the technology and policy
viewpoints underlying diabetes treatment and prevention, in order to control and manage
the disease in a cost-benefit balanced manner
The innovative performance of antidiabetic drug therapy is investigated by
analyzing the fifteen New Drug Applications (NDAs) of the antidiabetics approved by
the US Food and Drug Administration (FDA) since the early 1990s. I examine the
characteristics of the clinical trials supporting NDAs and observe how the complexity of
clinical trials has changed over time. Nine out of the twenty-five selected indicators are
found to exhibit an increasing trend of complexity. The trend is more pronounced in the oral
antiglycemics group (seven indicators) than the subcutaneous group (two indicators).
Interestingly, this trend of increasing complexity in clinical trials is generally consistent
with that of increasing R&D costs in the pharmaceutical industry, suggesting a partial
plausible explanation for the declining innovative performance of the industry observed
over the time period under investigation.
A system dynamics approach is applied to assess the current public health policies
in diabetes control and prevention. This approach emphasizes the importance of system
thinking, critical for designing a public health policy and particularly important in
chronic diseases management. The benefit of system thinking is to avoid potential policy
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resistance by identifying the problematic characteristics of the system, such as time-
delays, feedback, and structure of stocks and flows. In the case of diabetes management,
the public health system can be considered a "dynamic-complex" system in terms of
current policies made by the National Diabetes Control and Prevention Program. Despite
providing earlier and expanded screening as well as improved availability and
accessibility of treatment for diabetes, the policy results in an increase of prevalence.
More undiagnosed people are diagnosed, this increases the incidence, and people already
diagnosed prolong their lifespan due to the better and more accessible medical care. As a
consequence, the policy fails to reach the goal of reducing prevalence. A future
successful chronic disease management should integrate the efforts from both the
treatment and prevention perspectives in a systematic way. Understanding the drivers for
developing treatment and prevention is critical to achieving a robust healthcare system.
12
1 BACKGROUND
A recent report by the Congressional Budget Office studied the phenomena of
rising costs and declining performance in R&D of the pharmaceutical industry. It
identified 17 therapeutic classes where the industry's recent R&D spending has been
directed'. The products in each of these 17 therapeutic classes: (1) include at least three
brand-name drugs ranked in the top 200 for prescriptions in 2003; and (2) are mostly
newer drugs since sales of brand-name drugs typically drop sharply once generic versions
become available. The 17 therapeutic classes are summarized in the following table:
Table 1.1 Leading Therapeutic Classes in 2003
Number of Total Prescriptions
Ranking Therapeutic Class (Major subclasses) tDrugs in SBilions f(Millions of
200 dollars) units sold)
1 Antidepressants (SSRIs, SNRIs) 8 11.6 114.5
2 Antihyperlipidemics (Statins) 6 11.1 108.4
3 Antiulcerants (Proton-pump inhibitors) 5 10.4 70.0
4 Antihypertensives (ARBs, ACE inhibitors) 11 5.8 88.1
5 Antibiotics (Broad- and medium-spectrum) 9 5.5 89.2
6 Antidiabetics (Oral, injectable) 6 4.9 63.5
7 Antiarthritics (COX-2 inhibitors) 4 4.8 48.4
8 Antipsychotics 3 4.2 20.2
9 Antihistamines (Oral) 3 4.1 63.2
10 Neurological Drugs (For seizures or pain) 5 4.0 36.2
11 Other Vascular Drugs (Calcium- or beta-blockers) 7 3.7 68.7
12 Antiasthmatics 5 3.6 28.1
13 Analgesics (Nonnarcotic) 3 2.8 20.1
14 Bone Density Regulators 4 2.3 32.0
15 Oral Contraceptives 3 2.1 44.4
16 Antiallergy Drugs (Nasal steroids) 4 2.0 29.9
17 Analeptics (ADHD treatments) 3 1.3 16.9
(Source: Adapted from the Congressional Budget Office, A CBO Study-Research and Development in the
Pharmaceutical Industry, Oct. 2006)
This thesis represents an attempt to shed some light on why R&D costs have risen
and performance in the pharmaceutical industry has suffered. It is based on "Changes in
the Characteristics of Pivotal Clinical Trials in Support of New Drug Applications for
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Antidiabetics," a report produced by a collaborative project between the US Food and
Drug Administration (FDA) and the Center for Biomedical Innovation at MIT. The report
was designed to study changes in the characteristics of pivotal clinical trials in support of
approved New Drug Applications (NDAs) since 1990s. To examine these changes, the
research team initially selected nine therapeutic classes, including antibiotics,
antihypertensives, antidiabetics, anti-cholesterol agents, anti-coagulants, anti-HIV agents,
anti-fungals, oncology drugs, and CNS drugs. Understanding how complexity in clinical
trials for NDAs has evolved over time will hopefully give us insights as to whether these
changes correlate with the trend of increasing costs and declining performance in R&D of
the pharmaceutical industry. The goal of this project is to improve efficiency in approval
of NDAs without compromising safety and also to achieve more cost-effective decision-
making in R&D investment. Ideally, novel therapies are delivered to the public in a
timely fashion with a reasonable price without tradeoffs in safety.
Since the early 1990s, clinical trials referenced in NDAs approved by the FDA for
antidiabetic treatments have become more complex over time. If true, this hypothesis
may help in part to explain the rising costs of R&D in the pharmaceutical industry, but I
leave analysis of the relationship between increasing complexity and costs as a future
research topic. Section 1 includes the background information for this thesis. Section 2
introduces the definition, classification, and diagnostic criteria of diabetes mellitus.
Section 3 discusses the etiology, complications, and treatment for the disease. Section 4
focuses on changes in the characteristics of the clinical trials that support the NDAs for
antidiabetic drugs, and investigates plausible causes for these changes. Section 5
elaborates on certain policy issues associated with the treatment and prevention of
14
diabetes. Section 6 summarizes the conclusions of my thesis and discusses the future
perspectives.
2 INTRODUCTION TO DIABETES MELLITUS
Diabetes mellitus (diabetes) is a growing health problem worldwide. In the
United States, the number of people with diabetes has grown since 1990 at a rate much
greater than that of the general population 2. Diabetes is a disease with high mortality and
consumes a substantial portion of the health care resources with its complications. It was
the sixth leading cause of death in the US in 2002. In the same year, this disease
accounted for a total cost of $132 billion--$92 billion in direct costs and $40 billion in
indirect costs--for the healthcare system in the US. According to the latest report from
the National Institutes of Health (NIH) in 2005, 1.5 million new cases of diabetes were
diagnosed in the population aged 20 years old or older. Currently in the United States,
20.8 million people, seven percent of the total population in the country, have diabetes--
with 14.6 million diagnosed and 6.2 million undiagnosed. Worldwide, more than 230
million people have diabetes. This number is projected to exceed 350 million by 2025g.
2.1 Definition
Diabetes mellitus is a disorder in which blood sugar (glucose) levels are
abnormally high because the body does not produce insulin or is resistant to the insulin
that is produced.
Insulin, a hormone released from the pancreas, controls the amount of sugar in the
blood. When a person eats or drinks, food is broken down into materials that include
sugar, a source of energy that the body needs to function. Sugar is absorbed into the
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bloodstream and stimulates the pancreas to produce insulin. Insulin allows sugar to move
from the blood into the cells. Once inside the cells, sugar is converted to energy, which is
either used immediately or stored until it is needed.
The levels of sugar in the blood vary normally throughout the day. They rise after
a meal and return to normal within about two hours after eating. Once the levels of sugar
in the blood return to normal, insulin production decreases. If the body does not produce
enough insulin to move the sugar into the cells, the resulting high levels of sugar in the
blood and the inadequate amount of sugar in the cells together produce the symptoms and
complications of diabetes.
Doctors often use the full name diabetes mellitus, DM, rather than diabetes alone,
to distinguish this disorder from diabetes insipidus, a relatively rare disease that does not
affect blood sugar levels. In the scope of this thesis I focus only on diabetes mellitus,
thus I will use the term "diabetes" to refer to diabetes mellitus.
2.2 Classification
In contrast to an earlier classification based on age of onset or type of therapy,
diabetes is currently classified on the basis of the pathogenic (disease-causing) process
leading to hyperglycemia (high blood sugar levels)4. Since diabetes comprises a
heterogeneous group of disorders characterized by high blood glucose levels, the major
types of diabetes have been identified and classified by the World Health Organization
(WHO) and the National Diabetes Data Group (NDDG) of NIH in the US. These
classifications are: type 1, type 2, gestational diabetes, and other types of diabetes
secondary to or associated with other conditions. The scope of discussion in this thesis is
limited to the first two types of diabetes, i.e. type 1 and type 2.
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2.2.1 Type 1 Diabetes-IDDM
In type 1 diabetes (formally called insulin-dependent diabetes mellitus, IDDM, or
juvenile-onset diabetes), more than 90 percent of the insulin-producing cells of the
pancreas are permanently destroyed. The pancreas, therefore, produces little or no
insulin. Only 10 percent of all people with diabetes are type 1. Most people with type 1
diabetes develop the disease before age 30.
Scientists believe that an environmental factor--possibly a viral infection, or a
nutritional factor in childhood or early adulthood--causes the immune system to destroy
the insulin-producing cells of the pancreas. A genetic predisposition may make some
people more susceptible to the environmental factor5 .
2.2.2 Type 2 Diabetes-NIDDM
In type 2 diabetes (formally called non-insulin-dependent diabetes, NIDDM, or
adult-onset diabetes), the pancreas continues to produce insulin, sometimes even at
higher than normal levels. However, the body develops resistance to the effects of
insulin, so there is not enough insulin to meet the body's needs.
Type 2 may occur in children and adolescents, but it usually begins in people
older than 30 and becomes progressively more common with age. Certain racial and
cultural groups are at increased risk of developing type 2 diabetes, including African-
Americans and Hispanic-Americans, who have a twofold to threefold increased risk.
Type 2 diabetes also tends to run in families.
Obesity is the major risk factor for developing type 2 diabetes, and 80 percent to
90 percent of people with this disease are obese6. Obesity causes insulin resistance;
obese people need very large amounts of insulin to maintain normal blood sugar levels.
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In addition, certain diseases and drugs can affect the way the body uses insulin and can
also lead to type 2 diabetes.
Type 2 diabetes has also become an epidemic worldwide in the past several
decades due to the advancing age of the global population, substantially increased
prevalence of obesity, and decreased physical activity, all of which have been attributed
to increased adoption of a Western lifestyle. In the US, almost eight percent of the adult
population and 19 percent of the population older than the age of 65 years has diabetes7 .
There are 800,000 new cases of diabetes per year, almost all of which are type 2.
2.3 Diagnosis for Diabetes in a Clinical Setting
Generally, medical tests are performed to screen for disease, diagnose disease,
classify and measure the severity of disease, and monitor the course of a disease,
especially its response to treatment. A screening test (for the purpose of detecting a
disease when there is no evidence that a person has the disease) must be accurate,
relatively inexpensive, carry little risk of injury, and cause little or no discomfort. On the
other hand, a diagnostic test (for the purpose of confirming or ruling out a disease when
there is suspicion that a person has the disease) does not have the same requirements
because of potential consequence for the patient.
Diagnosis of diabetes defines a group at high risk for micro- and macrovascular
disease. The diagnosis has profound implications for an individual from both a medical
and financial standpoint. Thus it is important to set up diagnostic criteria that act as valid
predictive metrics for identifying the development of diabetes at an early stage.
Furthermore, early and accurate diagnosis is needed to achieve effective disease
management, i.e. to prevent development of severe complications in later stages.
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Treating complications has been the major cost and a heavy burden to the medical system.
An American Diabetes Association (ADA) report8 estimated that treating diabetes in the
US cost $132 billion in 2002. Healthcare spending for a patient with diabetes is more
than double what spending would be for a patient without diabetes.
Diagnostic criteria are also slightly different between a clinical setting and an
epidemiologic setting. For the purpose of studying the characteristics of clinical trials for
antidiabetics in this research, I only consider diagnostic criteria in a clinical setting.
The classic symptoms of diabetes include polyuria (urinating large amounts
frequently), polydipsia (abnormal thirst due to excessive urination), recurrent infections,
unexplained weight loss, high levels of glycosuria (presence of sugar in urine), and in
severe cases, drowsiness and coma. According to the recommendations from NDDG and
WHO, in the absence of unequivocal hyperglycemia and acute metabolic decompensation,
an asymptomatic person with blood glucose values just above the diagnostic cut-off value
needs an additional plasma/blood glucose test result with a value in the diabetic range for
further diagnostic confirmation. A medical practitioner may obtain the glucose
concentration via one of the following measurements:
(1) a casual, or random blood glucose, defined as without regard to time since the last
meal, along with the presence of classic diabetic symptoms;
(2) a fasting plasma glucose (FPG), measured after at least eight hours of fast or no
caloric intake;
(3) a two-hour plasma glucose (2-h PG), measured in an oral-glucose-tolerance-test
(OGTT, see Appendix A)
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Among the above three measurements, OGTT is generally regarded as the gold
standard and final reference for the diagnosis of diabetes; however, accessibility and
availability may be constrained due to logistic or economic reasons.
2.4 Evolution of Diagnostic Criteria from 1980s
In 1985, WHO issued the diagnostic criteria for diabetes (WHO-1985 criteria).
This is summarized in the following table:
Table 2.1 WHO-1985 Diagnostic Criteria for Diabetes
Blood Sugar Levels Whole blood Plasma
(units: mg/dL) Venous Capillary Venous Capillary
Random (with symptoms) 180 200 200 220
Fasting 120 120 140 140
2-hour post glucose load 180 200 200 220
(Source: 1999 WHO report in Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications)
2.4.1 The ADA-1 997 Criteria
In 1997, the ADA Expert Committee proposed a revision to the widely used
WHO- 1985 diagnostic criteria for diabetes in lowering the cutoff value for FPG from
140mg/dL to 126mg/dL, intending to reduce the discrepancy between this measurement
and the 2-h PG cutoff value. Meanwhile, ADA also gave primacy to the use of FPG. A
Japanese study also confirmed the fasting value to be more predictive of mortality than
the 2-hour value9 .
2.4.2 The WHO-1999 Criteria
In recognition of a more predictive value, WHO revised its 1985 criteria in 1999,
lowering the diagnostic value of FPG from 140mg/dL to 126mg/dL and also the value for
whole blood from 120mg/dL to 1 10mg/dL. Table 2.2 summarizes the changes (marked
in yellow). Despite the fact that the ADA-1997 criteria and WHO-1999 criteria share the
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same threshold value of FPG, ADA's advocacy for adopting FPG and phasing out 2-h PG
remains controversial in the medical community. I will discuss the debates regarding
adoption of either the ADA- 1997 or WHO- 1999 criteria in Section 5.1.
Table 2.2 WHO-99 Diagnostic Criteria for Diabetes
Blood Glucose Levels Whole blood Plasma
(units: mg/dL) Venous Capillary Venous Capillary
Random (with symptoms) 180 200 200 220
Fasting 110 110 126 126
2-hour post glucose load 180 200 200 220
(Source: ibid.)
2.4.3 Glycosylated Hemoglobin
Besides measuring raw blood glucose concentrations, doctors can measure the
level of a protein in the blood, hemoglobin Al c (also called glycolated or glycosylated
hemoglobin; HbA lc) for diagnostic purposes. This is most useful in confirming the
diagnosis in adults in whom the levels of sugar in the blood are only mildly elevated.
Doctors can also use HbAlc to monitor antidiabetic treatment. When the blood sugar
levels are high, changes occur in the hemoglobin, the protein that carries oxygen in the
blood. HbAlc, reflecting average glycemia over a period of weeks, can give equal or
almost equal sensitivity (the likelihood that it will produce abnormal results for people
with the disease being tested for) and specificity (the likelihood that it will produce
normal results for people without that disease) to glucose measurement. However, since
HbA I c measurement is not available in many parts of the world and also not well
standardized, it is not recommended as an alternative means for diagnosing diabetes by
WHO. In the clinical trials under investigation in this thesis, HbAIc is fairly commonly
used in the inclusion/exclusion criteria when screening patients, and is also used as an
endpoint to assess the efficacy of a drug.
21
3 TREATMENT FOR DIABETES
3.1 Etiologies of Diabetes
3.1.1 Type 1 Diabetes
The etiologies, or causes of disease, are different for type IA and type lB diabetes.
Type 1A, which comprises the majority of type 1 diabetes, results from autoimmune beta
cell destruction, and leads to absolute insulin deficiency. In contrast, type lB diabetes is
idiopathic (without apparent cause). Individuals with type lB diabetes lack evidence of
an autoimmune destructive process of the beta cells; they develop insulin deficiency by
still unknown mechanisms and are prone to ketosis (overproduction of ketones).
Relatively few type 1 patients are in the type lB category; this form of diabetes is more
10
common among individuals of African and Asian origin
3.1.2 Type 2 Diabetes
Type 2 diabetes is a heterogeneous group of disorders characterized by variable
degrees of insulin resistance, impaired insulin secretion, and increased glucose
production. Distinct genetic and metabolic defects in insulin action and/or secretion give
rise to the common phenotype of hyperglycemia in type 2 diabetes. Type 2 diabetes is
preceded by a period of abnormal glucose homeostasis (state of equilibrium) classified as
impaired fasting glucose or impaired glucose intolerance. Individuals with type 2
diabetes do not need insulin to survive. Because of the distinct pathogenic processes in
this type of diabetes, treating this disease requires pharmacologic agents that target
specific metabolic derangements. I will discuss these drug therapies in Section 3.3.
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This form of diabetes is frequently undiagnosed for many years since the
hyperglycemia is often not severe enough to provoke obvious symptoms of diabetes.
Nevertheless, such patients are at risk of developing macrovascular and microvascular
complications.
Noticeably, according to many studies obesity is strongly associated with several
major health risks, including diabetes. The majority of patients with type 2 diabetes are
obese, and obesity itself causes or aggravates insulin resistance". Among the patients
with type 2 diabetes, many of those who are not obese by traditional weight criteria may
have an increased percentage of body fat distributed predominantly in the abdominal
region. A related concern raised by this observation relates to the increasing population
of overweight or obese people in the US, which has most likely contributed substantially
to the burden of chronic health conditions12 . Additionally, type 2 diabetes also correlates
with ethnicity. Medical research has shown several racial and ethnic groups in the US are
at particularly high risk for type 2 diabetes, including African Americans, Hispanics,
13Asian and Pacific Islanders, and Native Americans
3.2 Complications
3.2.1 Acute
The acute metabolic complications of diabetes include diabetic ketoacidosis
(DKA) and hyperosmolar nonketotic state (HNS). DKA was formerly considered as a
hallmark of type 1 diabetes, but it can also occur in type 2 diabetics treated with oral
glucose-lowering agents (these patients are often of Hispanic or African-American
descent)14 . HNS is primarily seen in individuals with type 2 diabetes.
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DKA is a condition in which a person's breath smells like nail polish remover due
to ketones escaping in the breath. Without treatment, DKA can progress to coma and
death, sometimes within hours. Due to lack of insulin, most cells cannot use the sugar
that is in the blood. Cells still need energy to survive, and they switch to a back-up
mechanism to obtain energy from fat cells, which break down to produce compounds
called ketones. Ketones provide some energy to cells but also make the blood too acidic
(ketoacidosis). The initial symptoms of DKA include excessive thirst (polydipsia) and
urination (polyuria), weight loss, nausea, vomiting, fatigue, and abdominal pain--
particularly in children. Breathing tends to become deep and rapid (the Kussmaul
breathing) as the body attempts to correct the blood's acidicity.
HNS is caused by insulin deficiency and inadequate fluid intake. The
prototypical patients with HNS are elderly individuals with type 2 diabetes, with a several
week history of polyuria, weight loss, and diminished oral intake of fluid that results in
mental confusion, lethargy (tiredness), or coma. Unlike DKA, HNS does not involve the
production of ketones, and therefore does not cause symptoms of nausea, vomiting, or
abdominal pain and the Kussmaul respirations.
3.2.2 Chronic
The chronic complications of diabetes affect many organ systems and are
responsible for the majority of morbidity and mortality associated with this disease. 70
percent of type 2 diabetic patients die of cardiovascular disease". In the US, the
estimated cost of providing care for diabetes and its complications is $100 billion per
year, with half the cost attributable to direct care' 6. Chronic complications are
summarized in the following table:
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Table 3.1 Long-term Complications of Diabetes
Tissue or Organ Affected Complications
* Poor circulation causes wounds to heal poorly and can
Blood vessels lead to heart disease, stroke, gangrene (death of tissue) of
the feet and hands, erectile dysfunction, and infections.
* Decreased vision and, ultimately, blindness
* Cataracts (clouding in the lens of the eye, which impairs
Eyes vision)
* Glaucoma (elevation of the pressure in one of the
chambers of the eye that can decrease vision and lead to
blindness)
Kidney * Poor kidney function
* Kidney failure
* Sudden or gradual weakness of a leg
Nerves * Reduced sensations, tingling, and pain in the hands andfeet
0 Chronic damage to nerves
* Swings in blood pressure
Autonomic nerves system 0 Swallowing difficulties and altered digestive function, with
bouts of diarrhea
Skin 0 Sores, deep infections (diabetic ulcers)
* Poor healing
Blood * Increased susceptibility to infection, especially of the
urinary tract and skin
* Carpal tunnel syndrome (a painful compression of the
median nerve as it passes through the wrist)
Connective Tissue * Dupuytren's contracture (a progressive shrinking of thebands of fibrous tissue (called fascia) inside the palms,
producing a curling in of the fingers that eventually can
result in a clawlike hand)
(Source: The Merck Manual of Medical Information, 2n Edition)
3.3 Therapies for Diabetes
3.3.1 An Overview
The overall goals of therapies for type 1 and type 2 diabetes are to: (1) eliminate
symptoms related to hyperglycemia; (2) reduce or eliminate the long-term microvascular
and macrovascular complications of diabetes; and (3) allow the patients to achieve as
normal a lifestyle as possible7 .
Change of lifestyle (including diet, exercise, and weight control), insulin
intervention, and oral antihyperglycemic (glucose-lowering) agents are three major
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therapies against diabetes. The main goal of these therapies is to maintain the level of
blood sugar within the normal range. The importance of blood sugar control lies in
preventing microvascular complications1 8,19,20. Although maintaining blood sugar
completely within the normal level is difficult, keeping the level as close to the normal
level as possible can still effectively prevent the development of complications. The
main problem in treating diabetes by controlling blood sugar levels is an increased risk of
overshooting, resulting in low blood sugar levels (hypoglycemia)21.
(1) Treating Type 1 Diabetes
The ADA recommendations for treating type 1 diabetes focus on achieving goals
for fasting, bedtime glycemic control, and HbA 1 c targets, as summarized in Table 3.2
(the targets of glycemic control is also discussed later in Section 3.3.2.).
According to a study by the Diabetes Control and Complications Trial Research
Group, intensive therapy has proved to be most effective in delaying the onset and also
slowing the progression of diabetic long-term complications for type 1 diabetic patients.
According to this study, intensive treatment--defined by the goal of maintaining blood
glucose concentrations close to the normal range--can decrease the frequency and
severity of long-term microvascular and neurologic complications, which cause major
morbidity and mortality in patients with type 1 diabetes. Another study shows the that
intensive therapy reduces the risk of cardiovascular disease in type 1 diabetic patients23
Intensive treatment consists of three or more daily injections of insulin or
treatment with an external insulin pump, with dose adjustments based on at least four
self-monitored glucose measurements per day. Daily glucose goals are 70 to 120 mg per
deciliter before meals and peak levels of less than 180 mg per deciliter after meals. The
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goal for HbA lc is less than 6.05 percent. In contrast, conventional therapy has no
glucose goals beyond those needed to prevent symptoms of hyperglycemia and
hypoglycemia and consists of only one or two daily injections of insulin.
(2) Treating Type 2 Diabetes
A traditional approach to treating type 2 diabetes involves a stepwise introduction
of nonmedication (lifestyle) approaches followed by oral glucose-lowering agents.
Insulin, despite being the most potent and durable therapy, is generally saved for last,
presumably because of the need to administer it by injection. The stepwise strategy is
usually applied at a slow pace with long delays between steps. By the time patients with
type 2 diabetes are treated with insulin, they usually have had diabetes for more than 10
to 15 years and have established complications24 . This treatment approach is illustrated
in Figure 3.1.
Year
0 4 7 10 16 20
Usual Sequence
of Interventions Diet and Oral Combination Insulin
Exercise agents therapy with oral
agents
Risk Factors for
Cardiovascular Disease
Typical Clinical
Course
More advanced
Impaired glucose microvascular and More
tolerance and Diagnosis Microvascular cardiovascular advanced Deathinsulin resistance of diabetes complications disease disease
Development of
diabetes
Figure 3.1 The Typical Clinical Course of Type 2 Diabetes, Including the
Progression of Glycemia and the Development of Complications, and the Usual
Sequence of Interventions (Source: Initial Management of Glycemia in Type 2 Diabetes Mellitus, NEJM
2002)
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Glycemia appears to increase progressively along with the presence of diabetes,
as a result of decreasing beta-cell function . However, at least some beta-cell
dysfunction is reversible, and insulin secretion can be restored by lowering glycemia,
either with diet and exercise or with hypoglycemic medications26.
Type 2 diabetes has been labeled as coronary heart disease risk equivalent.
Guidelines from the National Cholesterol Education Program27 and ADA 28 both
acknowledge that the presence of diabetes is a risk factor equivalent to having preexisting
coronary artery disease29 and have therefore adjusted treatment goals accordingly. Thus,
another critical element as part of the comprehensive diabetes care in treating type 2
diabetes is to aggressively detect lipid abnormalities in order to lower the risk of
developing long-term complications, particularly cardiovascular disease, which account
for the 70 percent mortality of type 2 diabetes.
Care of patients with type 2 diabetes has been revolutionized throughout the past
several years--first, through the realization of the importance of tight glycemic control in
forestalling complications, and second, by the availability of several unique classes of
oral antidiabetic agents.
When monotherapy (using one single oral antihyperglycemia agent) fails to
achieve the targets of glycemic control--metabolic control worsens within five years after
the initiation of an oral hypoglycemic agent--clinicians will use combination therapy to
achieve better and more effective glycemic control to treat type 2 diabetes. The UK
Prospective Diabetes Study clearly demonstrated that type 2 diabetes is a progressive
disease. After three years, for example, only 50 percent of type 2 patients were
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adequately controlled with a single drug, and after nine years, this percentage had
decreased to 25 percent
The principle behind combination therapy is to use drugs with different
mechanisms of action. The first commonly used combination regime--insulin at bedtime
and sulfonylurea (SU) during the day--combines two drugs to increase insulin levels3 1 .
Other popular combinations are SU and metformin, metformin and thiazolidinedione
(TZD), and SU and TZD. Another common combination therapy is oral agent/insulin
therapy. When using bedtime basal insulin (NPH or glargine), continuing one or two
daytime doses of oral mediation is reasonable. Combining SUs with insulin lowers
insulin doses (25%-50%) with less weight gain, but increases cost. Metformin with
insulin results in similar metabolic control, less weight gain, lower insulin doses, and
fewer hypoglycemic episodes than insulin alone or insulin/SU therapy. Thus, metformin
and insulin may be the best combination for the majority of patients with type 2 diabetes
who do not have contraindications. Although TZDs are effective insulin sensitizers,
TZDs are more expensive compared to SUs and metformin (see price comparison of the
oral agents in Table 3.4.).
The increasing number of available medications has given clinicians more choices
for first-line therapy and for changing or combining medications when the metabolic
disorder worsens over time. Several recommendation guidelines for the treatment of type
2 diabetes have been published32, which emphasize the long-term maintenance of
glycemic control, as estimated by levels of glycosylated hemoglobin (HbAIc), in an
effort to keep these levels as close to the non-diabetic range as is safely possible. They
also emphasize the initiation of treatment with metformin in patients who have newly
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diagnosed disease (concurrent with lifestyle interventions) and the changing of
medications no less frequently than every three months if glycosylated hemoglobin levels
are seven percent or more (See Figure 3.2). The algorithm provided in the guidelines
includes early, aggressive use of insulin, the most powerful antidiabetic drug, when
metabolic goals are not achieved. SUs, TZDs, and insulin are included as possible
second-step medications to be combined with metformin and lifestyle interventions if
metabolic goals are not achieved or maintained33
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Diagnosis
Lifestyle intervention
plus metformin
Hbalc >=
No 7
Yes
Add basal insulin Add SU (least
(most effective) expensive)
Hbalc >= Hbalc >=No 7% 7%
Yes Yes
Intensify insulin therapy Add TZD
Hbalc >=Hba
No7% No 7
Yes Ye
Add basal insulin or in
Intensify insulin therapy plus metformin with or without TZD
C >=
s
tensify insulin therapy
Figure 3.2 Metabolic Management of Type 2 Diabetes (Source: Thiazolidinedionesfor Initial
Treatment qf Type 2 Diabetes? NEJM Dec. 2006)
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3.3.2 Goals of Therapy
Establishing a target level of glycemic control is essential in order to reduce or
eliminate the complications of diabetes. The target for glycemic control (as reflected by
HbAIc) must be individualized, and the goals of therapy should be developed in
consultation with the patient after considering a number of medical, social, and life-style
issues.
The ADA's recommended goals of treatment, including target levels of blood
sugar, blood pressure, and blood lipids, are summarized in Table 3.2. Studies have
shown that aggressive treatment of hypertension also reduces the risk of retinopathy,
nephropathy, and certain cardiovascular outcomes34 . Reducing low-density lipoprotein
cholesterol levels 35 ,36 and reducing triglyceride levels while raising high-density
lipoprotein cholesterol levels3 7 can decrease the risk of cardiovascular disease.
Table 3.2 ADA's Recommended Goals of Treatment for Diabetes in Nonpregnant
Adults
Variable Value
Glucose
Glycosylated hemoglobin (HbA1C) <7 %
Fasting plasma glucose (FPG) 90-130 mg/dL
Peak postprandial glucose <180 mg/dL
Blood Pressure
Systolic <130 mm Hg
Diastolic <80 mm Hg
Lipids
Low-density lipoprotein cholesterol (LDL) <100 mg/dL
High-density lipoprotein cholesterol (HDL) >45 mg/dL
Triglyceride <200 mg/dL
(Source: Initial Management of Glycemia in Type 2 Diabetes Mellitus, NEJM 2002)
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3.3.3 Drug Therapy
1) Insulin Therapy
Insulin is a pancreatic hormone that regulates carbohydrate metabolism. It plays a
critical role in regulating blood sugar. Insulin is used medically in patients with type 1
diabetes and may be needed by patients with type 2 diabetes for intermittent or
continuous glycemic control. Over time, some people develop resistance to insulin.
Because the injected insulin is not exactly like the insulin the body manufactures, the
body can produce antibodies to the insulin. These antibodies interfere with the insulin's
activity, and as a result, a person with insulin resistance must take very large doses.
The goals of insulin therapy in both type 1 and type 2 diabetes are to reach the
target HbAlc level with a low rate of hypoglycemic episodes and the least amount of
weight gain. Goals must be individualized since older patients with type 2 diabetes and
with no complications may not benefit from intensive therapy. Certain types of insulin
may be mixed together in an injection to achieve the best control of blood sugar while
other types cannot be mixed together and may require two separate injections. Some
insulin can be purchased already mixed together, such as regular and NPH insulin, to
allow for injection of both types of insulin at the same time. Hypoglycemia is the most
common adverse effect of insulin therapy. Newer insulin therapies, including
physiologic basal-prandial insulin and insulin analogues (molecules with similar
chemical or structural properties) may convey similar function or activity, may be faster-
acting, or have better bioavailability, when compared to insulin. Through genetic
engineering of the underlying DNA, the primary amino acid sequence of insulin can be
changed to alter its ADME characteristics, which include absorption, distribution,
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metabolism, and excretion, These developments are changing clinical care for the
diabetic 38.
According to the definitions from NIDDK, insulin products are available in four
forms--rapid-acting, short-acting, intermediate-acting, and long-acting--depending on the
speed of onset (how quickly the insulin starts to work after it is injected), peak time (the
period of time when the insulin is most effective in lowering blood sugar levels), and
duration of action (how long the insulin remains working in the body). These four
different forms may be injected separately or mixed in the same syringe. Rapid-acting
insulin, which is known by brand names such as Humalog, Novolog, and Apidra, is the
fastest and shortest acting. It is often used by people who take several daily injections
and is injected after eating (post-prandially). It reaches its maximum activity in 45 to 90
minutes and works for 3 to 4 hours. Short-acting insulin starts to work in 30 minutes,
reaches its maximum effect in 2 to 5 hours, and works for 5 to 8 hours. Intermediate-
acting insulin, such as Neutral Protamine Hagedom (NPH; isophane insulin), starts to
work in 1 to 3 hours, reaches is maximum activity in 6 to 12 hours, and works for 16 to
24 hours. This type of insulin may be used in the morning to provide coverage for the
first part of the day or in the evening to provide coverage during the night. Traditionally,
NPH was the primary basal insulin and the most regularly-prescribed primary prandial
insulin. Long-acting insulin, including Lantus and Levemir, starts to work in 4 to 6 hours,
reaches its maximum effect in 8 to 20 hours, and works for 24 to 28 hours. A comparison
of insulin products is summarized in the following table:
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Table 3.3 Currently Available Insulin Products
Insulin Onset Peak Effective Duration
Rapid-acting
Lispro (Humalog)
Aspart (Novolog) 5-15 min 45-90 min 3-4 h
Glulisine (Apidra)
Short-acting
Regular insulin 30 min 2-5 h 5-8 h
Intermediate-acting
Isophane insulin (NPH) 1-3 h 6-12 h 16-24 h
Long-acting
Detemir (Levemir) 4-6 h 8-20 h 24-28 hGlargine (Lantus)
(Source: Adapted from a report of NIDDK)
Insulin has to enter the body's bloodstream to be effective. Unlike many
medicines, insulin cannot be taken orally (swallowed as a pill or tablet) since it loses its
activity when going through the gastrointestinal tract. Insulin is therefore delivered into
the body by injection under the skin (subcutaneously) into the fat layer, usually in the arm,
thigh, or abdominal wall. Recently in January 2006, FDA approved an insulin agent with
an alternative delivery system (i.e. needle-free), called Exubera, a rapid-acting insulin
agent in dry-powder form inhaled into the lungs (intrapulmonary) through a patient's
mouth using a specially designed inhaler.
The choice of insulin is complex. While some people, especially older people,
take the same amount of insulin every day, others adjust the insulin dose daily depending
on their diet, exercise, and blood sugar patterns. In addition, insulin needs may change if
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a person experiences weight changes, emotional stress, or illness--particularly infection
Several factors are considered before making choice of insulin40 :
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* Willingness to monitor blood sugar levels: How willing and able the person is to
monitor the blood sugar levels and adjust the insulin dosage;
" Daily activity levels: How varied the person's daily activity is;
" Understanding of the disease: How adept the person is at learning about and
understanding the disease;
" Stability of blood sugar levels: How stable the person's blood sugar levels are during
the day and from day to day.
2) Oral Glucose-lowering therapy
Until 1995, only one category of oral antihyperglycemic medicines was available
in the U.S--the sulfonylureas (SUs). Since sulfonylurea drugs were first introduced to the
US market in 1954, the number of oral antihyperglycemic agent classes, each with its
unique mechanism of action, has increased five-fold in the past ten years, to include
classes such as biguanides first introduced to the US in 1995, alpha-glucosidase inhibitors
(AGIs) in 1996, thiazolidinediones (TZD) in 1997, and non-sulfonylurea (non-SU)
insulin secretagogues in 199741. Recently in October 2006, a new oral agent, a
Dipeptidyl Peptidase-4 Inhibitor (DPP-4i), was introduced to the market. The following
table gives an overview of the oral glucose-lowering agents.
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Table 3.4 Oral Antihyperglycemic Agents: Drug Class, Mechanism, and Potency
Geneic Tade ApprvalReduction
Antidiabetic Drug Class Mechanism Generic Trae Approval in HbAlc
Name Name Date (%)
Sulfonylureas (SU) increase insulin secretons' glimepiride Amaryl 1994 1-2
Reduce hepatic glucose
Biguanides production, i.e. insulin metformin Glucophage 1993 1-2
sensitizers
Alpha-glucosidase Delay gastrointestinal acarbose Precose 1994
Inhibitors (AGIs) absorption of carbohydrate, 0.5-1i.e. starch blockers
meglitol Glyset 1995
Thiazolidinediones (TZD) Increase insulin sensitivity, rosiglitazone Avandia 1998 1-2i.e. insulin sensitizers pioglitazone Actos 1999
Meglitinides (Non-SU Increase insulin secretion, repaglinide Prandin 1997 1-2
Secretagogues) i.e. insulin secretagogues nateglinide Starlix 1999 0.5-1
Dipeptidyl Peptidase-4 Increase active levels of
Inhibitors (DPP-4i) incretins to help regulate Sitagliptin Januvia 2006 N/Ablood sugar I I I I
(Source: Cook D.A. et al., Concise Reviewfor Clinicians: Type 2 Diabetes Mellitus)
a) Sulfonylurea
Sulfonylureas (SUs), which are considered insulin secretagogues, act by stimulating
insulin secretion and are a reasonable first choice for oral therapy, although metformin
(from the biguanide class) is preferred in obese patients. SUs reduce both fasting and
postprandial glucose. SUs are inexpensive compared to other oral antihyperglycemic
agents, but they can cause hypoglycemia which at times can be a serious problem. Since
its first discovery, two generations of SUs have been developed. At maximum doses,
first-generation agents are similar in potency to second-generation agents but have a
longer half-life, a greater incidence of hypoglycemia, and more frequent drug interactions.
Thus, the second-generation SUs are generally preferred. For these new agents, an
advantage to a more rapid onset of action is better coverage of the postprandial glucose
rise, but the short half-life of such agents requires more than once-a-day dosing.
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Nowadays, new SU drugs with fewer side effects have been used as "monotherapy" or as
part of combination therapy with other types of antidiabetics to treat diabetic patients.
b) Biguanide
Currently metformin is the only drug in the biguanide class available in the US
market; both phenformin and buformin were withdrawn from the market due to the risk
of lactic acidosis (toxic effects) in 197842. Although available internationally (in Europe)
for decades, metformin was not released to the US market until 199343. Metformin is the
oral agent of the first choice in obese patients. In contrast to the SU, metformin does not
stimulate insulin secretion. The drug acts by decreasing hepatic glucose production; it is
therefore considered as an insulin sensitizer, and is the only oral agent shown to decrease
total mortality. Metformin should not cause hypoglycemia when used alone, does not
contribute to weight gain as much as other diabetes medications, and has beneficial albeit
limited effect on lipid profile (lowering triglycerides and LDL, raising HDL)44.
c) Alpha-glucosidase Inhibitor
Alpha-glucosidase Inhibitors (AGIs) act by delaying gastrointestinal absorption of
carbohydrates (controlling the blood sugar by slowing down the digestion and absorption
of carbohydrates in the small intestine after meals by blocking the enzyme that digests
carbohydrates), i.e. starch blockers. As such, they must be taken at the beginning of a
45,46
meal, and can mitigate postprandial glucose elevation . The efficacy of AGIs is
considerably less than either SUs or metformin (summarized in Table 3.4). Their
greatest effect is on postprandial glucose levels, whereas the effect on FPG levels is small.
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d) Thiazolidinedione
In 1997, troglitazone, a thiazolidinedione (TZD), was introduced in the US, but was
later removed from the market due to the risk of hepatotoxicity (liver damage). Currently,
TZDs are represented by rosiglitazone (Avandia) and pioglitazone (Actos). TZDs are
designed to reduce insulin resistance by increasing insulin sensitivity in peripheral tissue.
They do not cause hypoglycemia when used alone, and may reduce insulin resistance. In
both placebo-controlled and comparison trials, TZDs generally lower HbA I c as much as
SUs and metformin, and more than the AGIs (summarized in Table 3.4). One study47
has shown that in addition to the role as an insulin sensitizer, the TZDs also have certain
benefits in improving lipid profile and reducing cardiac events. TZDs can increase the
concentration of HDL cholesterol (good cholesterol) and reduce the concentration of
triglycerides. TZDs also slightly reduce blood pressure.
e) Meglitinides
Meglitinides, considered as non-SU insulin secretagogues, have a similar mechanism
as SUs--stimulating insulin secretion from the pancreas--but the duration of effect is
much shorter than with SUs. Meglitinides can cause hypoglycemia if taken without food.
The drug class of meglitinides is represented by two drugs--repaglinide (Prandin) and
nateglinide (Starlix). Nateglinide requires dose adjustment in patients with hepatic
impairment. The efficacy of repaglinide is similar to SUs whereas nateglinide appears to
be somewhat less potent a secretagogue (summarized in Table 3.4).
f) Dipeptidyl Peptidase-4 Inhibitor
Distinct from the mechanism of other oral agents, Dipeptidyl Peptidase-4 Inhibitors
(DPP-4is) act by enhancing a natural body system that lowers blood sugar, called the
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incretin system. When blood sugar increases, incretins work in two ways to help the
body regulate high blood sugar levels: they trigger the pancreas to increase insulin and
signal the liver to reduce glucose production. DPP-4is enhance the body's own ability to
control blood sugar levels by increasing the active levels of these incretin hormones in
the body, helping to decrease blood sugar levels in patients with type 2 diabetes49 .
Sitagliptin is currently the only approved and available DPP-4i in the US (approved by
FDA on October 16, 2006).
Table 3.5 summarizes the comparison in costs among the oral antihyperglycemic
drugs.
Table 3.5 Summary of Available Oral Agents and Costs
Administration
Monthly Coprtv
Antidiabetic Class total#of tl omparative
strength dosage tablets Cost, $
(mg) administration per
month
Sulfonylureas
Amaryl (glimepiride) 4 2 tablets/dose, qd 60 60 2-3
Biguanides
Glucophage (mefformin) 500 2 tablets/dose, bid 120 102 3-4
Alpha-glucosidase
inhibitors
Precose (acarbose) 100 1 tablet/dose, tid 90 78 2-3
Glyset (meglitol) 50 1 tablet/dose, tid 90 73 2-3
Thiazolidinediones
Avandia (rosiglitazone) 4 1 tablet/dose, bid 60 175 >4
Actos (pioglitazone) 45 1 tablet/dose, qd 30 169 >4
Meglitinides
Prandin (repaglinide) 2 2 tablets/dose, tid 180 165 >4
Starlix (nateglinide) 120 1 tablet/dose, tid 90 103 3-4
* qd indicates one time daily; bid, two times daily; tid, three times daily.
** Cost is based on the mean of retail costs in 2001 at 3 New Haven County, Connecticut,
national chain pharmacies and is adapted from Inzucchi's Yale Diabetes Center Facts and
Guidelines 2001. (Source: Oral Antihyperglycemic Therapyfor Type 2 Diabetes 50)
40
3.3.4 A Look at the Pipeline
According to a report from the Pharmaceutical Researchers and Manufacturers of
America (PhRMA), currently there are 24 new diabetes medicines in development.
These experimental pharmaceutical treatments include5 1 :
* A protein to promote increased insulin secretion when blood glucose levels are high
but not when they are normal;
* Dual-acting sensitizers that increase muscle cell uptake of blood sugar and
inhibit the liver's production of blood sugars, as well as reduce blood lipid levels; and
* Drugs that are designed to lessen diabetic nerve disease and complications
involving small blood vessels, such as those in the eye or kidney.
4 CHANGES IN CLINICAL TRIALS OF NDAs FOR
ANTIDIABETICS
A New Drug Application (NDA) is an application submitted by the manufacturer
of a "new drug" to the FDA, after clinical trials have been completed, for a license to
market the drug for a specified indication. According to the definition by the Center for
Drug Evaluation and Research of FDA, a "new drug" can include a new molecule entity
(NME) or can also be an active substance previously sold in a different form5 2. In this
section, I study the clinical trials submitted in support of NDAs for fifteen antidiabetic
drugs since the early 1990s (shown in Table 4.1), including eight oral agents, six
subcutaneous insulin agents, and one inhaled insulin agent. The purpose is to investigate
changes in the design of clinical trials in support of NDAs.
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Table 4.1 List of Antidiabetic Drugs
Group by Route First inSubmission Drug Class Generic Name Trade Name of ass Prorit(DaeAdministration Yes ()Standard(-
/No(-)
09-1993 Biguanide metformin Glucophage Oral + +
08-1994 SU glimepiride Amaryl Oral - -
09-1994 AGI acarbose Precose Oral - -
12-1995 AGI meglitol Glyset Oral - -
07-1997 Meglitinide repaglinide Prandin Oral + +
11-1998 TZD rosiglitazone Avandia Oral + +
12-1999 Meglitinide nateglinide Starlix Oral - -
12-2005 DPP-4i Sitagliptin Januvia Oral + -
03-1995 short-acting insulin lispro Humalog Subcutaneous - -
09-1998 isouling
09-1998 shol-acting insulin aspart Novolog Subcutaneous - -
04-1999 long-acting insulin Lantus Subcutaneous -
insulin glargine LausSbtnes --
12-2000 glucagon pramlinitide Symlin Subcutaneous - -lowering
12-2002 ng-acting estemir Levemir Subcutaneous - -
shr-iginsulin emi
06-2003 sho-acting suline Apidra Subcutaneous - -
1-04 11insulin 1llsn
12-2004 insulin inhaled Exubera Inhaled
Under 21 CFR314.50 regarding an application of a drug for human use, the
legislative definition and requirements of the content and format include:
1. Application form.
2. Index.
3. Summary.
4. Technical sections.
5. Samples and labeling.
6. Case reports forms and tabulations.
7. Other.
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Among all, the technical section--comprised of the following--includes the most
important and useful information for my research, particularly the clinical data and
statistical section:
a. Chemistry, manufacturing, and control section.
b. Nonclinical pharmacology and toxicology section.
c. Human pharmacokinetics and bioavailability section.
d. Microbiology section.
e. Clinical data section.
f. Statistical section.
g. Pediatric use section.
4.1 Clinical Trials
The definition of a clinical trial is a research study in human volunteers to answer
specific health questions about vaccines or new therapies or new ways of using known
treatments. Clinical trials are used to determine whether new drugs or treatments are
both safe and efficacious (effective). The essential characteristic of a clinical trial is that
one uses the results based on a limited sample size of patients in the study to make
inferences about how a future treatment could be applied to the general patient population.
According to 21 CFR314.126, "an adequate and well-controlled study" has the following
characteristics:
1. The objectives and the content of the investigation are clearly stated, summarizing the
proposed or actual analysis methods, protocol for the study, and the report of the
underlying results.
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2. The study uses a design, which permits an adequate comparison with respect to a
control, to provide a quantitative assessment of the drug effect. As such, placebo
concurrent, dose-comparison concurrent, no treatment concurrent, active treatment
concurrent, and historical controls are commonly used examples.
3. The method of selecting subjects provides the adequate assurance, under the basis
that patients have the disease or condition being studied, or evidence of susceptibility
and exposure to the condition against which prophylaxis (i.e. treatment to prevent
disease) is directed.
4. The method of assigning patients to treatment and control groups minimizes bias and
is intended to assure comparability of the groups with respect to pertinent variables
such as age, sex, severity of disease, duration of disease, and use of drugs or therapy
other than the test drug.
5. Adequate measures are taken to minimize bias on the part of the subjects, observers,
and analysts of the data. The protocol and report of the study should describe the
procedure used to accomplish this, such as blinding (a clinical trial is "blind" if
participants are unaware of whether they are in the experimental or control arm of the
study; also called masked).
6. The methods of assessment of subjects' response are well-defined and reliable.
7. There is an analysis of the results of the study, critical to adequately assessing the
drug effects.
Carefully conducted clinical trials are the fastest and safest way to find treatments
that work in people. In the legislative language (21CFR314.126), the purpose of
conducting clinical investigations of a drug is to distinguish the effect of a drug from
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other influences, such as spontaneous change in the course of the disease, placebo effect,
or biased observation.
Trials are in four phases: Phase I tests a new drug or treatment in a small group;
Phase II expands the study to a larger group of people; Phase III expands the study to an
even larger group of people; and Phase IV takes place after the drug or treatment has
been licensed and marketed.
4.1.1 Phase I Trials: Clinical Pharmacology and Toxicity
Clinical pharmacology is intended to include the initial introduction of a drug into
man. The first experiments in man are primarily concerned with drug safety, not efficacy,
and hence are usually performed on human volunteers. However, with some new drugs,
for ethical or scientific considerations, the initial introduction into man is more properly
done in selected patients. The first objective is to determine an acceptable drug dosage,
i.e. how much can be given without causing serious side-effects. Such information is
often obtained from dose-escalation experiments, in which a volunteer is subjected to
increasing doses of the drug according to a predetermined schedule. Phase I also
involves studies of drug metabolism and bioavailability, i.e. drug dynamic and metabolic
studies, such as absorption studies. Later, studies of multiple doses will also be
undertaken to determine appropriate dose schedules for use in Phase II. After studies in
normal volunteers, the initial trials in patients will also be of the Phase I type. Typically,
Phase I studies might require a total of around 20-80 subjects and patients5.
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4.1.2 Phase II Trials: Initial Clinical Investigation for Treatment Effect
Phase II trials are fairly small-scale investigations into the effectiveness and
safety of a drug, and require close monitoring of each patient. These trials can sometimes
be set up as a screening process of selecting out those relatively few drugs of genuine
potential from the larger number of inactive or overly toxic compounds, so that the
chosen drugs may proceed to Phase III trials. The size of the Phase II trials seldom goes
beyond 100-200 patients per drug.
4.1.3 Phase Ill Trials: Full-scale Evaluation of Treatment
After a drug is shown to be reasonably effective, it is essential to compare it either
with placebo or with the current standard treatment(s) for the same condition in a large
trial involving a substantial number of patients. Generally, a full-scale Phase III trial is
the most rigorous and extensive type of scientific clinical investigation of a new
treatment.
4.1.4 Phase IV Trials: Post-marketing Surveillance
Phase IV trials include research programs after a drug is approved for marketing.
FDA may specify actions as post-marketing commitments in the approval letter of an
NDA.
In light of the FDA's published Guidance of General Considerations for the
Clinical Evaluation for Drugs, there are several types of post-marketing clinical trials
including5 4:
1) Additional studies to elucidate the incidence of adverse reactions to explore a specific
pharmacologic effect, or to obtain more information of a circumscribed nature.
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2) Large scale, long-term studies to determine the effect of a drug on morbidity and
mortality.
3) Additional clinical trials similar to those in Phase III to supplement premarketing data
where it has been deemed in the public interest to release a drug for more widespread
use prior to acquisition of all data which would ordinarily be obtained before
marketing.
4) Clinical trials in a patient population not adequately studied in the premarketing phase,
e.g. children.
5) Clinical trials for an indication from which it is presumed that the drug, once
available, will be used.
4.2 Drug Evaluation in FDA
The Center for Drug Evaluation and Research (CDER) is one division of FDA with
about 2,200 employees, the largest of the five centers in the FDA, with a charter to
regulate human drugs for safety and effectiveness--reviewing drugs before marketing,
watching for drug problems, monitoring drug information and advertising, and protecting
drug quality55 . Hence, regarding NDA submission, CDER is in charge of reviewing and
evaluating the results of clinical trials submitted by pharmaceutical sponsors to approve a
drug as safe and efficacious to be licensed and marketed in the US.
4.2.1 Review of NDA
CDER has different project teams to perform drug reviews, which allow team
members to apply their individual special technical expertise to review applications. The
project teams include5 6:
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1. Biologists, biochemists and immunologists: to evaluate the manufacturing processes
for biological products to ensure the continued purity, potency and safety of these
products; also to provide insights into the mechanism of action as well as potential
and observed adverse events associated with specific products.
2. Chemists: focusing on how a drug is manufactured to make sure that the
manufacturing control, quality control testing, and packaging are adequate to preserve
the drug product's identity, strength, potency, purity and stability.
3. Clinical pharmacologist and biopharmaceutists: to evaluate factors that influence
the relationship between the body's response and the drug dose as well as evaluate the
rate and extent to which a drug's active ingredient is available to the body and the
way it is distributed, metabolized and eliminated; also to assess the clinical
significance to changes the body's response to drugs through the use of exposure-
response relationships and check for interactions between drugs.
4. Microbiologists: to evaluate the effects of anti-infective drugs on germs. These
medicines--antibiotics, antivirals and antifungals-are intended to affect the germs
instead of patients. Another group of microbiologists evaluates the manufacturing
processes and tests for sterile products, such as those used intravenously
(administered into blood vessels).
5. Pharmacologists and toxicologists: to evaluate the effects of the drug on laboratory
animals in short-term and long-term studies, including the potential based on animal
studies for drugs to induce birth defects for cancer in humans.
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6. Physicians: to evaluate the results of the clinical trials, including the drug's adverse
and therapeutic effects, and determine whether the benefits of the product outweigh
the known risks at the proposed working doses.
7. Project managers: to orchestrate and coordinate the drug review team's interactions,
efforts and reviews; also to serve as the regulatory expert for the review team and as
the primary contact for the drug industry.
8. Safety reviewers: to propose and evaluate risk management plans as well as review
proposed brand names, packaging and labeling to minimize errors when a drug is
prescribed, dispensed or administered.
In the scope of this thesis in analyzing changes of characteristics of clinical trials,
I focus on pivotal trials--essential to approval of an NDA in terms of safety and
effectiveness--from the FDA's view (to approve an NDA), and from the sponsor's view
(to acquire the approval of an NDA). However, whether a clinical trial is considered as a
pivotal trial may vary from the FDA's viewpoint or from the sponsor's.
4.2.2 FDA's Guidelines on Submission of Clinical Trials
Under the 21 CFR1 0.115 clause of "Good Guidance Practice," guidance consists
of documents prepared for FDA staff, applicants/sponsors, and the public that describe
the agency's interpretation of policy on a regulatory issue. In light of the definition, these
documents include, but are not limited to documents that relate to: the design, production,
labeling, promotion, manufacturing, and testing of regulated products; the processing,
content, and evaluation or approval/submissions; and inspection and enforcement policies.
On this legislative ground, FDA has issued guidelines for drug development programs in
the US since 1977. The guidelines include recommendations on how Phase I, II, and III
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trials should be structured for drugs, including the procedure, subject and setting of
clinical trials. These guidelines include Guidance for General Considerations for the
Clinical Evaluation of Drugs, and also guidances in several other specific disease areas,
for instance drugs for anxiety, depression, treatment of osteoarthritis, inflammation,
diarrhea, lipid-altering, weight-control etc".
4.3 Data Sources
The data for the analysis work in this research come from three sources: the
Drugs@FDA public website, the CDER's Division File System (DFS) database and the
CDER's Action Package archival system. The Drugs@FDA is a public website
providing information on a drug's characteristics: general information (drug name, active
ingredient(s), NDA number, company, chemical type, review classification, strength,
dosage form and route of administration), approval history, letter, review and related
documents, and label information. However, due to proprietary reasons, a fair amount of
relevant material is often redacted. Thus, the DFS and the Action Package have become
two major sources in my research. Both the DFS and the Action Package hold complete
electronic information for an NDA's approval, including the following elements:
* Action letter(s)
* Discipline reviews (chemistry, medical, labeling, chemistry/manufacturing/ controls,
and consults)
* Correspondence from the FDA to Sponsor (letters and faxes)
* Internal FDA correspondence (emails and inspection results)
* Meeting notes
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Because the FDA has began the electronic archival process only in the 1980s, the
DFS database holds more complete review reports of newer NDAs while the Action
Package is more useful to access data for older NDAs.
Among the files available for approval of an NDA--either from the DFS or the
Action Package--the Medical Officer's Review is the most insightful in that it is a
comprehensive evaluation and assessment of a drug's safety and efficacy, with emphasis
on pivotal trials from the FDA's view in order to approve the NDA. In addition, the
Statistical Review and the Clinical Pharmacology Review may also be useful for
collecting data for analysis.
4.4 Methodology of Analysis
The following procedure, categorized by two stages and four steps, is applied to
perform data analysis and hypothesis validation:
Stage 1 (completed at FDA)
Step 1: Generate the hypothesis and define the metrics.
Step 2: Create the data collection instrument from the CDER DFS database and Action
Packages.
Stage 2 (completed at MIT)
Step 3: Display distribution of data points by different complexity indicators,
respectively, in response to a fixed X variable (the Submission Date, SDATE). Then, run
the multiple regression analyses by different groups of route of administration (i.e. the
oral vs. the subcutaneous vs. the inhaled)
Step 4: Validate the hypothesis with the insights acquired by comparing results from the
regression analyses and discuss observations on trends in complexity. When comparing
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the outcomes of the regression analyses, I assess the statistical significance of each
regression equation based on the P-value of the coefficient. The assessment is denoted
by accenting the coefficient in the regression equation with a positive mark ("+") when
statistically significant, as defined in the following table:
Table 4.2 Statistical Significance of Regression Equations
Statistical Significance of Coefficient
Estimate in Regression Equation
If P-value < 0.01 +++ /
If 0.01< P-value < 0.05 ++ / --
If 0.05< P-value < 0.1 + / -
If P-value > 0.1 0
"0" is a zero, meaning not significantly different from zero.
overview of the analysis process is summarized in the following figure:
Hypotheses
Generation
Metric
Definition
Data Collection
Instrument
Creation
Hypotheses
Validation
Multiple
Stage 2 Regression
Analyses
Figure 4.1 Overview of Analysis Process
4.5 Data Collection Instrument
For each of the approved antidiabetics for which complete data were available,
selected relevant information was extracted from the reviews, captured on a data
collection sheet (the data collection instrument), and entered into a database for further
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*Note that
An
Stage 1
analysis. The following table summarizes the data collection instrument designed for use
in this research:
Table 4.3 Data Collection Instrument
NDA SUMMARY PIVOTAL TRIAL SUMMARY
Drug Identification Study Design
1. NDA # 1. Study Name
2. Generic Name 2. Study Features
3. Brand Name
4. Sponsor Name
5. Therapeutic Class
General Reviewing Information Study Structure
1. FDA Reviewing Division 1. Comparator
2. # of Review Cycles 2. Dosages
3. Priority/Standard 3. Dose Frequency
4. Fast Track/Accelerated Subpart H 4. Dose Duration
5. First in Class (Y/N) 5. # of Patients Enrolled
6. Submission Date 6. # of Drop-Outs
7. Approval Date 7. Attrition (%)
Dosage Endpoints
1. Route of Administration 1. Primary
2. Dosage Form 2. Secondary
3. Dosage Strengths
4. Inpatient/Outpatient
Safety Study Size
1. Black Box Warning at Approval # of Total Patients in Pivotal Trials
2. Black Box Warning Ever
3. # of Patients in Safety Database
Study Summary
1. Indications
a. Applied
b. Approved
2. Special Studies
a. Elderly (>65 yrs)
b. Pediatric
c. Cardiac
d. Liver Insufficiency
e. Renal Insufficiency
3. # of Pivotal Trials
a. According to sponsor
b. According to FDA
4. Total Studies in NDA
5. # of Drug/Drug Interaction Studies
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Post-Marketing Commitments
1. Safety
2. Clinical
3. Pediatric
4. Special Population Studies
(Source: Adapted from Dere M.E. et al, Changes in Characteristics of Pivotal Clinical Trials in Support of Approved
New Drug Applications for Antibiotics, 2006)
4.6 Metrics to Observe Changes in Clinical Trial Designs
Supporting NDAs
I define the following twenty-five quantitative variables as the indicators of
complexity to observe in NDAs of the antidiabetics approved by the FDA since the early
1990s. Among the twenty-five indicators, seventeen are related to evaluating efficacy of
a drug, six to evaluating safety, and two are related to more general information (e.g.
Review Time, Total Number of Studies for NDA).
1. Review Time (REVTIME, Month)= Approval Date - Submission Date (SDATE,
Month)
2. Total Number of Studies for NDA (include all studies to establish the safety and
efficacy parameters and as well as the tolerability, pharmacokinetic and
pharmacodynamic parameters of the drug) (NSTUDIES)
3. Total Number of Patients in Safety Database (NSAFETY)
4. Total Number of Special Studies in NDA (NSPECSTD)
5. Number of Special Studies in Elderly Population (NSPELD)
6. Number of Special Studies in Liver Impaired Population (NSPECLIV)
7. Number of Special Studies in Renal Impaired Population (NSPECREN)
8. Total Number of Drug-Drug Interaction Studies in NDA (NINTERST)
9. Number of Indications Proposed by Sponsor (NINDSP)
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10. Number of Indications Approved by FDA (NINDFDA)
11. Number of Pivotal Trials Submitted by Sponsor (NPIVSP)
12. Number of Pivotal Trials for FDA to Approve NDA (NPIVFDA)
13. Number of Patients in Pivotal Trials Submitted by Sponsor (NPATSP)
14. Number of Patients in Pivotal Trials for FDA to Approve NDA (NPATFDA)
15. Patients per Pivotal Trial Submitted by Sponsor = Number of Patients in Pivotal
Trials Submitted by Sponsor / Number of Pivotal Trials Submitted by Sponsor
(AVNPATSP)
16. Patients per Pivotal Trial for FDA to Approve NDA = Number of Patients in Pivotal
Trials for FDA to Approve NDA / Number of Pivotal Trials for FDA to Approve
NDA (AVNPATFDA)
17. Average Number of Patients to Support Each Indication Proposed by Sponsor
Number of Patients in Pivotal Trials Submitted by Sponsor / Number of Indications
Proposed by Sponsor (AVNPINDSP)
18. Average Number of Patients to Support Each Indication Approved by FDA
Number of Patients in Pivotal Trials for FDA to Approve NDA / Number of
Indications Approved by FDA (AVNPINDFDA)
19. Average Number of Pivotal Trials to Support Each Indication Proposed by Sponsor
Number of Pivotal Trials Submitted by Sponsor / Number of Indications Proposed by
Sponsor (AVNTINDSP)
20. Average Number of Pivotal Trials to Support Each Indication Approved by FDA
Number of Pivotal Trials for FDA to Approve NDA / Number of Indications
Approved by FDA (AVNTINDFDA)
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21. Number of Comparators in Pivotal Trials (NARM)
22. Length of Follow-up Period in Pivotal Trials (FOLTM, Days)
23. Number of Primary Endpoints in Pivotal Trials (NPEND)
24. Number of Secondary Endpoints in Pivotal Trials (NSEND)
25. Dose Duration (DOSDUR)
4.7 Results from the Multiple Regression Analyses
The details of the multiple regression analyses by twenty-five indicators are
provided in Appendix B and Appendix C. I summarize results in the following section.
4.8 Observations of Trends
The scope of this thesis focuses on fifteen antidiabetic drugs with submission
dates from 1990, including oral, subcutaneous, and inhaled agents. The observations of
trends in changes of the characteristics of clinical trials referenced in NDAs based on
regression analyses are also summarized in the following table (Note: One drug in my
sample is Exubera, an inhalant that is neither subcutaneous nor oral, and contains insulin.
To preserve confidentiality in the figures that follow, this observation will not be plotted,
even though it is included in the pooled regression):
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Table 4.4 Summary of Trends in Changes of Clinical Trials in Antidiabetic NDAs
by Statistical Significance
Indicator Results
Oral Subcutaneous Pooled
General
1 Review Time RIEVTIME 0 0 0
2 Total Number of Studies for NDA NSTUDIES 0 0 0
Safety-Specific
Total Number of Patients in Safety
3 Database NSAFETY 0 0 0
4 Total Number of Special Studies in NDA NSPECSTD ++ 0 0
Number of Special Studies in Elderly
5 Population NSPELD + 0 0
Number of Special Studies in Liver
6 Impaired Population NSPECLIV 0 0 0
Number of Special Studies in Renal
7 Impaired Population SPECREN 0 0 --
Total Number of Drug-drug Interaction
8 Studies in NDA NINTERST 0 0 0
Efficacy-Specific
Number of Indications Proposed by
9 Sponsor NINDSP 0 ++ 0
10 Number of Indications Approved by FDA NINDFDA 0 ++ 0
Number of Pivotal Trials Submitted by
11 Sponsor NPIVSP 0 0 0
Number of Pivotal Trials for FDA to
12 Approve NDA NPIVFDA + 0 0
Number of Patients in Pivotal Trials
13 Submitted by Sponsor NPATSP 0 0 0
Number of Patients in Pivotal Trials for
14 FDA to Approve NDA NPATFDA +++ 0 0
Patients per Pivotal Trial Submitted by
15 Sponsor AVNPATSP 0 0 0
Patients per Pivotal Trial for FDA to
16 Approve NDA AVNPATFDA 0 0 0
Average Number of Patients to Support
17 Each Indication Proposed by Sponsor AVNPINDSP 0 0 0
Average Number of Patients to Support
18 Each Indication Approved by FDA AVNPINDFDA +++ --- 0
Average Number of Pivotal Trials to
Support Each Indication Proposed by
19 Sponsor AVNTINDSP 0 0 0
Average Number of Pivotal Trials to
Support Each Indication Approved by
20 FDA AVNTINDFDA + --- 0
21 Number of Arms in Pivotal Trials NARM 0 0 0
Length of Follow-up Period in Pivotal
22 Trials FOLTM + 0 0
Number of Primary Endpoints in Pivotal
23 Trials NPEND 0 - -
Number of Secondary Endpoints in
24 Pivotal Trials NSEND 0 0 0
25 Dose Duration DOSDUR 0 0 0
* "+++" meaning a positive trend with statistical significance (with p-value < 0.01); "---" meaning a negative trend
with statistical significance (with p-value < 0.01)
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* "++" meaning a positive pattern trending to statistical significance (with 0.01 < p-value < 0.05) ; "--" meaning a
negative pattern trending to statistical significance (with 0.01 < p-value < 0.05)
* "+" meaning a positive pattern with slight trending to statistical significance (with 0.05 < p-value < 0.1);
"meaning a negative pattern with slight trending to statistical significance (with 0.05 < p-value < 0.1)
* "0" meaning not significantly different from zero
4.8.1 Oral vs. Subcutaneous
Among the twenty-five sets of analyses by different indicators, the oral group
showed an increasing trend in fourteen indicators while the subcutaneous group only
showed an increasing trend in eight. In the analyses, I often observed quite different--
even opposite--trends in the two groups when grouping the antidiabetics by route of
administration, for instance, in the following six indicators: Number of Pivotal Trials for
FDA to Approve NDA (NPIVFDA), Number of Patients in Pivotal Trials for FDA to
Approve NDA (NPATFDA), Average Number of Patients to Support Each Indication
Proposed by Sponsor (AVNPINDSP), Average Number of Patients to Support Each
Indication Approved by FDA (AVNPINDFDA), Average Number of Pivotal Trials to
Support Each Indication Proposed by Sponsor (AVNTINDSP), and Average Number of
Pivotal Trials to Support Each Indication Approved by FDA (AVNTINDFDA). Due to
the opposite phenomena I observed in each group, they often cancelled out the patterns
and resulted in no obvious composite trend when I pooled all agents for analysis. These
results are presented in the following figures:
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The regression equations:
For the oral agents:
NPATFDA"+= 1011.1961*
+ 20.425 SDATE..
(R2= 0.963; P-value <0.0001)
For the subcutaneous agents:
NPATFDA =
2878.582 - 8.173 SDATE
(R2= 0.117; -P-value = 0.507)
For all agents (Pooled):
NPATFDA =
1531.686 + 7.877 SDATE
(2 = 0.166; P-value = 0.132)
(For details, see Appendix C)
Figure 4.3 Regression Analysis of "Number of Patients in Pivotal Trials for FDA to
Approve NDA" By "Submission Date"
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The regression equations:
For the oral agents:
NPIVFDA+ =
4.377+ + 0.028 SDATE+
(R2 = 0.415; P-value = 0.276)
For the subcutaneous agents:
NPIVFDA =
7.593 - 0.044 SDATE
(R2= 0.488; P-value = 0.123)
For all agents (Pooled):
NPIVFDA =
5.067 + 0.000002 SDATE
(R2 < 0.001; P-value = 0.999)
(For details, see Appendix C)
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Figure 4.4 Regression Analysis of "Average Number of Patients to Support Each
Indication Applied by Sponsor" By "Submission Date"
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Figure 4.5 Regression Analysis of "Average Number of Patients to Support Each
Indication Approved by FDA" By "Submission Date"
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The regression equations:
For the oral agents:
AVNPINDFDA**=
505.598*
+ 10.212 SDATE*
(R2= 0.963; P-value <0.0001)
For the subcutaneous agents:
AVNPINDFDA~-=
3264.087-~
- 20.360 SDATE-
(R2= 0.847; P-value = 0.009)
For all agents (Pooled):
AVNPINDFDA =
1164.924 + 0.958 SDATE
(R2 = 0.004; P-value = 0.827)
(For details, see Appendix C)
The regression equations:
For the oral agents:
AVNPINDSP =
898.451 + 6.545 SDATE
(R2 = 0.293; P-value = 0.166)
For the subcutaneous agents:
AVNPINDSP =
2879.571 - 6.954 SDATE
(R2= 0.199; P-value = 0.375)
For all agents (Pooled):
AVNPINDSP =
1443.915 + 2.453 SDATE
(R2= 0.019; P-value = 0.628)
(For details, see Appendix C)
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Figure 4.6 Regression Analysis of "Average Number of Pivotal Trials to Support
Each Indication Applied by Sponsor" By "Submission Date"
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The regression equations:
For the oral agents:
AVNTINDFDA+ =
2.189+ + 0.014 SDATE+
(R = 0.415; P-value = 0.085)
For the subcutaneous agents:
AVNTINDFDA-- = 8.129~~
- 0.063 SDATE-
(R2= 0.860; P-value = 0.008)
For all agents (Pooled):
AVNTINDFDA =
3.508 - 0.009 SDATE
(R2= 0.059; P-value = 0.381)
(For details, see Appendix C)
Figure 4.7 Regression Analysis of "Average Number of Pivotal Trials to Support
Each Indication Approved by FDA" By "Submission Date"
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The regression equations:
For the oral agents:
AVNTINDSP =
2.505 + 0.009 SDATE
(R2 = 0.193; P-value = 0.276)
For the subcutaneous agents:
AVNTINDSP =
7.238 - 0.034 SDATE
(R2= 0.338; P-value = 0.226)
For all agents (Pooled):
AVNTINDSP =
3.667 - 0.003 SDATE
(W2= 0.005; P-value = 0.794)
(For details, see Appendix C)
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In the subset of the seventeen efficacy-specific indicators among the total twenty-
five indicators, first, I observed an increasing trend in the following five indicators for
both groups: Number of Pivotal Trials Submitted by Sponsor (NPIVSP), Number of
Patients in Pivotal Trials Submitted by Sponsor (NPATSP), Patients per Pivotal Trial
Submitted by Sponsor (AVNPATSP), Patients per Pivotal Trial for FDA to Approve
NDA (AVNPATFDA), and Length of Follow-up Period in Pivotal Trials (FOLTM).
These results are presented in the following figures:
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The regression equations:
For the oral agents:
NPIVSP =
5.010 + 0.018 SDATE
(R2= 0.193; P-value = 0.276)
For the subcutaneous agents:
NPIVSP =
5.253 + 0.016 SDATE
(R2= 0.035; P-value = 0.723)
For all agents (Pooled):
NPIVSP =
5.260 + 0.012 SDATE
(R2= 0.059; P-value = 0.383)
(For details, see Appendix C)
Figure 4.8 Regression Analysis of "Number of Pivotal Trials Submitted by Sponsor"
By "Submission Date"
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Figure 4.9 Regression Analysis of "Number of Patients in Pivotal Trials Submitted
by Sponsor" By "Submission Date"
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The regression equations:
For the oral agents:
AVNPATSP =
375.714 + 0.791 SDATE
(R2= 0.105; P-value = 0.434)
For the subcutaneous agents:
AVNPATSP =
430.830 + 1.638 SDATE
(R2= 0.211; P-value = 0.360)
For all agents (Pooled):
AVNPATSP =
412.079 + 0.749 SDATE
(W2= 0.059; P-value = 0.383)
(For details, see Appendix C)
Figure 4.10 Regression Analysis of "Patients per Pivotal Trials Submitted by
Sponsor" By "Submission Date"
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The regression equations:
For the oral agents:
NPATSP =
1796.902 + 13.090 SDATE
(2= 0.293; P-value = 0.166)
For the subcutaneous agents:
NPATSP =
1806.760 + 20.203 SDATE
(R2 = 0.373; P-value = 0.198)
For all agents (Pooled):
NPATSP =
2021.892 + 10.795 SDATE
(R2= 0.164; P-value = 0.134)
(For details, see Appendix C)
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Figure 4.11 Regression Analysis of "Patients per Pivotal Trials for FDA to Approve
NDA" By "Submission Date"
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The regression equations:
For the oral agents:
FOLTM+ =
51.753++ 1.966 SDATE+
(R2 = 0.403; P-value = 0.09 1)
For the subcutaneous agents:
FOLTM =
-54.439 + 1.091 SDATE
(R2 = 0.290; P-value = 0.270)
For all agents (Pooled):
FOLTM =
46.527 + 0.666 SDATE
(R2 = 0.058; P-value = 0.387)
(For details, see Appendix C)
Figure 4.12 Regression Analysis of "Length of Follow-up Period in Pivotal Trials"
By "Submission Date"
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The regression equations:
For the oral agents:
AVNPATFDA =
304.756 + 1.181 SDATE
2(R = 0.201; P-value = 0.265)
For the subcutaneous agents:
AVNPATFDA =
400.352 + 2.305 SDATE
(R = 0.252; P-value = 0.3 10)
For all agents (Pooled):
AVNPATFDA =
351.284 + 1.379 SDATE
(R = 0.131; P-value = 0.184)
(For details, see Appendix C)
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In the following three indicators: Review Time (REVTIME), Number of
Indications Proposed by Sponsor (NINDSP), and Number of Indications Approved by
FDA (NINDFDA), only the subcutaneous group showed an increasing trend while the
oral group showed no trend or even a decreasing trend. These results are presented in the
following figures:
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The regression equations:
For the oral agents:
REVTIME =
13.453 - 0.033 SDATE
(R2 = 0.186; P-value = 0.286)
For the subcutaneous agents:
REVTIME =
16.713 + 0.094 SDATE
(R2 = 0.050; P-value = 0.672)
For all agents (Pooled):
REVTIME =
14.531 + 0.035 SDATE
(R2 = 0.022; P-value = 0.600)
(For details, see Appendix C)
Figure 4.13 Regression Analysis of "Review Time" By "Submission Date"
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Figure 4.14 Regression Analysis of "Number of Indications Applied by Sponsor" By
"Submission Date"
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Figure 4.15 Regression Analysis of "Number of Indications Approved by FDA" By
"Submission Date"
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The regression equations:
For the oral agents:
NINDSP = 2
For the subcutaneous agents:
NINDSP* =
0.518+ + 0.013 SDATE+* (R2
= 0.716; P-value = 0.034)
For all agents (Pooled):
NINDSP =
1.531 + 0.006 SDATE
(12= 0.167; P-value = 0.13 1)
(For details, see Appendix C)
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The regression equations:
For the oral agents:
NINDFDA = 2
For the subcutaneous agents:
NINDFDA+* =
0.518+ + 0.013 SDATE++
(R2= 0.716; P-value = 0.034)
For all agents (Pooled):
NINDFDA =
1.531 + 0.006 SDATE
(R2= 0.167; P-value = 0.131)
(For details, see Appendix C)
4.5
41
9 M
-f XX
In the subset of safety-specific indicators, I observed an increasing trend in the
oral group with the following three indicators: Total Number of Special Studies in NDA
(NSPECSTD), Number of Special Studies in Elderly Population (NSPELD), and Number
of Special Studies in Liver Impaired Population (NSPELIV). No obvious trend was
observed in the subcutaneous group. These results are presented in the following figures:
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Figure 4.16 Regression Analysis of "Total Number of
"Submission Date"
The regression equations:
For the oral agents:
NSPECSTD* =
2.411" + 0.030 SDATE"
(R2= 0.515; P-value = 0.045)
For the subcutaneous agents:
NSPECSTD=
1.045 - 0.003 SDATE
(R2= 0.010; P-value = 0.848)
For all agents (Pooled):
NSPECSTD =
2.345 + 0.002 SDATE
(R2= 0.001; P-value = 0.889)
(For details, see Appendix C)
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Figure 4.17 Regression Analysis of "Number of Special Studies in Elderly
Population" By "Submission Date"
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Figure 4.18 Regression Analysis of "Number of Special Studies in Liver Impaired
Population" By "Submission Date"
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The regression equations:
For the oral agents:
NSPECLIV =
0.253 + 0.003 SDATE
(2 = 0.055; P-value = 0.577)
For the subcutaneous agents:
NSPECLIV = 0
For all agents (Pooled):
NSPECLIV =
0.225 - 0.0003 SDATE
(R2 = 0.002; P-value = 0.879)
(For details, see Appendix C)
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The regression equations:
For the oral agents:
NSPELD =
0.360+ + 0.016 SDATE+
(R2= 0.373; P-value = 0.108)
For the subcutaneous agents:
NSPELD =0
For all agents (Pooled):
NSPELD =
0.310 + 0.005 SDATE
(R2= 0.060; P-value = 0.381)
(For details, see Appendix C)
In only two efficacy-specific indicators: Number of Primary Endpoints in Pivotal
Trials (NPEND) and Number of Secondary Endpoints in Pivotal Trials (NSEND), both
related to selection of endpoints to evaluate the patient response, I observed a decreasing
trend in both groups. These results are shown in the following figures:
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The regression equations:
For the oral agents:
NPEND =
1.725 - 0.005 SDATE
(2= 0.059; P-value = 0.564)
For the subcutaneous agents:
NPEND-=
3.533~ - 0.026 SDATE-
(R2= 0.614; P-value = 0.065)
For all agents (Pooled):
NPEND =
2.073~ - 0.009 SDATE-
(R2 = 0.192; P-value = 0.103)
(For details, see Appendix C)
Figure 4.19 Regression Analysis of "Number of Primary Endpoints in Pivotal
Trials" By "Submission Date"
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Figure 4.20 Regression Analysis of "Number of Secondary Endpoints in Pivotal
Trials" By "Submission Date"
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The regression equations:
For the oral agents:
NSEND =
4.674 - 0.022 SDATE
(R2 = 0.142; P-value = 0.358)
For the subcutaneous agents:
NSEND =
4.369 - 0.028 SDATE
(R = 0.499; P-value = 0.117)
For all agents (Pooled):
NSEND =
4.295 - 0.018 SDATE
(R2 = 0.128; P-value = 0.191)
(For details, see Appendix C)
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4.8.2 FDA vs. Sponsor
Another interesting finding in my research is that the indicators related to FDA's
evaluation of the data in the NDAs showed more statistical significance when compared
to those related to the sponsor's NDA submission. Here, I summarize these results in
Table 4.5.
Table 4.5 Statistical Significance of Indicators between the FDA and the Sponsor
Indicators I Results
Oral Subcutaneous Pooled
FDA's Evaluation Related
Number of Indications NINDFDA 0 + 0
Number of Pivotal Trials NPIVFDA + 0 0
Number of Patients in Pivotal Trials NPATFDA +++ 0 0
Patients per Pivotal Trial AVNPATFDA 0 0 0
Average Number of Patients to Support
Each Indication AVNPINDFDA +++ --- 0
Average Number of Pivotal Trials to
Support Each Indication AVNTINDFDA + 0
Sponsor's Submission Related
Number of Indications NINDSP 0 ++ 0
Number of Pivotal Trials NPIVSP 0 0 0
Number of Patients in Pivotal Trials NPATSP 0 0 0
Patients per Pivotal Trial AVNPATSP 0 0 0
Average Number of Patients to Support
Each Indication AVNPINDSP 0 0 0
Average Number of Pivotal Trials to
Support Each Indication AVNTINDSP 0 0 0
* "+++" meaning a positive trend with statistical significance (with p-value < 0.01); "---
"meaning a negative trend with statistical significance (with p-value < 0.01)
* "++" meaning a positive pattern trending to statistical significance (with 0.01 < p-value <
0.05) ; "--" meaning a negative pattern trending to statistical significance (with 0.01 < p-value <
0.05)
* "+" meaning a positive pattern with slight trending to statistical significance (with 0.05 < p-
value < 0.1); "-" meaning a negative pattern with slight trending to statistical significance (with
0.05 < p-value < 0.1)
* "0" meaning not significantly different from zero
I also present the results related to the FDA's evaluation, which show more
statistical significance in the trend, in the figures below:
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4.5 The regression equations:
4-
For the oral agents:
I. NINDFDA = 2U-
For the subcutaneous agents:
02.5 NINDFDA* =
$c 2- 90.518++ +0.013 SDATE**
(R2= 0.716; P-value = 0.034)
- 1.5-
1 X XX For all agents (Pooled):
05 NINDFDA =
01/1993 01/1997 01/2001 01/2005 1.531 + 0.006 SDATE(R2 = 0.167; P-value = 0.131)
Submission Date (For details, see Appendix C)
- Linear Fit Route of Administration=="Oral"
-Linear Fit Route of Administration=="Subcutaneous"
- Linear Fit Route of Administration=="Pooled"
Figure 4.21 Regression Analysis of "Number of Indications Approved by FDA" By
"Submission Date"
10 The regression equations:
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8- OX For the oral agents:
NPIVFDA*=
7- 4.377k + 0.028 SDATE+
( 6- X(= 0.415; P-value = 0.276)
I5-
"5 _For the subcutaneous agents:
. NPIVFDA =
-3-XX X 7.593 - 0.044 SDATE
2- o X (R2 = 0.488; P-value = 0.123)
1 -- - - Fralaet(Pod)
01/1993 01/1997 01/2001 01/2005 For all agents (Pooled):
NPIVFDA =
5.067 + 0.000002 SDATE
Submission Date (R2< 0.001; P-value = 0.999)
- Linear Fit Route of Administration=="OraI" (For details, see Appendix C)
-Linear Fit Route of Administration=="Subcutaneous"
- Linear Fit Route of Administration=="Pooled"
Figure 4.22 Regression Analysis of "Number of Pivotal Trials for FDA to Approve
NDA" By "Submission Date"
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Figure 4.23 Regression Analysis of "Number of Patients in Pivotal Trials for FDA to
Approve NDA" By "Submission Date"
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The regression equations:
For the oral agents:
AVNPATFDA =
304.756 + 1.181 SDATE
(R2= 0.201; P-value = 0.265).
For the subcutaneous agents:
AVNPATFDA =
400.352 + 2.305 SDATE
(R2= 0.252; P-value = 0.3 10)
For all agents (Pooled):
AVNPATFDA =
351.284 + 1.379 SDATE
(R2 = 0.131; P-value = 0.184)
(For details, see Appendix C)
Figure 4.24 Regression Analysis of "Patients per Pivotal Trials for FDA to Approve
NDA" By "Submission Date"
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I , The regression equations:
For the oral agents:
NPATFDA.*= 1011.196..
+ 20.425 SDATE..
(R2= 0.963; P-value <0.0001)
For the subcutaneous agents:
NPATFDA =
2878.582 - 8.173 SDATE
(R2= 0.117; P-value = 0.507)
For all agents (Pooled):
NPATFDA =
1531.686 + 7.877 SDATE
(R2 = 0.166; P-value = 0.132)
(For details, see Appendix C)
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Figure 4.25 Regression Analysis of "Average Number
Indication Approved by FDA" By "Submission Date"
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of Patients to Support Each
The regression equations:
For the oral agents:
AVNTINDFDA+ =
2.189+ + 0.014 SDATE+
(R2= 0.415; P-value = 0.085)
For the subcutaneous agents:
AVNTINDFDA = 8.129~
- 0.063 SDATE~
(R2 = 0.860; P-value = 0.008)
For all agents (Pooled):
AVNTINDFDA =
3.508 - 0.009 SDATE
(R2 = 0.059; P-value = 0.38 1)
(For details, see Appendix C)
I I.
Figure 4.26 Regression Analysis of "Average Number of Pivotal Trials to Support
Each Indication Approved by FDA" By "Submission Date"
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The regression equations:
For the oral agents:
AVNPINDFDA **=
505.598..
+ 10.212 SDATE
(R2 = 0.963; P-value <0.000 1)
For the subcutaneous agents:
AVNPINDFDA~ =
3264.087~
- 20.360 SDATE~~
(R2 = 0.847; P-value = 0.009)
For all agents (Pooled):
AVNPINDFDA =
1164.924 + 0.958 SDATE
(R2 = 0.004; P-value = 0.827)
(For details, see Appendix C)
4.9 Post-marketing Commitments
In this section, I provide more qualitative analyses regarding post-marketing
commitments in the antidiabetic NDAs I study.
When comparing the post-marketing commitments (PMCs) of the oral
antihyperglycemic agents, there appears to be an increasing trend in the PMC of safety
and pediatric studies, as summarized in the following table and figure:
Table 4.6 Summary of Post-marketing Commitments for Oral Antihyperglycemic
Agents
Oral Antihyperglycemic Agents
Glucophage Amaryl Precose Glyset Prandin Avandia Starlix J Januvia
Safety 0 0 0 0 1 1 0 1
Clinical 1 0 0 0 0 0 0 1
Pediatric 0 0 0 0 0 0 1 1
Special Population
Studies 0 0 0 0 1 0 0 0
Others (Chemistry,
Manufacturing and
Controls) 0 0 0 0 0 0 0 0
Total PMCs 1 0 0 0 2 1 1 3
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0Oral antihyperglycemic Agents
Figure 4.27 Post-marketing Commitments of Oral Antihyperglycemic Agents
Overall in the subcutaneous group, there appears to be a decreasing trend in the
total number of PMCs, despite the fact that the pediatric study is often requested by FDA
as a PMC. This is because insulin is considered as standard care in treating type 1
diabetes, which has its onset in children and adolescents. However, only the inhaled
insulin has more PMCs due to safety concerns. These results are summarized in the
following table and figure:
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Table 4.7 Summary of Post-marketing Commitments for Insulin Agents
Insulin Agents
Subcutaneous I nhaled
Humalog Novolog Lantus I Symlin Levemir Apidra Exubera
Safety 0 0 0 1 0 0 1
Clinical 1 0 1 1 0 0 1
Pediatric 1 1 0 1 1 1 1
Special Population Studies 1 1 0 0 0 0 0
Others (Chemistry,
Manufacturing and Controls) 1 0 1 0 0 0 1
Total PMCs 4 2 2 3 1 1 4
PMCs of Insulin Agents
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Figure 4.28 Post-marketing Commitments of Insulin Agents
4.10 Summary of Observations
Comparing the characteristics of the clinical trials in the 15 antidiabetic NDAs
approved by the FDA in the early 1990s, I observe different trends in these two groups--
the oral glucose-lowering and subcutaneous insulin. Among the selected 25 indicators,
seven of them exhibit increasing complexity in the oral group; two others suggest
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increasing complexity in the subcutaneous group. More surprisingly, three indicators
suggest an otherwise decreasing trend of complexity.
Regarding to the safety evaluation of the oral agent group, I observe an increasing
trend in the total number of special studies for NDA, particularly in the elderly
population. With respect to the evaluation of a drug's efficacy, four indicators suggest an
increasing complexity: the average number of patients for FDA to approve each
indication, the average number of pivotal trials for FDA to approve each indication, total
number of pivotal trials for FDA to approve NDA, and total number of patients in pivotal
trials. In addition, I observe an increasing trend in the length of follow-up period of
pivotal trials in the design of clinical trials.
In the subcutaneous insulin group, two indicators are found to exhibit an increasing
trend of complexity: the number of indications proposed by the sponsor and number of
indications approved by FDA. On the other hand, this group in fact exhibits a trend of
decreasing complexity in the following three indicators: the average number of patients to
support each indication approved by FDA, the average number of pivotal trials to support
each indication approved by FDA, and decreasing number of primary endpoints in
pivotal trials.
These results are summarized in the following table:
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Table 4.8 Summary of Complexity Changes in Antidiabetics
gpents Oral Antiglycemics Subcutaneous Insulin
* Total Number of Special * Number of Indications
Studies in NDA Proposed by Sponsor
" Number of Special Studies in * Number of Indications
Elderly Population Approved by FDA
" Average Number of Patients
for FDA to Approve Each
Indication
Increasing 0 Average Number of Pivotal
Complexity Trials for FDA to Approve
Each Indication
* Number of Pivotal Trials for
FDA to Approve NDA
* Number of Patients in pivotal
trials
" Length of Follow-up Period in
Pivotal Trials
" Average Number of Patients
for FDA to Approve Each
Indication
Decreasing 0 0 Average Number of Pivotal
Complexity Trials for FDA to Approve
Each Indication
* Number of Primary Endpoints
in Pivotal Trials
Based on the observations mentioned above, nine out of the twenty-five selected
indicators are found to exhibit an increasing trend of complexity. The trend is more
pronounced in the oral antiglycemics group (seven indicators) than the subcutaneous group
(two indicators). While there is no obvious overall tendency in the Total Number of
Studies for NDA over time, the aforementioned observations suggest a complexity
increase in the clinical trials referenced in the NDAs of antidiabetics since the early
1990s, which may have correlated to the rising R&D costs in the pharmaceutical industry.
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5 DISCUSSION OF POLICY ISSUES
5.1 Debate of ADA-1997 and WHO-1999 Diagnostic Criteria
Changes in the threshold levels for blood glucose have begun to identify more
people with diabetes and changes in the definition of pre-diabetes have identified more
people who are likely to develop type 2 diabetes. The advocacy by WHO in using FPG
in the ADA- 1997 criteria remains controversial. Particularly, it remains uncertain
whether these criteria will increase or decrease the measured prevalence of diabetes.
While some studies 58'59 demonstrated the benefits of using the ADA- 1997 criteria,
including the simplicity of obtaining a FPG value and decreased undiagnosed cases
among subjects with low FPG, these same studies or other studies60 also addressed
concerns. One concern was that cases diagnosed by the ADA-1997 criteria are more
likely to have hyperglycemia with higher HbA 1 c values and a greater proportion of
values above the normal range. Also, these cases are more likely to have increased
undiagnosed cases due to omission of the 2-h PG and underestimate glucose
abnormalities more with increasing age. In another study61, research showed that the
WHO- 1999 criteria are more likely to diagnose diabetes in lean individuals while the
ADA-1997 criteria are more likely to identify middle aged obese individuals. This result,
however, raised the question: should the criteria adopted in designing clinical trials
depend on the phenotypes of subjects?
I summarized the diagnostic criteria used as the patient inclusion/exclusion
criteria for the clinical trials referenced in the antidiabetic NDAs in my thesis (see
Section 4). Interestingly, I observed a trend of adopting the WHO- 1999 criteria (which
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accommodates the ADA- 1997 Criteria) in the oral group and a trend of more adoption of
HbA 1 c as part of the inclusion/exclusion criteria in the insulin group since 1999 (see the
comparison in Table
Table 5.1 Summary
Inclusion/Exclusion
5.1).
of the Diagnostic Criteria Used in the Patient
Criteria in Clinical Trials for Antid iabetic NDAs
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Submission Drug Generic Trade Group by Sponsor's Diagnostic
Date Class Name Name Rot f Sosr Oii f CriteriaAdministration Country
1993 Biguanide metformin Glucophage Oral Lipha France WHO-85(EU)
1994 SU glimepiride Amaryl Oral HMR Germany WHO-85(EU)
1994 AGI acarbose Precose Oral Bayer Germany DiagnosedPharms (EU) > 6 months
Diagnosed
1995 AGI meglitol Glyset Oral Bayer Germany >6 months;(EU) HbA1c
Novo Diagnosed
1997 Meglitinide repaglinide Prandin Oral Nordisk Denmark >3 months;
Inc (EU) HbAlc
1998 TZD rosiglitazone Avandia Oral SB us WHO-85Pharmaco
1999 Meglitinide nateglinide Starlix Oral Novartis (werland WHO-85;
2005 DPP-4i Sitagliptin Januvia Oral rck Co US HO-99;
1995 Insulin lispro Humalog Subcutaneous Lilly US Diagnosed
Novo
1998 Insulin aspartate Novolog Subcutaneous Nordisk eUnmark Diagnosed
Inc (U 2mnh
Aventis France Diagnosed
1999 Insulin glargine Lantus Subcutaneous Pharms (EU) Type 1;
HbAlc
Glucagon Diagnosed2000 Lowering pramlinitide Symlin Subcutaneous Amylin US Type 1;
HbA1c
Novo Diagnosed
2002 Insulin detemir Levemir Subcutaneous Nordisk eUnmark Type 1;
Inc HbAlc
2003 Insulin glulisine Apidra Subcutaneous Aventis France Diagnosed;
insulin
2004 Insulin recombinant Exubera Inhalation Pfizer US Diagnosed;
human 1b1lc
I consider this phenomenon--more prevalent adoption of WHO- 1999 (which was
revised from WHO-1985 by incorporating ADA-1997)--as an effort of regulatory
harmonization (seeking regulatory convergence). Since 1980s, the international
community started harmonizing regulatory requirements for the pharmaceutical industry.
In 1990, the International Conference on Harmonization of Technical Requirements for
Registration of Pharmaceuticals for Human Use (ICH), which brings together the
regulatory authorities and pharmaceutical firms of Europe, Japan, and US to discuss
scientific and technical aspects of pharmaceutical product registration, was established.
A recent study, which concluded an increasing trend in the globalization of clinical
trials 62 , also shed some light on the importance of regulatory harmonization in today's
drug development. In the pharmaceutical industry, firms' investments are with
multinational asset specificity (meaning that assets are specific to international
transactions). This creates incentives for firms to push for common regulations across
borders since regulatory diversity may inhibit effective use of assets and increase
transaction costs. These investments include human, dedicated, physical, site, and brand
63specificity
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5.2 R&D of the Pharmaceutical Industry
The pharmaceutical industry--considered an R&D-intensive industry--spends
more money on research and development, relative to its sales revenue, than any other
industry in the US. In addition, the industry's real (inflation-adjusted) spending on R&D
has grown between threefold and sixfold over the past 25 years. This increase has been
closely matched by growth in drug sales, according to an estimate by the Congressional
Budget Office in a report released in October 200664. However, there has been little
change in the number of innovative new drugs approved for use each year, even though
the federal government has streamlined its drug-approval process (PDUFA, see
Appendix D). This has generated concern over whether the innovative performance in
this industry has declined and what drivers are contributing to this trend.
5.2.1 R&D Intensity
The pharmaceutical industry is one of the most research-intensive industries in the
US. Pharmaceutical firms invest as much as five times more in R&D, relative to their
65sales, than the average US manufacturing firm . Over the past 25 years, the R&D
intensity of the industry (defined as the ratio of R&D spending to total sales revenue) has
grown by about 50 percent (see Figure 5.1).
Interestingly, the pattern of the growth in the industry's R&D intensity does not
quite match the pattern of the growth in the industry's R&D spending (see Figure 5.2).
According to the data from PhRMA66 , while the industry's R&D spending has soared
since 1980s, the industry's R&D intensity reached the high of more than 20 percent in
1990s and has hovered around 18 percent since then.
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5.2.2 Assessment of R&D Performance
According to the estimate in the report 67 by the Congressional Budget Office,
total spending on health-related R&D by the drug industry and the federal government
has tripled since 1990 in real terms. However, the number of innovative new drugs
approved by FDA each year has not shown a comparable upward trend. Thus, by
defining the number of drugs approved per dollar of R&D as a measurement of R&D
performance, the report concludes that the innovative performance of the industry
appears to have declined68.
5.2.3 Costs of R&D
The average success rate for new molecular entities (NMEs) illustrates how
relatively few drugs survive the clinical-trial process (see Figure 5.3 and 5.4).
- Stage 1
Drug Discovery
Stage 2
Pre-Clinical
Stage 3
Clinical Trials
Stage 4
FDA Review
6.5 Years 6 Years
Figure 5.3 An Overview of a Drug Pipeline (Source: Adapted from www.innovation.org)
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Figure 5.4 Percentage of New Molecular Entities Entering Each Phase of Clinical
Trials (Source: Generated from the DHG Study, The Price of Innovation: New Estimates of Drug Development Costs)
According to the report by PhRMA69, its members' R&D costs in the preclinical
phase and Phase III after entering the clinical stage account for more than half of R&D
costs in drug discovery and development (shown in Figure 5.5).
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Figure 5.5 Share of R&D Costs of PhRMA Members by Research Phases
(Source: Generated from PhRMA, Pharmaceutical Industry Profile 2006)
A frequently cited study by Joseph DiMasi, Ronald Hansen, and Henry Grawski
(DHG study) 70 estimated that the average cost of successfully developing an NME,
including R&D spending on filed drug projects, was $802 million in 2000. This estimate
included the direct costs and opportunity costs (the costs associated with keeping capital
tied up in a specific drug development project for a given period; in other words, the
foregone interest or earnings that a company might have gained from investing its capital
in other ways). A breakdown of this estimated figure is shown in Table 5.2 and Figure
5.6.
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Table 5.2 Estimate of Average R&D Costs and Times for Successfully Developed
New Molecular Entities Based on DHG Study
Average Length of Research Phase
Clinical Trials and FDA
Preclinical Phase Approval Total
(4.3 years) (7.5 years) (11.8 years)
R&D Costs (in Millions of
2000 dollars)
Direct Costs 121 282 403
Opportunity Costs 214 185 399
Total Costs 335 467 802
Figure 5.6 Changes in Composition of R&D Costs by Different Research Phases
5.2.4 Drivers for Rising R&D Costs
Various surveys conducted between 1976 and 2000 suggest that the average
amount that surveyed firms reported spending on R&D of NMEs, during that period,
increased nearly sixfold in real term (inflation-adjusted) 71. This trend is summarized in
the figure below.
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Figure 5.7 Estimates of Growth in Average R&D Costs in the Drug Industry
(Source: Generated based on CBO, "A CBO Study-Research and Development in the Pharmaceutical Industry")
Several factors have been mentioned in the DHG study as drivers for the trend of
rising R&D costs in the pharmaceutical industry, including:
. Higher Failure Rate: An increase in the percentage of drug projects that fail in
clinical trials;
. Changes in Clinical Trials: A trend toward bigger and lengthier clinical trials as
well as possible rise in the number of trials that firms are conducting (including trials
for marketing purposes, such as to differentiate a product from its competitors);
. Changes in the Types of Drugs Being Developed: A shift in the types of drugs that
companies work on toward those intended to treat chronic and degenerative disease;
. Scientific Advances: Advances in the research technology and in the scientific
opportunities facing the pharmaceutical industry, including the increased
commercialization of basic research, as firms more often pay for access to basic
89
research findings that in earlier years might have been freely available, as well as
longer average time that drugs spend in preclinical research.
Since the thrust of my research is to examine if there are changes in
characteristics of the clinical trials referenced in NDAs; secondarily to observe if these
changes have generally been consistent with the trend of rising costs and declining
performance in R&D in the pharmaceutical industry, I thus further discuss the factor of
"changes in clinical trials" here.
Two reasons have been proposed as to why the changes of clinical trials have
been contributing to the rising costs72 . First of all, several of studies have indicated that
the trend of the increasing size and duration of clinical trials has resulted in the growth of
R&D costs. In one study, the researcher estimates that the average number of people per
trial grew by 7.5 percent annually, from 2,300 in 1980s to more than 5,600 by the early
200s73 . The other study shows that the average length of the clinical trial phase
increased by 27 percent over the 1980s and then declined by four percent over the
1990s71.
The second reason is the intention of marketing and product differentiation.
Companies may be undertaking more clinical trials now than in the past, performing
head-to-head trials (trials designed to compare a drug with other drugs rather than a
placebo) to prove a drug's non-inferiority7 5 , or, in some cases, even its superiority. In
some cases, a firm may sponsor clinical trials whose primary purpose is to familiarize
participating doctors with the company's new drugs; such trials may not even be intended
to be scientifically rigorous76. A recent study concludes that doctors, who conduct
clinical trials sponsored by a pharmaceutical company, subsequently increase their
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subscription frequency of the drug from the sponsoring firm77 . In other cases, firms may
face pressure from health insurers to demonstrate their drugs' superiority with scientific
rigor as a condition of being included in insurers' formularies of the preferred drugs.
Such tests, establishing a drug's superiority to available substitutes, also allow firms to
set higher prices7 8 . However, the quality of differences between approved drugs are
likely to be smaller than differences between a drug and a placebo, so showing that the
differences with clinical and statistical significance may require larger and more costly
clinical trials.
5.3 Applying System thinking in Diabetes Management
A chronic disease, diabetes, similar to other dynamically complex problems, is
characterized by long delays between causes and effects. The public effort to address
such complexity is characterized by multiple concurrent goals that may conflict with one
another. For example, although the original goal of policy planners is to reduce the
diabetes prevalence and the consequent deaths due to its complications, the fact is that
fewer deaths would lead to an otherwise increased patient population, and thus the
prevalence. Given such interconnections, a satisfactory solution will be found not in
focusing on one single aspect of the overall health system--such as detection, or risk
79factor reduction--but rather in addressing all major components together as a system
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5.3.1 System Dynamics Approach
(1) Dynamic Complexity
A general definition of complexity is in terms of the number of components or
possible states in a system. The "dynamic complexity" refers to the often
counterintuitive behavior of complex systems that arises from the interactions of the
agents over time 0 .
(2) Characteristics of Complex Systems
The following are the characteristics of the complex systems:
* Constantly changing;
" Tightly coupled;
" Governed by feedback;
" Nonlinear;
* History-dependent;
* Self-organizing;
* Adaptive and evolving;
* Characterized by trade-offs;
" Counterintuitive; and
* Policy Resistant.
(3) Challenges in Decision-Making in a Complex World
Even though the world is dynamic, evolving, and interconnected, we tend to make
decisions using mental models that are static, narrow, and reductionist. Among all the
elements of the dynamic complexity, people find the most problematic are feedback, time
delays, and stocks and flows 1.
92
Social systems contain the intricate networks of the feedback processes, both self-
reinforcing (positive) and self-correcting (negative) loops. However, studies show that
people recognize few feedbacks; rather, people usually think in short and causal chains,
tend to assume each effect has a single cause, and often cease their search for
explanations when the first sufficient cause is found 2 83
The time delays in the feedback are common and particularly troublesome. The
delays slow down the accumulation of evidence. More problematically, the short- and
long-run impacts of our policies are often different. For example, smoking gives
immediate pleasure while increasing the potential risk of developing the lung cancer over
decades.
The stocks and flows, which alter the stocks, are fundamental. The concept of the
prevalence (stock) and incidence (flow) in epidemiology is such an example. However,
our intuitive understanding of the stocks and flows is poor in two ways. First, people
possess their own limited scope, based on their narrow mental models, in thoroughly
identifying the feedback between stocks and flows in the entire network. Second, people
have poor intuitive sense of the process of accumulation in the stocks. Most people can
perceive the system inputs and outputs and assume that they are intuitively correlated (e.g.
the more the incidence of HIV, the greater the number of people with HIV will be)8 4.
However, stocks integrate (accumulate) their net inflows, from both inputs and outputs.
A stock rises even though the net inflow falls, as long as the net inflow is positive. For
instance, the number of people with HIV continues to rise even as incidence falls--
prevalence falls only when infection falls below mortality. A poor understanding of
accumulation may pose a profound consequence in public health during policy making.
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The National Diabetes Prevention and Control Program (NDPCP) will be used as an
example to illustrate this point. It is discussed in Section 5.3.2.
The following figure demonstrates how policy resistance may occur when the
policy fails to reach, and even alter, its original goal because of the unawareness of the
hidden side effects (Figure 5.8).
Actions Actions-
Side Effects fromGoals alsActions()Gao <2cton
Environnent Environment
Figure 5.8 Policy Resistance Due to Side Effects of the Policy
5.3.2 Challenges in Diabetes Management
A study, using System Dynamics as a methodology of simulation modeling and
experimentation to assess a policy from the Center for Disease Control and Prevention
(CDC)--the National Diabetes Prevention and Control Program (NDPCP), concludes the
following characteristic dynamics, as challenges encountered in the complex system of
diabetes management8 5:
(1) The role of obesity in driving the growth of prediabetes and diabetes prevalence;
(2) The side effect of the action--a "backing up" phenomenon: when actions (such as
NDPCP's policies of early and expanded detection, improved treatment with better
quality, availability and accessibility) reduce outflow for the stock (population of the
diabetes patients) causes a buildup in that stock (more prevalence of diabetes). As
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such, it may undercut the benefits of management and control efforts (the more
patients with diabetes, the more health care resources needed).
(3) The inability of management and control efforts, which seek to reduce diabetes
prevalence in the long term (CDC lacks the ability of upstream management for
prevention of diabetes, such as changing people's lifestyle by improving diet,
reducing obesity, and increasing physical activity); and
(4) The significant time delays between the primary prevention efforts and downstream
improvements (e.g. screening and treatment) in diabetes outcomes.
The basic structure of this model is summarized as follows (more details are listed in
Appendix E).
Available
Resources
Resources for
NesbrPrevention Demand forNees br B2 Downstream Resources
Prevention e
+ Prevention
Premiuenc of R2
Diabetes R1 + Treatment
Obesity, Poor Diet, - Dstr Tn Pressure
Sedentary Lifestyle Screening t Priority DostreaTr
+ People w/ People
Healthy People 
-Udiagnosed 4- 5 Diagnosed w/ ~
Population Onset I Diabetes Diagnosis Diabetes Death of
Increase Diagnosed
Death of Healthy Death of
People Undiagnosed
Figure 5.9 System Dynamics Model for Diabetes Management (Source: Based on Sterman J.,
Dynamics of the Diabetes Epidemic; Jones A.P. et al., Understanding Diabetes Population Dynamics through
Simulation Modeling and Experimentation; Homer J.B. et al., System Dynamics Modelingfor Public Health:
Background and Opportunities)
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6 CONCLUSION
6.1 Summary
In this thesis, I study the chronic disease, diabetes mellitus (diabetes), including
its definition, classification, etiologies and complications. Due to morbidity and
mortality of its complications, this disease has been causing a huge burden on the health
care system. Medical advances in novel therapies and public health policies of disease
control and prevention have been undertaken to manage the disease. Despite all these
efforts, the prevalence of diabetes still increases over time. I thus investigate this
phenomenon by analyzing technology and policy in the treatment and prevention of
diabetes in order to achieve the goal of managing the disease in a manner of balancing
costs and benefits.
With respect to treatment, I inspect the innovative performance in the antidiabetic
drug therapy. I analyze fifteen New Drug Applications (NDAs) of the antidiabetics from
the 1990s. I examine the characteristics of clinical trials supporting NDAs and seek to
uncover trends in how the complexity of clinical trials has changed over time. In the
statistical analyses of the twenty-five indicators of complexity I select to measure the
changes in clinical trials, I find nine out of the twenty-five selected indicators to exhibit an
increasing trend of complexity. The trend is more pronounced in the oral antiglycemics
group (seven indicators) than the subcutaneous group (two indicators). Noticeably, this
trend of increasing complexity in clinical trials is generally consistent with the trend of
increasing R&D costs in the pharmaceutical industry, and may have partially explained
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the declining performance and innovation of the industry over the time period under
investigation.
I also assess the current public health policies in diabetes control and prevention
by a system dynamics approach. This approach emphasizes the importance of system
thinking, which is extremely essential for the public health policy, particularly in the
arena chronic diseases management. Considering the public health system as a
"dynamic-complex" system, during policy-design phase, recognition of characteristics of
time-delays, stocks and flows, and feedbacks in the system can make the policy more
efficacious. In the case of diabetes management, the policy of the National Diabetes
Control and Prevention Program provides earlier and expanded screening and also
improves availability and accessibility of treatment for diabetes. Despite these
management and control efforts, this policy, rather than reducing the prevalence of
diabetes, in fact increases the prevalence. The counterintuitive result addresses the
consequence of failure in system thinking.
A successful chronic disease management has an enormous role in the public
health system. It requires collective efforts from the perspective of treatment and
prevention. Understanding the drivers for developing treatment and prevention is critical
to achieve a robust healthcare system.
6.2 Limits and the Future Perspectives
Since I only examined the antidiabetics from the 1990s, the limited sample size
may have imposed some constraints. In spite of time frame and the limited data points
(eight oral antihyperglycemic agents, six subcutaneous insulin agents, and one inhaled
insulin agent), several sets of analyses still showed statistical significance, as I have
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discussed in previous sections. Additionally, except for the chemical class of SUs--the
oldest antidiabetic agent--most of the development of antidiabetics occurred in 1990s,
which contributes to the legitimacy of this research timeframe.
As for the future perspectives, a promising avenue is to examine other therapeutic
classes of drugs and compare the trends observed in antidiabetics with that from other
classes of drugs. As such, one may also be able to trace back the development of other
earlier antidiabetics in order to acquire a more complete picture of the trend in changes of
characteristics of clinical trials for NDAs.
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Appendix A Oral Glucose Tolerance Test
The Oral Glucose Tolerance Test (OGTT) is principally used for diagnosis when blood
glucose levels are equivocal in epidemiological studies. The test is not recommended for
clinical use.
The OGTT should be performed in the morning after at least three days of unrestricted
diet (greater than 150g of carbohydrate daily) and usual physical activity. The test should
be preceded by an overnight fast of 8-14 hours, during which water may be drunk.
Smoking is not permitted during the test. The presence of factors that influence
interpretation of the test must be recorded (e.g. medications, inactivity, infection, etc.)
After collection of the fasting blood sample, the subject should drink 75g of anhydrous
glucose or 82.5g of glucose monohydrate (or partial hydrolysates of starch of the
equivalent carbohydrate content) in 250-300ml of water over the course of 5 minutes.
For children, the test load should be 1.75g of glucose per kg body weight up to a total of
75g of glucose. Timing of the test is from the beginning of the drink. Blood samples
must be collected two hours after the test load.
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Appendix B Observations on Complexity from 25 Indicators
Analysis 1: "Review Time" as an Indicator of Complexity over Time
<Definition of Indicator> "Review Time (REVTIME, Months)" equals to an NDA's
"Approval Date" subtract by its "Submission Date (SDATE)."
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Figure 1 Distribution of "Review Time" By "Submission Date"
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The regression equations:
For the oral agents:
REVTIME =
13.453 - 0.033 SDATE
(R2 = 0.186; P-value = 0.286)
For the subcutaneous agents:
REVTIME =
16.713 + 0.094 SDATE
(R2 = 0.050; P-value = 0.672)
For all agents (Pooled):
REVTIME =
14.531 + 0.035 SDATE
(R2 = 0.022; P-value = 0.600)
(For details, see Appendix C)
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Figure 2 Regression Analysis of "Review Time" By "Submission Date"
Analysis 2: "Total Number of Studies for NDA" as an Indicator of Complexity over Time
<Definition of Indicator> "Total Number of Studies for NDA (NSTUDIES)" include all
studies to establish the safety and efficacy parameters and as well as the tolerability,
pharmacokinetic and pharmacodynamic parameters of the drug.
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Figure 3 Distribution of "Total Number of Studies for NDA" By "Submission Date"
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--- Linear Fit
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Route of Administration=="Oral"
Route of Administration=="Subcutaneous"
Route of Administration=="Pooled"
The regression equations:
For the oral agents:
NSTUDIES =
39.470 + 0.021 SDATE
(R2= 0.003; P-value = 0.906)
For the subcutaneous agents:
NSTUDIES =
14.646 ± 0.056 SDATE
(R2= 0.016; P-value = 0.809)
For all agents (Pooled):
NSTUDIES =
32.799 - 0.004 SDATE
(R2 < 0.001; P-value = 0.974)
(For details, see Appendix C)
Figure 4 Regression Analysis of "Total Number of Studies for NDA" By "Submission Date"
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Analysis 3: "Total Number of Patients in Safety Database" as an Indicator of Complexity
over Time
<Definition of Indicator> Total Number of Patients in Safety Database (NSAFETY)
cc
CU
.
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Group by Route of Administration
a Oral
* Oral-1st in Class
x Subcutaneous
0 -t-
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Figure 5 Distribution of "Total Number of Patients in Safety Database" By "Submission
Date"
10000- The regression equations:
8000- For the oral agents:
NSAFETY=
cc
00- X6069.688 - 28.331 SDATE
~6000 X2 (R = 0.346; P-value = 0.165)
(n)
c 4000~ For the subcutaneous agents:
NSAFETY =
S2000- 1269 +17 SDATE
X- X- (R2= 0.096; P-value = 0.613)
01/1993 01/1997 01/2001 01/2005 For all agents (Pooled):
NSAFETY =
4890.805 - 16.492 SDATE
Submission Date (R2= 0.117; P-value = 0.252)
-- Linear Fit Route of Administration=="Oral" (For details, see Appendix C)
--- Linear Fit Route of Administration=="Subcutaneous"
- Linear Fit Route of Administration=="Pooled"
Analysis 4: "Total Number of Special Studies" as an Indicator of Complexity over Time
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<Definition of Indicator> Total Number of Special Studies in NDA (NSPECSTD)
10-
Group by Route of Administration
8- M a Oral
* Oral-1st in Class
._ 6- x Subcutaneous
0 U
4-
U 2- 0 XX
X
0- X X X
-2-
01/1993 01/1997 01/2001 01/2005
Submission Date
Figure 7 Distribution of "Total Number of Special Studies" By "Submission Date"
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-- Linear Fit
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Figure 8 Regression Analysis of "Total Number of Special Studies" By "Submission Date"
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The regression equations:
For the oral agents:
NSPECSTD* =
2.411" + 0.030 SDATE"
(2= 0.515; P-value = 0.045)
For the subcutaneous agents:
NSPECSTD =
1.045 - 0.003 SDATE
(R2= 0.010; P-value = 0.848)
For all agents (Pooled):
NSPECSTD =
2.345 + 0.002 SDATE
(R2= 0.001; P-value = 0.889)
(For details, see Appendix C)
Analysis 5: "Number of Special Studies in Elderly Population" as an Indicator of
Complexity over Time
<Definition of Indicator> Number of Special Studies in Elderly Population (NSPELD)
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Figure 9
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--- Linear Fit Route of Administration=="Oral"
---- Linear Fit Route of Administration=="Subcutaneous"
- Linear Fit Route of Administration=="Pooled"
Elderly Population" By "Submission
The regression equations:
For the oral agents:
NSPELD+ =
0.360+ + 0.016 SDATE+
(R2= 0.373; P-value = 0.108)
For the subcutaneous agents:
NSPELD = 0
For all agents (Pooled):
NSPELD =
0.310 + 0.005 SDATE
(R2= 0.060; P-value = 0.38 1)
(For details, see Appendix C)
Figure 10 Regression Analysis of "Number of Special Studies in Elderly Population" By
"Submission Date"
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Analysis 6: "Number of Special Studies in Liver Impaired Population" as an Indicator of
Complexity over Time
<Definition of Indicator> Number of Special Studies in Liver Impaired Population
(NSPECLIV)
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Figure 11 Distribution of "Number of Special Studies in
"Submission Date"
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--- Linear Fit Route of Administration=="Oral"
-Linear Fit Route of Administration=="Subcutaneous"
- Linear Fit Route of Administration=="Pooled"
Liver Impaired Population" By
Figure 12 Regression Analysis of "Number of Special Studies in Liver Impaired
Population" By "Submission Date"
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The regression equations:
For the oral agents:
NSPECLIV =
0.253 + 0.003 SDATE
(R2 = 0.055; P-value = 0.577)
For the subcutaneous agents:
NSPECLIV = 0
For all agents (Pooled):
NSPECLIV =
0.225 - 0.0003 SDATE
(R2= 0.002; P-value = 0.879)
(For details, see Appendix C)
Analysis 7: "Number of Special Studies in Renal Impaired Population" as an Indicator of
Complexity over Time
<Definition of Indicator> Number of Special Studies
(NSPECREN)
in Renal Impaired Population
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Figure 13 Distribution of "Number of Special Studies in Renal Impaired Population" By
"Submission Date"
-2.5- The regression equations:
E
S2- 0C. For the oral agents:E NSPECREN =
-6 1.5-
1.487 - 0.007 SDATE
-_ (R2= 0.316; P-value = 0.147)
0.5- For the subcutaneous agents:
NSPECREN = 0
For all agents (Pooled):
-0.5 NSPECREN~=
01/1993 01/1997 01/2001 01/2005 1.191- - 0.009 SDATE-
(R2= 0.330; P-value = 0.025)
Submission Date (For details, see Appendix C)
- Linear Fit Route of Administration=="Oral"
----Linear Fit Route of Administration=="Subcutaneous"
--- Linear Fit Route of Administration=="Pooled"
Figure 14 Regression Analysis of "Number of Special Studies in Renal Impaired
Population" By "Submission Date"
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Analysis 8: "Total Number of Drug-drug Interaction Studies" as an Indicator of Complexity
over Time
<Definition of Indicator> Total Number of Drug-Drug Interaction Studies in NDA
(NINTERST)
1 10 .
I I I 1 2
01/1997 01/2001 01/2005
Group by Route of Administration
a Oral
* Oral-1st in Class
x Subcutaneous
Submission Date
Figure 15 Distribution of "Total Number of Drug-drug Interaction Studies" By "Submission
Date"
01/1993 01/1997 01/2001 01/2005
Submission Date
- Linear Fit Route of Administration=="Oral"
--- Linear Fit Route of Administration=="Subcutaneous"
-Linear Fit Route of Administration=="Pooled"
The regression equations:
For the oral agents:
N1NTERST =
5.769 + 0.007 SDATE
(R2= 0.081; P-value = 0.494)
For the subcutaneous agents:
NJNTERST=
0.284 + 0.009 SDATE
(R2 = 0. 019; P-value = 0.794)
For all agents (Pooled):
NINTERST =
4.872 - 0.017 SDATE
(2= 0.067; P-value = 0.352)
(For details, see Appendix C)
Figure 16 Regression Analysis of "Total Number of Drug-drug Interaction Studies" By
"Submission Date"
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Analysis 9: "Number of Indications Proposed by Sponsor" as an indicator of Complexity
over Time
<Definition of Indicator> Number of Indications Proposed by Sponsor (NINDSP)
4.5
Group by Route of Administration
4- a Oral
3.5- * Oral-1st in Class
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- Linear Fit
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Route of Administration=="Oral"
Route of Administration=="Subcutaneous"
Route of Administration=="Pooled"
Figure 18 Regression Analysis of "Number of Indications Proposed by Sponsor" By
"Submission Date"
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The regression equations:
For the oral agents:
NINDSP = 2
For the subcutaneous agents:
NINDSP+ =
0.518" + 0.013 SDATE"
(R2= 0.716; P-value = 0.034)
For all agents (Pooled):
NINDSP =
1.531 + 0.006 SDATE
(R2= 0.167; P-value = 0.131)
(For details, see Appendix C)
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Analysis 10: "Number of Indications Approved by FDA" as an Indicator of Complexity over
Time
<Definition of Indicator> Number of Indications Approved by FDA (NINDFDA)
4.5-
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Figure 19 Distribution of "Number of Indications Approved by FDA" By "Submission Date"
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--- Linear Fit Route of Administration=="Oral"
--- Linear Fit Route of Administration=="Subcutaneous"
--- Linear Fit Route of Administration=="Pooled"
Figure 20 Regression Analysis of "Number of Indications Approved by FDA" By
"Submission Date"
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The regression equations:
For the oral agents:
NINDFDA = 2
For the subcutaneous agents:
NINDFDA =
0.518"+ 0.013 SDATE"
(R2 = 0.716; P-value = 0.034)
For all agents (Pooled):
NINDFDA =
1.531 + 0.006 SDATE
(R2= 0.167; P-value = 0.131)
(For details, see Appendix C)
Analysis 11: "Number of Pivotal Trials Submitted by Sponsor" as an Indicator of
Complexity over Time
<Definition of Indicator> Number of Pivotal Trials Submitted by Sponsor (NPIVSP)
12.5- X Group by Route of Administration
a Oral
00 10-1-C Oral-1st in Class
0.0 x Subcutaneous
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Figure 21 Distribution of "Number of Pivotal Trials Submitted by Sponsor" By
"Submission Date"
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--- Linear Fit Route of Administration=="Oral"
--- Linear Fit Route of Administration=="Subcutaneous"
--- Linear Fit Route of Administration=="Pooled"
The regression equations:
For the oral agents:
NPIVSP =
5.010 + 0.018 SDATE
(R2 = 0.193; P-value = 0.276)
For the subcutaneous agents:
NPIVSP =
5.253 + 0.016 SDATE
(R2 = 0.035; P-value = 0.723)
For all agents (Pooled):
NPIVSP =
5.260 + 0.012 SDATE
(R2 = 0.059; P-value = 0.383)
(For details, see Appendix C)
Figure 22 Regression Analysis of "Number of Pivotal Trials Submitted by Sponsor" By
"Submission Date"
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Analysis 12: "Number of Pivotal Trials for FDA to Approve NDA" as an Indicator of
Complexity over Time
<Definition of Indicator> Number of Pivotal Trials for FDA to Approve NDA (NPIVFDA)
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Figure 23 Distribution of "Number of Pivotal Trials for FDA to Approve NDA" By
"Submission Date"
10- The regression equations:
9-
For the oral agents:
o ~NPIVFDA* =
4.377k + 0.028 SDATE*
6- 0 X (R2 = 0.415; P-value = 0.276)
i5--
For the subcutaneous agents:
> NPIVFDA =
- 3- XX X 7.593 - 0.044 SDATE
2- 0 X (R2= 0.488; P-value = 0.123)
1-1 1 For all agents (Pooled):
01/1993 01/1997 01/2001 01/2005 NP1VFDA =
5.067 + 0.000002 SDATE
Submission Date (R2 < 0.001; P-value = 0.999)
---- Linear Fit Route of Administration=="Oral" (For details, see Appendix C)
-- Linear Fit Route of Administration=="Subcutaneous"
--- Linear Fit Route of Administration=="Pooled"
Figure 24 Regression Analysis of "Number of Pivotal Trials for FDA to Approve NDA" By
"Submission Date"
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Analysis 13: "Number of Patients In Pivotal Trials Submitted by Sponsor" as an Indicator
of Complexity over Time
<Definition
(NPATSP)
of Indicator> Number of Patients in Pivotal Trials Submitted by Sponsor
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Figure 25 Distribution of "Number of Patients in Pivotal Trials Submitted by Sponsor" By
"Submission Date"
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Figure 26 Regression Analysis of "Number of Patients in
Sponsor" By "Submission Date"
The regression equations:
For the oral agents:
NPATSP=
1796.902 + 13.090 SDATE
(R2= 0.293; P-value = 0.166)
For the subcutaneous agents:
NPATSP=
1806.760 + 20.203 SDATE
(R2= 0.373; P-value = 0.198)
For all agents (Pooled):
NPATSP=
2021.892 + 10.795 SDATE
(R2= 0.164; P-value = 0.134)
(For details, see Appendix C)
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Analysis 14: "Number of Patients in Pivotal Trials for FDA to Approve NDA" as an
Indicator of Complexity over Time
<Definition of Indicator> Number of Patients in Pivotal Trials for FDA to Approve NDA
(NPATFDA)
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Figure 27 Distribution of "Number of Patients in Pivotal Trials for FDA to Approve NDA" By
"Submission Date"
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Figure 28 Regression Analysis of "Number of Patients in
NDA" By "Submission Date"
The regression equations:
For the oral agents:
NPATFDA**= 1011.196**
+ 20.425 SDATE 1
(R2 = 0.963; P-value <0.0001)
For the subcutaneous agents:
NPATFDA =
2878.582 - 8.173 SDATE
(R2 = 0.117; P-value = 0.507)
For all agents (Pooled):
NPATFDA =
1531.686 + 7.877 SDATE
(R2= 0.166; P-value = 0.132)
(For details, see Appendix C)
Pivotal Trials for FDA to Approve
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Analysis 15: "Patients per Pivotal Trials Submitted by Sponsor" as an Indicator of
Complexity over Time
<Definition of Indicator> "Patients per Pivotal Trials Submitted by Sponsor
(AVNPATSP)" equals to "Number of Patients in Pivotal Trials Submitted by Sponsor"
divided by "Number of Pivotal Trials Submitted by Sponsor."
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Figure 29 Distribution of Patients per Pivotal Trials Submitted by Sponsor "" By
"Submission Date"
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- Linear Fit Route of Administration=="Oral"
- Linear Fit Route of Administration=="Subcutaneous"
- Linear Fit Route of Administration=="Pooled"
The regression equations:
For the oral agents:
AVNPATSP =
375.714 + 0.791 SDATE
(R = 0.105; P-value = 0.434)
For the subcutaneous agents:
AVNPATSP =
430.830 + 1.638 SDATE
(R = 0.211; P-value = 0.360)
For all agents (Pooled):
AVNPATSP =
412.079 + 0.749 SDATE
(R2 = 0.059; P-value = 0.383)
(For details, see Appendix C)
Figure 30 Regression Analysis of "Patients per Pivotal Trials Submitted by Sponsor" By
"Submission Date"
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Analysis 16: "Patients per Pivotal Trials for FDA to Approve NDA" as an Indicator of
Complexity over Time
<Definition of Indicator> "Patients per Pivotal Trials for FDA to Approve NDA
(AVNPATFDA)" equals to "Number of Patients in Pivotal Trials for FDA to Approve
NDA" divided by "Number of Pivotal Trials for FDA to Approve NDA"
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Figure 31 Distribution of "Patients per Pivotal Trials for FDA to Approve NDA" By
"Submission Date"
900- The regression equations:
800- X
L 7-For the oral agents:
AVNPATFDA =
~ 600 304.756 + 1.181 SDATE
> _(R 2= 0.201; P-value = 0.265)
400- For the subcutaneous agents:C)
3 AVNPATFDA =
400.352 + 2.305 SDATE
200- (R2 = 0.252; P-value = 0.3 10)
100 1
01/1993 01/1997 01/2001 01/2005 For all agents (Pooled):
AVNPATFDA =
351.284 + 1.379 SDATE
Submission Date (R2 = 0.131; P-value = 0.184)
---- Linear Fit Route of Administration=="Oral" (For details, see Appendix C)
--- Linear Fit Route of Administration=="Subcutaneous"
- Linear Fit Route of Administration=="Pooled"
Figure 32 Regression Analysis of "Patients per Pivotal Trials for FDA to Approve NDA" By
"Submission Date"
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Analysis 17: "Average Number of Patients to Support Each Indication Proposed by
Sponsor" as an Indicator of Complexity over Time
<Definition of Indicator> "Average Number of Patients to Support Each Indication
Proposed by Sponsor (AVNPINDSP)" equals to "Number of Patients in Pivotal Trials
Submitted by Sponsor" divided by "Number of Indications Proposed by Sponsor."
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Figure 33 Distribution of "Average Number of Patients
Proposed by Sponsor" By "Submission Date"
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--- Linear Fit Route of Administration=="Oral"
- Linear Fit Route of Administration=="Subcutaneous"
- Linear Fit Route of Administration=="Pooled"
to Support Each Indication
Figure 34 Regression Analysis of "Average Number of Patients to Support Each Indication
Proposed by Sponsor" By "Submission Date"
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The regression equations:
For the oral agents:
AVNPINDSP =
898.451 + 6.545 SDATE
(R2 = 0.293; P-value = 0.166)
For the subcutaneous agents:
AVNPINDSP =
2879.571 - 6.954 SDATE
(R2 = 0.199; P-value = 0.375)
For all agents (Pooled):
AVNPINDSP =
1443.915 + 2.453 SDATE
(R2 = 0.019; P-value = 0.628)
(For details, see Appendix C)
Analysis 18: "Average Number of Patients to Support Each Indication Approved by FDA"
as an Indicator of Complexity over Time
<Definition of Indicator> "Average Number of Patients to Support Each Indication
Approved by FDA (AVNPINDFDA)" equals to "Number of Patients in Pivotal Trials for
FDA to Approve NDA" divided by "Number of Indications Approved by FDA."
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Figure 35 Distribution of "Average Number of Patients to
Approved by FDA" By "Submission Date"
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Figure 36 Regression Analysis of "Average Number of Patients to Support Each Indication
Approved by FDA" By "Submission Date"
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The regression equations:
For the oral agents:
AVNPINDFDA**-
505.5981**
+ 10.212 SDATE*
(R2 = 0.963; P-value <0.0001)
For the subcutaneous agents:
AVNPINDFDA~ =
3264.087-~- 20.360 SDATE-
(R2 = 0.847; P-value = 0.009)
For all agents (Pooled):
AVNPINDFDA =
1164.924 + 0.958 SDATE
(R2= 0.004; P-value = 0.827)
(For details, see Appendix C)
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Analysis 19: "Average Number of Pivotal Trials to Support Each Indication Proposed by
Sponsor" as an Indicator of Complexity over Time
<Definition of Indicator> "Average Number of Pivotal Trials to Support Each Indication
Proposed by Sponsor (AVNTINDSP)" equals to "Number of Pivotal Trials Submitted by
Sponsor" divided by "Number of Indications Proposed by Sponsor."
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Figure 37 Distribution of "Average Number of Pivotal Trials to Support Each Indication
Proposed by Sponsor" By "Submission Date"
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Route of Administration=="Subcutaneous"
Route of Administration=="Pooled"
The regression equations:
For the oral agents:
AVNTINDSP =
2.505 + 0.009 SDATE
(R2= 0.193; P-value = 0.276)
For the subcutaneous agents:
AVNTINDSP =
7.238 - 0.034 SDATE
(R2= 0.338; P-value = 0.226)
For all agents (Pooled):
AVNTINDSP =
3.667 - 0.003 SDATE
(R2= 0.005; P-value = 0.794)
(For details, see Appendix C)
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Figure 38 Regression Analysis of "Average Number of Pivotal Trials to Support Each
Indication Proposed by Sponsor" By "Submission Date"
Analysis 20: "Average Number of Pivotal Trials to Support Each Indication Approved by
FDA" as an Indicator of Complexity over Time
<Definition of Indicator> "Average Number of Pivotal Trials to Support Each Indication
Approved by FDA (AVNTINDFDA)" equals to "Number of Pivotal Trials for FDA to
Approve NDA" divided by "Number of Indications Approved by FDA."
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Figure 39 Distribution of "Average Number of Pivotal Trials to Support Each Indication
Approved by FDA" By "Submission Date"
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The regression equations:
For the oral agents:
AVNTINDFDA =
2.189+ ± 0.014 SDATE+
(R2= 0.415; P-value = 0.085)
For the subcutaneous agents:
AVNTINDFDA =
8.129-~ - 0.063 SDATE~
(R2= 0.860; P-value = 0.008)
For all agents (Pooled):
AVNTINDFDA =
3.508 - 0.009 SDATE
(R2= 0.059; P-value = 0.38 1)
(For details, see Appendix C)
Figure 40 Regression Analysis of "Average Number of Pivotal Trials to Support Each
Indication Approved by FDA" By "Submission Date"
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Analysis 21: "Number of Arms in Pivotal Trials" as an Indicator of Complexity over Time
<Definition of Indicator> Number of Arms in Pivotal Trials (NARM)
4.5
Group by Route of Administration
4- M 0 X a Oral
* Oral-1st in Class
S3.5 - x Subcutaneous
c3- 00 M 0 X U
E
2- X M XX X
1.5-
01/1993 01/1997 01/2001 01/2005
Submission Date
Figure 41 Distribution of "Number of Arms in Pivotal Trials" By "Submission Date"
/1993
I I I
01/1997 01/2001
I I
01/2005
Submission Date
--- Linear Fit
--- Linear Fit
--- Linear Fit
Route of Administration=="Oral"
Route of Administration=="Subcutaneous"
Route of Administration=="Pooled"
The regression equations:
For the oral agents:
NARM =
3.287 - 0.003 SDATE
(R2 = 0.063; P-value = 0.548)
For the subcutaneous agents:
NARM =
1.865 + 0.008 SDATE
(R2 = 0.129; P-value = 0.485)
For all agents (Pooled):
NARM =
3.059 - 0.004 SDATE
(R2= 0.057; P-value = 0.391)
(For details, see Appendix C)
Figure 42 Regression Analysis of "Number of Arms in Pivotal Trials" By "Submission
Date"
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Analysis 22: "Length of Follow-up Period in Pivotal Trials" as an Indicator of Complexity
over Time
<Definition of Indicator> Length of Follow-up Period in Pivotal Trials (FOLTM, Days)
400-
350-
..300 -
250-0
O 200-
0 150 
-
-C
100-
00
50-
0- ED< 0
-50-
01/1993 01/1997
I 1 1
01/2001 01/2005
Group by Route of Administration
a Oral
N Oral-1st in Class
x Subcutaneous
Submission Date
Figure 43 Distribution of "Length of Follow-up Period in Pivotal Trials" By "Submission
Date"
400- The regression equations:
350-
0.300_ For the oral agents:
250 FOLTM =
51.753+ + 1.966 SDATE+
10 (R2 = 0.403; P-value = 0.091)
0150-0
100- For the subcutaneous agents:
50 FOLTM =
-54.439 + 1.091 SDATE
0 - 11V(0 X X (R2= 0.290; P-value = 0.270)
-50- 1 1 1 1 1
01/1993 01/1997 01/2001 01/2005 For all agents (Pooled):
FOLTM =
46.527 + 0.666 SDATE
Submission Date (R2= 0.058; P-value = 0.387)
---- Linear Fit Route of Administration=="Oral" (For details, see Appendix C)
-Linear Fit Route of Administration=="Subcutaneous"
-Linear Fit Route of Administration=="Pooled"
Figure 44 Regression Analysis of "Length of Follow-up Period in Pivotal Trials" By
"Submission Date"
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Analysis 23: "Number of Primary Endpoints in Pivotal Trials" as an Indicator of Complexity
over Time
<Definition of Indicator> Number of Primary Endpoints in Pivotal Trials (NPEND)
4.5
4-
0
jK3.5
3-
C
a 2-
01.5-
0.5
01/ 1993 01/1997
Group by Route of Administration
a Oral
m Oral-Ist in Class
x Subcutaneous
01/2001
Submission Date
Figure 45 Distribution of "Number of Primary Endpoints in Pivotal Trials" By "Submission
Date"
4.5 The regression equations:
4 - X
. For the oral agents:
d: 3.5- NPEND =
3- 0 1.725 - 0.005 SDATE
(R 2 = 0.059; P-value = 0.564)
w 2- For the subcutaneous agents:
1.5 NPEND~=
-r 3.533 - 0.026 SDATE
.1 0 M 0 N(<0 (R2 = 0.614; P-value = 0.065)
0.5 - I I I I 1
01/1993 01/1997 01/2001 01/2005 For all agents (Pooled):
NPEND =
2.073- - 0.009 SDATE~
Submission Date (R 2 = 0.192; P-value = 0.103)
--- Linear Fit Route of Administration=="Oral" (For details, see Appendix C)
-- Linear Fit Route of Administration=="Subcutaneous"
- Linear Fit Route of Administration=="Pooled" II
Figure 46 Regression Analysis of "Number of Primary Endpoints in Pivotal Trials" By
"Submission Date"
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Analysis 24: "Number of Secondary Endpoints in Pivotal Trials" as an Indicator of
Complexity over Time
<Definition of Indicator> Number of Secondary Endpoints in Pivotal Trials (NSEND)
10-
Group by Route of Administration
8- a Oral
E~ Oral-1st in Class
6- U x Subcutaneous
S4- ox
w 0 a X
2- x0 M
X~0
0- U X
-2-
01/1993 01/1997 01/2001 01/2005
Submission Date
Figure 47 Distribution of "Number of Secondary Endpoints
"Submission Date"
Figure 48 Regression.Analysis of "Number of Secondary
"Submission Date"
in Pivotal Trials" By
Endpoints in Pivotal Trials" By
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10- The regression equations:
- 0
. 8- For the oral agents:
a_ NSEND =
- 4.674 - 0.022 SDATE
C2 (R2= 0.142; P-value = 0.358)
C
W0 X For the subcutaneous agents:
2- NSEND =
-0
C8 4.369 - 0.028 SDATEX(R 2 = 0.499; P-value = 0.117)
-2- For all agents (Pooled):
01/1993 01/1997 01/2001 01/2005 NSEND=
4.295 - 0.018 SDATE
Submission Date (R2 = 0.128; P-value = 0.191)
----Linear Fit Route of Administration=="Oral" (For details, see Appendix C)
--- Linear Fit Route of Administration=="Subcutaneous"
--- Linear Fit Route of Administration=="Pooled"
Analysis 25: "Dose Duration" as an Indicator of Complexity over Time
<Definition of Indicator> Dose Duration in Pivotal Trials (DOSDUR)
350
X Group by Route of Administration300- X a Oral
$250- Oral-1st in Class
-o x Subcutaneous
0200 - X X
~100- 050-
500
01/1993 01/1997 01/2001 01/2005
Submission Date
Figure 49 Distribution of "Dose Duration In Pivotal Trials" By "Submission Date"
01/1993 01/1997
I I 1 1
01/2001 01/2005
Submission Date
--- Linear Fit
-- Linear Fit
- Linear Fit
Route of Administration=="Oral"
Route of Administration=="Subcutaneous"
Route of Administration=="Pooled"
Figure 50 Regression Analysis of "Dose Duration in Pivotal Trials" By "Submission Date"
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The regression equations:
For the oral agents:
DOSDUR =
137.210 + 0.032 SDATE
(R2 = 0.0003;P-value = 0.964)
For the subcutaneous agents:
DOSDUR=
305.040 - 1.164 SDATE
(R2= 0.327; P-value = 0.236)
For all agents (Pooled):
DOSDUR =
172.845 - 0.051 SDATE
(R2= 0.001; P-value = 0.916)
(For details, see Appendix C)
0
Appendix C Results from Multiple Regression Analyses
Regression Analysis 1: "Review Time" as an Indicator of Complexity over Time
Linear Fit - Route of Administration=="Oral"
REVTIME = 13.453 - 0.033 SDATE
Summary of Fit
RSquare
RSquare Adj
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)
Analysis of Variance
Source DF
Model
Error
C. Total
Parameter Estimates
Term
Intercept
SDATE (Month)
0.186044
0.050385
3.549558
11.875
8
Sum of Squares
17.278847
75.596153
92.875000
Estimate
13.453219
-0.032625
Mean Square
17.2788
12.5994
Std Error
1.841504
0.027859
t Ratio
7.31
-1.17
F Ratio
1.3714
Prob > F
0.2860
Prob>|t
0.0003
0.2860
Linear Fit - Route of Administration=="Subcutaneous"
REVTIME = 16.713 + 0.094 SDATE
Summary of Fit
RSquare
RSquare Adj
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)
Analysis of Variance
Source DF
Model 1
Error 4
C. Total 5
Parameter Estimates
Term
Intercept
SDATE (Month)
0.049501
-0.18812
16.85821
24
6
Sum of Squares
59.2032
1136.7968
1196.0000
Estimate
16.712976
0.0938243
Mean Square
59.203
284.199
Std Error
17.38596
0.205568
t Ratio
0.96
0.46
Linear Fit - Route of Administration=="Pooled"
REVTIME = 14.531 + 0.035 SDATE
Summary of Fit
RSquare
RSquare Adj
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)
Analysis of Variance
Source DF
0.021704
-0.05355
11.64418
16.86667
15
Sum of Squares
F Ratio
0.2083
Prob > F
0.6718
Prob>|t
0.3908
0.6718
Mean Square F Ratio
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1
Source DF Sum of Squares Mean Square F Ratio
Model 1 39.1041 39.104 0.2884
Error 13 1762.6292 135.587 Prob > F
C. Total 14 1801.7333 0.6003
Parameter Estimates
Term Estimate Std Error t Ratio Prob>|t
Intercept 14.530998 5.287211 2.75 0.0166
SDATE (Month) 0.0354247 0.065963 0.54 0.6003
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Regression Analysis 2: "Total Number of Studies for NDA" as an Indicator of Complexity
over Time
Linear Fit - Route of Administration=="Oral"
NSTUDIES = 39.470 + 0.021 SDATE
Summary of Fit
RSquare
RSquare Adj
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)
Analysis
Source
Model
Error
C. Total
of Variance
DF
1
6
7
Parameter Estimates
Term
Intercept
SDATE
0.002541
-0.1637
21.93417
40.5
8
Sum of Squares
7.3532
2886.6468
2894.0000
Estimate
39.470451
0.0212827
Std Error
11.37941
0.172151
Mean Square
7.353
481.108
t Ratio
3.47
0.12
F Ratio
0.0153
Prob > F
0.9056
Prob>jtj
0.0133
0.9056
Linear Fit - Route of Administration=="Subcutaneous"
NSTUDIES = 14.646 + 0.056 SDATE
Summary of Fit
RSquare
RSquare Adj
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)
Analysis of Variance
Source DF
Model
Error
C. Total
1
4
5
Parameter Estimates
Term
Intercept
SDATE
Sum of Squares
21.1334
1268.8666
1290.0000
Estimate
14.646263
0.0560567
Std Error
18.36814
0.217181
Mean Square F Ratio
21.133 0.0666
317.217 Prob > F
0.8091
t Ratio Prob>t|
0.80 0.4699
0.26 0.8091
Linear Fit - Route of Administration=="Pooled"
NSTUDIES = 32.799 - 0.004 SDATE
Summary of Fit
RSquare
RSquare Adj
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)
Analysis of Variance
Source DF
0.000083
-0.07683
21.65326
32.53333
15
Sum of Squares
0.016382
-0.22952
17.81058
19
6
Mean Square F Ratio
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Source DF Sum of Squares Mean Square F Ratio
Model 1 0.5052 0.505 0.0011
Error 13 6095.2282 468.864 Prob > F
C. Total 14 6095.7333 0.9743
Parameter Estimates
Term Estimate Std Error t Ratio Prob>t
Intercept 32.798808 9.831983 3.34 0.0054
SDATE -0.004026 0.122664 -0.03 0.9743
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Regression Analysis 3: "Total Number of Patients in Safety Database" as an Indicator of
Complexity over Time
Linear Fit - Route of Administration=="Oral"
NSAFETY = 6069.688 - 28.331 SDATE
Summary of Fit
RSquare
RSquare Adj
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)
0.345662
0.214795
2120.989
4556
7
Analysis
Source
Model
Error
C. Total
of Variance
DF
1
5
6
Parameter Estimates
Term Estimate
Intercept 6069.6884
SDATE -28.33107
Sum of Squares
11882191
22492963
34375154
Std Error
1228.871
17.43223
Mean Square F Ratio
11882191 2.6413
4498592.7 Prob > F
0.1650
t Ratio Prob>t
4.94 0.0043
-1.63 0.1650
Linear Fit - Route of Administration=="Subcutaneous"
NSAFETY = 1269 + 17 SDATE
Summary of Fit
RSquare 0.095511
RSquare Adj -0.20599
Root Mean Square Error 2456.233
Mean of Response 2622.2
Observations (or Sum Wgts) 5
Analysis of Variance
Source DF
Model 1
Error 3
C. Total 4
Sum of Squares
1911215
18099246
20010461
Parameter Estimate
Term
Intercept
SDATE
Estimate Std Error
1269 2643.286
17 3020395
t Ratio Prob>|t
0.48 0.6640
0.56 0.6129
Linear Fit - Route of Administration=="Pooled"
NSAFETY = 4890.805 - 16.492 SDATE
Summary of Fit
RSquare
RSquare Adj
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)
Analysis of Variance
Source DF
0.117246
0.036996
2289.404
3738.923
13
Sum of Squares
Mean Square
1911215
6033082
F Ratio
0.3168
Prob > F
0.6129
Mean Square F Ratio
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Source DF Sum of Squares Mean Square F Ratio
Model 1 7657675 7657675 1.4610
Error 11 57655070 5241370 Prob > F
C. Total 12 65312745 0.2521
Parameter Estimates
Term Estimate Std Error t Ratio Prob>|t|
Intercept 4890.8047 1145.14 4.27 0.0013
SDATE -16.4917 13.64392 -1.21 0.2521
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Regression Analysis 4: "Total Number of Special Studies in NDA" as an Indicator of
Complexity over Time
Linear Fit - Route of Administration=="Oral"
NSPECSTD** = 2.411* + 0.030 SDATE**
Summary of Fit
RSquare 0.515089
RSquare Adj 0.43427
Root Mean Square Error 1.527624
Mean of Response 3.875
Observations (or Sum Wgts) 8
Analysis of Variance
Source DF Sum of Squares Mean Square F Ratio
Model 1 14.873183 14.8732 6.3734
Error 6 14.001817 2.3336 Prob > F
C. Total 7 28.875000 0.0450
Parameter Estimates
Term Estimate Std Error t Ratio Prob>t|
Intercept 2.4107614 0.792529 3.04 0.0227
SDATE 0.0302685 0.01199 2.52 0.0450
Linear Fit - Route of Administration=="Subcutaneous"
NSPECSTD = 1.045 - 0.003 SDATE
Summary of Fit
RSquare 0.01034
RSquare Adj -0.23707
Root Mean Square Error 1.093544
Mean of Response 0.833333
Observations (or Sum Wgts) 6
Analysis of Variance
Source DF Sum of Squares Mean Square F Ratio
Model 1 0.0499769 0.04998 0.0418
Error 4 4.7833565 1.19584 Prob > F
C. Total 5 4.8333333 0.8480
Parameter Estimates
Term Estimate Std Error t Ratio Prob>jt|
Intercept 1.0450535 1.127778 0.93 0.4066
SDATE -0.002726 0.013335 -0.20 0.8480
Linear Fit - Route of Administration=="Pooled"
NSPECSTD = 2.345 + 0.002 SDATE
Summary of Fit
RSquare 0.001565
RSquare Adj -0.07524
Root Mean Square Error 2.280812
Mean of Response 2.466667
Observations (or Sum Wgts) 15
Analysis of Variance
Source DF Sum of Squares Mean Square F Ratio
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Source DF Sum of Squares Mean Square F Ratio
Model 1 0.105979 0.10598 0.0204
Error 13 67.627354 5.20210 Prob > F
C. Total 14 67.733333 0.8887
Parameter Estimates
Term Estimate Std Error t Ratio Prob>|t
Intercept 2.3450731 1.035636 2.26 0.0413
SDATE 0.0018442 0.012921 0.14 0.8887
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Regression Analysis 5: "Number of Special Studies in Elderly Population" as an Indicator
of Complexity over Time
Linear Fit - Route of Administration=="Oral"
NSPELD* = 0.360* + 0.016 SDATE*
Summary of Fit
RSquare
RSquare Adj
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)
Analysis of Variance
Source DF
Model 1
Error 6
C. Total 7
Parameter Estimates
Term
Intercept
SDATE
0.373032
0.268538
1.066011
1.125
Sum of Squares
4.056726
6.818274
10.875000
Estimate
0.3602883
0.015808
Std Error
0.553045
0.008367
Mean Square
4.05673
1.13638
t Ratio Prob>t|
0.65 0.5389
1.89 0.1077
Linear Fit - Route of Administration=="Subcutaneous"
NSPELD = 0
Summary of Fit
RSquare
RSquare Adj
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)
Analysis of Variance
Source DF
Model 1
Error
C. Total
4
0
0
6
Sum of Squares
0
0
Mean Square F Ratio
0
0 Prob > F
Parameter Estimates
Term E
Intercept
SDATE
stimate Std Error t Ratio Prob>t|
0
0
0
0
Linear Fit - Route of Administration=="Pooled"
NSPELD = 0.310 + 0.005 SDATE
Summary of Fit
RSquare
RSquare Adj
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)
Analysis of Variance
Source DF
0.05954
-0.0128
1.053214
0.666667
15
Sum of Squares
F Ratio
3.5699
Prob > F
0.1077
Mean Square F Ratio
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Source DF Sum of Squares Mean Square F Ratio
Model 1 0.912952 0.91295 0.8230
Error 13 14.420381 1.10926 Prob > F
C. Total 14 15.333333 0.3808
Parameter Estimates
Term Estimate Std Error t Ratio Prob>|t
Intercept 0.3097853 0.478227 0.65 0.5284
SDATE 0.0054128 0.005966 0.91 0.3808
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Regression Analysis 6: "Number of Special Studies in Liver Impaired Population" as an
Indicator of Complexity over Time
Linear Fit - Route of Administration=="Oral"
NSPECLIV = 0.253 + 0.003 SDATE
Summary of Fit
RSquare
RSquare Adj
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)
Analysis
Source
Model
Error
C. Total
of Variance
DF
1
Parameter Estimates
Term
Intercept
SDATE
0.05489
-0.10263
0.543458
0.375
8
Sum of Squares
0.1029185
1.7720815
1.8750000
Estimate
0.2531974
0.0025179
Std Error
0.281945
0.004265
Mean Square
0.102918
0.295347
t Ratio
0.90
0.59
F Ratio
0.3485
Prob > F
0.5765
Prob>t|
0.4038
0.5765
Linear Fit - Route of Administration=="Subcutaneous"
NSPECLIV = 0
Summary of Fit
RSquare
RSquare Adj
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)
Analysis of Variance
Source DF
Model 1
Error 4
C. Total 5
0
0
6
Sum of Squares
0
0
0
Mean Square F Ratio
0
0 Prob > F
Parameter Estimates
Term Estimate Std Error t Ratio Prob>|t
Intercept
SDATE
0
0
0
0
Linear Fit - Route of Administration=="Pooled"
NSPECLIV = 0.225 - 0.0003 SDATE
Summary of Fit
RSquare
RSquare Adj
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)
Analysis of Variance
Source DF
0.001862
-0.07492
0.429269
0.2
15
Sum of Squares Mean Square F Ratio
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Source DF Sum of Squares Mean Square F Ratio
Model 1 0.0044684 0.004468 0.0242
Error 13 2.3955316 0.184272 Prob > F
C. Total 14 2.4000000 0.8786
Parameter Estimates
Term Estimate Std Error t Ratio Prob>jt
Intercept 0.2249676 0.194916 1.15 0.2692
SDATE -0.000379 0.002432 -0.16 0.8786
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Regression Analysis 7: "Number of Special Studies in Renal Impaired Population" as an
Indicator of Complexity over Time
Linear Fit - Route of Administration=="Oral"
NSPECREN = 1.487 - 0.007 SDATE
Summary of Fit
RSquare
RSquare Adj
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)
0.315645
0.201585
0.572643
1.125
8
Analysis
Source
Model
Error
C. Total
of Variance
DF
1
6
7
Parameter Estimates
Term Estimate
Intercept 1.4866829
SDATE -0.007477
Sum of Squares
0.9074784
1.9675216
2.8750000
Std Error
0.297086
0.004494
Mean Square F Ratio
0.907478 2.7674
0.327920 Prob > F
0.1473
t Ratio Prob>jt
5.00 0.0024
-1.66 0.1473
Linear Fit - Route of Administration=="Subcutaneous"
NSPECREN = 0
Summary of Fit
RSquare
RSquare Adj
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)
Analysis of Variance
Source DF
Model 1
Error 4
C. Total 5
Sum of Squares
0
0
0
Parameter Estimate
Term
Intercept
SDATE
Estimate Std Error
0 0
0 0
t Ratio Prob>|t|
Linear Fit - Route of Administration=="Pooled"
NSPECREN** = 1.191** - 0.009 SDATE**
Summary of Fit
RSquare 0.329632
RSquare Adj 0.278065
Root Mean Square Error 0.626025
Mean of Response 0.6
Observations (or Sum Wgts) 15
Analysis of Variance
Source DF Sum of Squares
0
0
6
Mean Square
0
0
F Ratio
Prob > F
Mean Square F Ratio
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Source DF Sum of Squares Mean Square F Ratio
Model 1 2.5051997 2.50520 6.3923
Error 13 5.0948003 0.39191 Prob > F
C. Total 14 7.6000000 0.0252
Parameter Estimates
Term Estimate Std Error t Ratio Prob>t
Intercept 1.1911817 0.284256 4.19 0.0011
SDATE -0.008966 0.003546 -2.53 0.0252
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Regression Analysis 8: "Total Number of Drug-Drug Interaction Studies in NDA" as an
Indicator of Complexity over Time
Linear Fit - Route of Administration=="Oral"
NINTERST = 5.769 + 0.007 SDATE
Summary of Fit
RSquare 0.081057
RSquare Adj -0.0721
Root Mean Square Error 1.290575
Mean of Response 6.125
Observations (or Sum Wgts) 8
Analysis of Variance
Source DF Sum of Squares Mean Square F Ratio
Model 1 0.881499 0.88150 0.5292
Error 6 9.993501 1.66558 Prob > F
C. Total 7 10.875000 0.4943
Parameter Estimates
Term Estimate Std Error t Ratio Prob>|t|
Intercept 5.7685319 0.669548 8.62 0.0001
SDATE 0.0073689 0.010129 0.73 0.4943
Linear Fit - Route of Administration=="Subcutaneous"
NINTERST = 0.284 + 0.009 SDATE
Summary of Fit
RSquare 0.019052
RSquare Adj -0.22618
Root Mean Square Error 2.712399
Mean of Response 1
Observations (or Sum Wgts) 6
Analysis of Variance
Source DF Sum of Squares Mean Square F Ratio
Model 1 0.571570 0.57157 0.0777
Error 4 29.428430 7.35711 Prob > F
C. Total 5 30.000000 0.7943
Parameter Estimates
Term Estimate Std Error t Ratio Prob>jtj
Intercept 0.2840008 2.797311 0.10 0.9240
SDATE 0.0092189 0.033075 0.28 0.7943
Linear Fit - Route of Administration=="Pooled"
NINTERST = 4.872 - 0.017 SDATE
Summary of Fit
RSquare 0.066923
RSquare Adj -0.00485
Root Mean Square Error 3.157841
Mean of Response 3.733333
Observations (or Sum Wgts) 15
Analysis of Variance
Source DF Sum of Squares Mean Square F Ratio
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Source DF Sum of Squares Mean Square F Ratio
Model 1 9.29789 9.29789 0.9324
Error 13 129.63544 9.97196 Prob > F
C. Total 14 138.93333 0.3519
Parameter Estimates
Term Estimate Std Error t Ratio Prob>|t|
Intercept 4.8722503 1.433864 3.40 0.0048
SDATE -0.017274 0.017889 -0.97 0.3519
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Regression Analysis 9: "Number of Indications Proposed by Sponsor" as an Indicator of
Complexity over Time
Linear Fit - Route of Administration=="Oral"
NINDSP = 2
Summary of Fit
RSquare
RSquare Adj
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)
Analysis of Variance
Source DF
Model 1
Error 6
C. Total 7
Sum of Squares
0
0
0
Parameter Estimates
Term Estimate
Intercept 2
SDATE 0
Std Error
0
0
t Ratio Prob>|t|
Linear Fit - Route of Administration=="Subcutaneous"
NINDSP** = 0.518** + 0.013 SDATE**
Summary of Fit
RSquare 0.716197
RSquare Adj 0.645247
Root Mean Square Error 0.32623
Mean of Response 1.5
Observations (or Sum Wgts) 6
Analysis of Variance
Source DF
Model 1
Error 4
C. Total 5
Parameter Estimates
Term Estimate
Intercept 0.5183882
SDATE 0.0126388
Sum of Squares
1.0742962
0.4257038
1.5000000
Std Error
0.336443
0.003978
Mean Square F Ratio
1.07430 10.0943
0.10643 Prob > F
0.0336
t Ratio Prob>|t
1.54 0.1982
3.18 0.0336
Linear Fit - Route of Administration=="Pooled"
NINDSP = 1.531 + 0.006 SDATE
Summary of Fit
RSquare 0.166974
RSquare Adj 0.102895
Root Mean Square Error 0.666544
Mean of Response 1.933333
Observations (or Sum Wgts) 15
Analysis of Variance
Source DF Sum of Squares
0
2
8
Mean Square
0
0
F Ratio
Prob > F
Mean Square F Ratio
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Source DF Sum of Squares Mean Square F Ratio
Model 1 1.1576890 1.15769 2.6058
Error 13 5.7756443 0.44428 Prob > F
C. Total 14 6.9333333 0.1305
Parameter Estimates
Term Estimate Std Error t Ratio Prob>|t|
Intercept 1.5314539 0.302654 5.06 0.0002
SDATE 0.0060952 0.003776 1.61 0.1305
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Regression Analysis 10: "Number of Indications Approved by FDA" as an Indicator of
Complexity over Time
Linear Fit - Route of Administration=="Oral"
NINDFDA = 2 + 0 SDATE
Summary of Fit
RSquare
RSquare Adj
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)
Analysis of Variance
Source DF
Model 1
Error 6
C. Total 7
0
2
8
Sum of Squares
0
0
0
Mean Square
0
0
F Ratio
Prob > F
Parameter Estimate
Term
Intercept
SDATE
Estimate Std Error
2 0
0 0
t Ratio Prob>t
Linear Fit Route of Administration=="Subcutaneous"
NINDFDA** = 0.518** + 0.013 SDATE**
Summary of Fit
RSquare 0.716197
RSquare Adj 0.645247
Root Mean Square Error 0.32623
Mean of Response 1.5
Observations (or Sum Wgts) 6
Analysis of Variance
Source DF
Model 1
Error 4
C. Total 5
Parameter Estimates
Term Estimate
Intercept 0.5183882
SDATE 0.0126388
Sum of Squares
1.0742962
0.4257038
1.5000000
Std Error
0.336443
0.003978
Mean Square F Ratio
1.07430 10.0943
0.10643 Prob > F
0.0336
t Ratio Prob>|t|
1.54 0.1982
3.18 0.0336
Linear Fit - Route of Administration=="Pooled"
NINDFDA = 1.531 + 0.006 SDATE
Summary of Fit
RSquare 0.166974
RSquare Adj 0.102895
Root Mean Square Error 0.666544
Mean of Response 1.933333
Observations (or Sum Wgts) 15
Analysis of Variance
Source DF Sum of Squares Mean Square F Ratio
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Source DF Sum of Squares Mean Square F Ratio
Model 1 1.1576890 1.15769 2.6058
Error 13 5.7756443 0.44428 Prob > F
C. Total 14 6.9333333 0.1305
Parameter Estimates
Term Estimate Std Error t Ratio Prob>t|
Intercept 1.5314539 0.302654 5.06 0.0002
SDATE 0.0060952 0.003776 1.61 0.1305
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Regression Analysis 11: "Number of Pivotal Trials Submitted by Sponsor" as an Indicator
of Complexity over Time
Linear Fit - Route of Administration=="Oral"
NPIVSP = 5.010 + 0.018 SDATE
Summary of Fit
RSquare 0.193263
RSquare Adj 0.058806
Root Mean Square Error 1.900924
Mean of Response 5.875
Observations (or Sum Wgts) 8
Analysis of Variance
Source DF Sum of Squares Mean Square F Ratio
Model 1 5.193932 5.19393 1.4374
Error 6 21.681068 3.61351 Prob > F
C. Total 7 26.875000 0.2758
Parameter Estimates
Term Estimate Std Error t Ratio Prob>t|
Intercept 5.0097173 0.986196 5.08 0.0023
SDATE 0.017887 0.014919 1.20 0.2758
Linear Fit - Route of Administration=="Subcutaneous"
NPIVSP = 5.253 + 0.016 SDATE
Summary of Fit
RSquare 0.035037
RSquare Adj -0.2062
Root Mean Square Error 3.455635
Mean of Response 6.5
Observations (or Sum Wgts) 6
Analysis of Variance
Source DF Sum of Squares Mean Square F Ratio
Model 1 1.734338 1.7343 0.1452
Error 4 47.765662 11.9414 Prob > F
C. Total 5 49.500000 0.7225
Parameter Estimates
Term Estimate Std Error t Ratio Prob>t
Intercept 5.2527756 3.563815 1.47 0.2145
SDATE 0.0160587 0.042138 0.38 0.7225
Linear Fit - Route of Administration=="Pooled"
NPIVSP = 5.260 + 0.012 SDATE
Summary of Fit
RSquare 0.059038
RSquare Adj -0.01334
Root Mean Square Error 2.390257
Mean of Response 6.066667
Observations (or Sum Wgts) 15
Analysis of Variance
Source DF Sum of Squares Mean Square F Ratio
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Source DF Sum of Squares Mean Square F Ratio
Model 1 4.660060 4.66006 0.8156
Error 13 74.273274 5.71333 Prob > F
C. Total 14 78.933333 0.3829
Parameter Estimates
Term Estimate Std Error t Ratio Prob>|t|
Intercept 5.2603688 1.085332 4.85 0.0003
SDATE 0.012229 0.013541 0.90 0.3829
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Regression Analysis 12: "Number of Pivotal Trials for FDA to Approve NDA" as an
Indicator of Complexity over Time
Linear Fit - Route of Administration=="Oral"
NPIVFDA* = 4.377* + 0.028 SDATE*
Summary of Fit
RSquare 0.415143
RSquare Adj 0.317667
Root Mean Square Error 1.752284
Mean of Response 5.75
Observations (or Sum Wgts) 8
Analysis of Variance
Source DF Sum of Squares Mean Square F Ratio
Model 1 13.077011 13.0770 4.2589
Error 6 18.422989 3.0705 Prob > F
C. Total 7 31.500000 0.0846
Parameter Estimates
Term Estimate Std Error t Ratio Prob>|t|
Intercept 4.3770203 0.909082 4.81 0.0030
SDATE 0.028382 0.013753 2.06 0.0846
Linear Fit - Route of Administration=="Subcutaneous"
NPIVFDA = 7.593 - 0.044 SDATE
Summary of Fit
RSquare 0.487696
RSquare Adj 0.35962
Root Mean Square Error 1.853836
Mean of Response 4.166667
Observations (or Sum Wgts) 6
Analysis of Variance
Source DF Sum of Squares Mean Square F Ratio
Model 1 13.086505 13.0865 3.8079
Error 4 13.746828 3.4367 Prob > F
C. Total 5 26.833333 0.1228
Parameter Estimates
Term Estimate Std Error t Ratio Prob>t|
Intercept 7.5926844 1.91187 3.97 0.0165
SDATE -0.044112 0.022606 -1.95 0.1228
Linear Fit - Route of Administration=="Pooled"
NPIVFDA = 5.067 + 0.000002 SDATE
Summary of Fit
RSquare 2.131e-9
RSquare Adj -0.07692
Root Mean Square Error 2.269079
Mean of Response 5.066667
Observations (or Sum Wgts) 15
Analysis of Variance
Source DF Sum of Squares Mean Square F Ratio
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Source DF Sum of Squares Mean Square F Ratio
Model I 1.42629e-7 1.426e-7 0.0000
Error 13 66.933333 5.14872 Prob > F
C. Total 14 66.933333 0.9999
Parameter Estimates
Term Estimate Std Error t Ratio Prob>|t|
Intercept 5.0665256 1.030309 4.92 0.0003
SDATE 0.0000021 0.012854 0.00 0.9999
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Regression Analysis 13: "Number of Patients in Pivotal Trials Submitted by Sponsor" as
an Indicator of Complexity over Time
Linear Fit - Route of Administration=="Oral"
NPATSP = 1796.902 + 13.090 SDATE
Summary of Fit
RSquare 0.293085
RSquare Adj 0.175266
Root Mean Square Error 1057.446
Mean of Response 2430.125
Observations (or Sum Wgts) 8
Analysis of Variance
Source DF Sum of Squares Mean Square F Ratio
Model 1 2781596.5 2781597 2.4876
Error 6 6709148.3 1118191 Prob > F
C. Total 7 9490744.9 0.1658
Parameter Estimates
Term Estimate Std Error t Ratio Prob>|t|
Intercept 1796.9016 548.601 3.28 0.0169
SDATE 13.089889 8.299405 1.58 0.1658
Linear Fit - Route of Administration=="Subcutaneous"
NPATSP = 1806.760 + 20.203 SDATE
Summary of Fit
RSquare 0.372524
RSquare Adj 0.215655
Root Mean Square Error 1075.12
Mean of Response 3375.833
Observations (or Sum Wgts) 6
Analysis of Variance
Source DF Sum of Squares Mean Square F Ratio
Model 1 2744929.6 2744930 2.3747
Error 4 4623529.3 1155882 Prob > F
C. Total 5 7368458.8 0.1982
Parameter Estimates
Term Estimate Std Error t Ratio Prob>|t|
Intercept 1806.7596 1108.777 1.63 0.1785
SDATE 20.202667 13.10992 1.54 0.1982
Linear Fit - Route of Administration=="Pooled"
NPATSP = 2021.892 + 10.795 SDATE
Summary of Fit
RSquare 0.164319
RSquare Adj 0.100036
Root Mean Square Error 1191.92
Mean of Response 2733.667
Observations (or Sum Wgts) 15
Analysis of Variance
Source DF Sum of Squares Mean Square F Ratio
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Source DF Sum of Squares Mean Square F Ratio
Model 1 3631493 3631493 2.5562
Error 13 18468755 1420673 Prob > F
C. Total 14 22100247 0.1339
Parameter Estimates
Term Estimate Std Error t Ratio Prob>t|
Intercept 2021.8922 541.2089 3.74 0.0025
SDATE 10.795366 6.752147 1.60 0.1339
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Regression Analysis 14: "Number of Patients in Pivotal Trials for FDA to Approve NDA" as
an Indicator of Complexity over Time
Linear Fit - Route of Administration=="Oral"
NPATFDA*** = 1011.196*** + 20.425 SDATE***
Summary of Fit
RSquare
RSquare Adj
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)
0.963094
0.956943
207.9746
1999.25
8
Analysis
Source
Model
Error
C. Total
of Variance
DF
1
Parameter Estimates
Term
Intercept
SDATE
Estima
1011.19
20.4248
Sum of Squares
6772390.8
259520.7
7031911.5
te Std Error
55 107.8969
99 1.632297
Linear Fit - Route of Administration=="Subcutaneous"
NPATFDA = 2878.582 - 8.173 SDATE
Summary of Fit
RSquare
RSquare Adj
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)
Analysis of Variance
Source DF
Model 1
Error 4
C. Total 5
Parameter
Term
Intercept
SDATE
Estimates
Estima
2878.5
-8.172
Sum of Squares
449208.7
3390636.2
3839844.8
te Std Error
82 949.5062
73 11.22674
Mean Square F Ratio
449209 0.5299
847659 Prob > F
0.5070
t Ratio Prob>|t|
3.03 0.0387
-0.73 0.5070
Linear Fit - Route of Administration=="Pooled"
NPATFDA = 1531.686 + 7.877 SDATE
Summary of Fit
RSquare
RSquare Adj
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)
Analysis of Variance
Source DF
0.165737
0.101563
865.2802
2051.067
15
Sum of Squares
Mean Square
6772391
43253
t Ratio
9.37
12.51
F Ratio
156.5746
Prob > F
<.0001
Prob>t|
<.0001
<.0001
0.116986
-0.10377
920.684
2243.833
6
Mean Square F Ratio
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Source DF Sum of Squares Mean Square F Ratio
Model 1 1933626 1933626 2.5826
Error 13 9733227 748710 Prob > F
C. Total 14 11666853 0.1320
Parameter Estimates
Term Estimate Std Error t Ratio Prob>t
Intercept 1531.6857 392.8932 3.90 0.0018
SDATE 7.8773657 4.901754 1.61 0.1320
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Regression Analysis 15: "Patients per Pivotal Trials Submitted by Sponsor" as an
Indicator of Complexity over Time
Linear Fit - Route of Administration=="Oral"
AVNPATSP = 375.714 + 0.791 SDATE
Summary of Fit
RSquare 0.104838
RSquare Adj -0.04436
Root Mean Square Error 120.1726
Mean of Response 413.9606
Observations (or Sum Wgts) 8
Analysis of Variance
Source DF Sum of Squares Mean Square F Ratio
Model 1 10147.932 10147.9 0.7027
Error 6 86648.766 14441.5 Prob > F
C. Total 7 96796.698 0.4340
Parameter Estimates
Term Estimate Std Error t Ratio Prob>|t
Intercept 375.71345 62.34536 6.03 0.0009
SDATE 0.790638 0.94318 0.84 0.4340
Linear Fit - Route of Administration=="Subcutaneous"
AVNPATSP = 430.830 + 1.638 SDATE
Summary of Fit
RSquare 0.210602
RSquare Adj 0.013252
Root Mean Square Error 130.0192
Mean of Response 558.0333
Observations (or Sum Wgts) 6
Analysis of Variance
Source DF Sum of Squares Mean Square F Ratio
Model 1 18040.174 18040.2 1.0672
Error 4 67619.966 16905.0 Prob > F
C. Total 5 85660.141 0.3600
Parameter Estimates
Term Estimate Std Error t Ratio Prob>|t|
Intercept 430.83011 134.0895 3.21 0.0325
SDATE 1.6378098 1.585443 1.03 0.3600
Linear Fit - Route of Administration=="Pooled"
AVNPATSP = 412.079 + 0.749 SDATE
Summary of Fit
RSquare 0.058951
RSquare Adj -0.01344
Root Mean Square Error 146.4608
Mean of Response 461.4456
Observations (or Sum Wgts) 15
Analysis of Variance
Source DF Sum of Squares Mean Square F Ratio
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Source DF Sum of Squares Mean Square F Ratio
Model 1 17468.94 17468.9 0.8144
Error 13 278860.04 21450.8 Prob > F
C. Total 14 296328.97 0.3832
Parameter Estimates
Term Estimate Std Error t Ratio Prob>|tj
Intercept 412.07906 66.5027 6.20 <.0001
SDATE 0.7487348 0.829691 0.90 0.3832
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Regression Analysis 16: "Patients per Pivotal Trials for FDA to Approve NDA" as an
Indicator of Complexity over Time
Linear Fit - Route of Administration=="Oral"
AVNPATFDA = 304.756 + 1.181 SDATE
Summary of Fit
RSquare 0.201088
RSquare Adj 0.067936
Root Mean Square Error 122.4485
Mean of Response 361.8882
Observations (or Sum Wgts) 8
Analysis of Variance
Source DF Sum of Squares Mean Square F Ratio
Model 1 22643.60 22643.6 1.5102
Error 6 89961.86 14993.6 Prob > F
C. Total 7 112605.46 0.2651
Parameter Estimates
Term Estimate Std Error t Ratio Prob>t|
Intercept 304.75578 63.52609 4.80 0.0030
SDATE 1.1810319 0.961042 1.23 0.2651
Linear Fit - Route of Administration=="Subcutaneous"
AVNPATFDA = 400.352 + 2.305 SDATE
Summary of Fit
RSquare 0.252084
RSquare Adj 0.065105
Root Mean Square Error 162.7999
Mean of Response 579.375
Observations (or Sum Wgts) 6
Analysis of Variance
Source DF Sum of Squares Mean Square F Ratio
Model 1 35732.36 35732.4 1.3482
Error 4 106015.25 26503.8 Prob > F
C. Total 5 141747.61 0.3102
Parameter Estimates
Term Estimate Std Error t Ratio Prob>|t
Intercept 400.3521 167.8964 2.38 0.0756
SDATE 2.3050159 1.985168 1.16 0.3102
Linear Fit - Route of Administration=="Pooled"
AVNPATFDA = 351.284 + 1.379 SDATE
Summary of Fit
RSquare 0.131286
RSquare Adj 0.064462
Root Mean Square Error 173.6789
Mean of Response 442.2104
Observations (or Sum Wgts) 15
Analysis of Variance
Source DF Sum of Squares Mean Square F Ratio
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Source DF Sum of Squares Mean Square F Ratio
Model 1 59262.49 59262.5 1.9647
Error 13 392136.52 30164.3 Prob > F
C. Total 14 451399.00 0.1844
Parameter Estimates
Term Estimate Std Error t Ratio Prob>t|
Intercept 351.28402 78.86145 4.45 0.0006
SDATE 1.3790649 0.983879 1.40 0.1844
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Regression Analysis 17: "Average Number of Patients to Support Each Indication
Proposed by Sponsor" as an Indicator of Complexity over Time
Linear Fit - Route of Administration=="Oral"
AVNPINDSP = 898.451 + 6.545 SDATE
Summary of Fit
RSquare 0.293085
RSquare Adj 0.175266
Root Mean Square Error 528.7228
Mean of Response 1215.063
Observations (or Sum Wgts) 8
Analysis of Variance
Source DF Sum of Squares Mean Square F Ratio
Model 1 695399.1 695399 2.4876
Error 6 1677287.1 279548 Prob > F
C. Total 7 2372686.2 0.1658
Parameter Estimates
Term Estimate Std Error t Ratio Prob>jtj
Intercept 898.45081 274.3005 3.28 0.0169
SDATE 6.5449446 4.149703 1.58 0.1658
Linear Fit - Route of Administration=="Subcutaneous"
AVNPINDSP = 2879.571 - 6.954 SDATE
Summary of Fit
RSquare 0.199499
RSquare Adj -0.00063
Root Mean Square Error 571.155
Mean of Response 2339.5
Observations (or Sum Wgts) 6
Analysis of Variance
Source DF Sum of Squares Mean Square F Ratio
Model 1 325197.1 325197 0.9969
Error 4 1304871.9 326218 Prob > F
C. Total 5 1630069.0 0.3746
Parameter Estimates
Term Estimate Std Error t Ratio Prob>|t|
Intercept 2879.5713 589.0351 4.89 0.0081
SDATE -6.953707 6.964614 -1.00 0.3746
Linear Fit - Route of Administration=="Pooled"
AVNPINDSP = 1443.915 + 2.453 SDATE
Summary of Fit
RSquare 0.018585
RSquare Adj -0.05691
Root Mean Square Error 872.7164
Mean of Response 1605.65
Observations (or Sum Wgts) 15
Analysis of Variance
Source DF Sum of Squares Mean Square F Ratio
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Source DF Sum of Squares Mean Square F Ratio
Model 1 187504 187504 0.2462
Error 13 9901242 761634 Prob > F
C. Total 14 10088745 0.6281
Parameter Estimates
Term Estimate Std Error t Ratio Prob>t|
Intercept 1443.9147 396.2698 3.64 0.0030
SDATE 2.4530122 4.94388 0.50 0.6281
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Regression Analysis 18: "Average Number of Patients to Support Each Indication
Approved by FDA" as an Indicator of Complexity over Time
Linear Fit - Route of Administration=="Oral"
AVNPINDFDA*** = 505.598*** + 10.212 SDATE***
Summary of Fit
RSquare
RSquare Adj
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)
Analysis of Variance
Source DF
Model 1
Error
C. Total
6
7
Parameter Estimates
Term
Intercept
SDATE
0.963094
0.956943
103.9873
999.625
8
Sum of Squares
1693097.7
64880.2
1757977.9
Estimate
505.59777
10.212449
Std Error
53.94844
0.816149
Linear Fit - Route of Administration=="Subcutaneous"
AVNPINDFDA*** = 3264.087*** - 20.360 SDATE***
Summary of Fit
RSquare
RSquare Adj
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)
Analysis of Variance
Source DF
Model
Error
C. Total
1
4
5
Parameter Estimates
Term
Intercept
SDATE
0.846825
0.808531
355.0513
1682.833
6
Sum of Squares
2787709.1
504245.7
3291954.8
Estimate
3264.0868
-20.35949
Std Error
366.1663
4.329465
Mean Square F Ratio
2787709 22.1139
126061 Prob > F
0.0093
t Ratio Prob>|tj
8.91 0.0009
-4.70 0.0093
Linear Fit - Route of Administration=="Pooled"
AVNPINDFDA = 1164.924 + 0.958 SDATE
Summary of Fit
RSquare
RSquare Adj
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)
Analysis of Variance
Source DF Sum of Squares
0.003803
-0.07283
759.1073
1228.083
15
Mean Square
1693098
10813
t Ratio
9.37
12.51
F Ratio
156.5746
Prob > F
<.0001
Prob>t|
<.0001
<.0001
Mean Square F Ratio
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Source DF Sum of Squares Mean Square F Ratio
Model 1 28594.4 28594 0.0496
Error 13 7491170.1 576244 Prob > F
C. Total 14 7519764.5 0.8272
Parameter Estimates
Term Estimate Std Error t Ratio Prob>|t
Intercept 1164.9236 344.6839 3.38 0.0049
SDATE 0.9579329 4.300292 0.22 0.8272
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Regression Analysis 19: "Average Number of Pivotal Trials to Support Each Indication
Proposed by Sponsor" as an Indicator of Complexity over Time
Linear Fit - Route of Administration=="Oral"
AVNTINDSP = 2.505 + 0.009 SDATE
Summary of Fit
RSquare
RSquare Adj
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)
Analysis
Source
Model
Error
C. Total
of Variance
DF
1
6
7
0.193263
0.058806
0.950462
2.9375
8
Sum of Squares
1.2984830
5.4202670
6.7187500
Mean Square
1.29848
0.90338
F Ratio
1.4374
Prob > F
0.2758
Parameter Estimates
Term E
Intercept
SDATE
stimate
2.5048587
0.0089435
Std Error
0.493098
0.00746
t Ratio Prob>t
5.08 0.0023
1.20 0.2758
Linear Fit - Route of Administration=="Subcutaneous"
AVNTINDSP = 7.238 - 0.034 SDATE
Summary of Fit
RSquare
RSquare Adj
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)
Analysis of Variance
Source DF
Model
Error
C. Total
1
4
5
Parameter Estimates
Term Estimate
Intercept 7.2375347
SDATE -0.034174
0.33843
0.173037
1.959206
4.583333
6
Sum of Squares
7.854386
15.353948
23.208333
Std Error
2.020539
0.02389
Mean Square F Ratio
7.85439 2.0462
3.83849 Prob > F
0.2258
t Ratio Prob>t|
3.58 0.0231
-1.43 0.2258
Linear Fit - Route of Administration=="Pooled"
AVNTINDSP = 3.667 - 0.003 SDATE
Summary of Fit
RSquare
RSquare Adj
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)
Analysis of Variance
Source DF
0.005453
-0.07105
1.846313
3.483333
15
Sum of Squares Mean Square F Ratio
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Source DF Sum of Squares Mean Square F Ratio
Model 1 0.242993 0.24299 0.0713
Error 13 44.315340 3.40887 Prob > F
C. Total 14 44.558333 0.7937
Parameter Estimates
Term Estimate Std Error t Ratio Prob>t
Intercept 3.6674517 0.838346 4.37 0.0008
SDATE -0.002792 0.010459 -0.27 0.7937
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Regression Analysis 20: "Average Number of Pivotal Trials to Support Each Indication
Approved by FDA" as an Indicator of Complexity over Time
Linear Fit - Route of Administration=="Oral"
AVNTINDFDA* = 2.189* + 0.014 SDATE*
Summary of Fit
RSquare
RSquare Adj
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)
0.415143
0.317667
0.876142
2.875
8
Analysis of Variance
Source DF
Model 1
Error 6
C. Total 7
Parameter Estimates
Term E
Intercept
SDATE
Sum of Squares
3.2692528
4.6057472
7.8750000
stimate
2.1885101
0.014191
Std Error
0.454541
0.006876
Mean Square F Ratio
3.26925 4.2589
0.76762 Prob > F
0.0846
t Ratio Prob>|t|
4.81 0.0030
2.06 0.0846
Linear Fit - Route of Administration=="Subcutaneous"
AVNTINDFDA*** = 8.129*** - 0.063 SDATE***
Summary of Fit
RSquare
RSquare Adj
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)
Analysis of Variance
Source DF
Model 1
Error 4
C. Total 5
Parameter Estimates
Term E
Intercept 8.1
SDATE -0.
Sum of Squares
26.542365
4.332635
30.875000
stimate
291881
062822
Std Error
1.07333
0.012691
Mean Square F Ratio
26.5424 24.5046
1.0832 Prob > F
0.0078
t Ratio Prob>|t
7.57 0.0016
-4.95 0.0078
Linear Fit - Route of Administration=="Pooled"
AVNTINDFDA = 3.508 - 0.009 SDATE
Summary of Fit
RSquare
RSquare Adj
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)
Analysis of Variance
Source DF
0.059431
-0.01292
1.747522
2.916667
15
Sum of Squares
0.859672
0.82459
1.040749
3.25
6
Mean Square F Ratio
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Source DF Sum of Squares Mean Square F Ratio
Model 1 2.508488 2.50849 0.8214
Error 13 39.699845 3.05383 Prob > F
C. Total 14 42.208333 0.3813
Parameter Estimates
Term Estimate Std Error t Ratio Prob>t
Intercept 3.5082363 0.793488 4.42 0.0007
SDATE -0.008972 0.0099 -0.91 0.3813
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Regression Analysis 21: "Number of Arms in Pivotal Trials" as an Indicator of Complexity
over Time
Linear Fit - Route of Administration=="Oral"
NARM = 3.287 - 0.003 SDATE
Summary of Fit
RSquare
RSquare Adj
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)
Analysis of Variance
Source DF
Model
Error 6
C. Total 7
Parameter Estimates
Term
Intercept
SDATE
Estima
3.2870
-0.0033
0.063349
-0.09276
0.669934
3.125
8
Sum of Squares
0.1821278
2.6928722
2.8750000
te Std Error
31 0.347561
49 0.005258
Mean Square F Ratio
0.182128 0.4058
0.448812 Prob > F
0.5476
t Ratio Prob>jt
9.46 <.0001
-0.64 0.5476
Linear Fit - Route of Administration=="Subcutaneous"
NARM = 1.865 + 0.008 SDATE
Summary of Fit
RSquare
RSquare Adj
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)
Analysis of Variance
Source DF
Model 1
Error
C. Total
4
0.128512
-0.08936
0.873242
2.5
6
Sum of Squares
0.4497918
3.0502082
3.5000000
Parameter Estimates
Estimate
1.8648394
0.008178
Std Error
0.900579
0.010648
t Ratio Prob>|t
2.07 0.1071
0.77 0.4853
Linear Fit - Route of Administration=="Pooled"
NARM = 3.059 - 0.004 SDATE
Summary of Fit
RSquare
RSquare Adj
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)
Analysis of Variance
Source DF
0.05705
-0.01549
0.780571
2.8
15
Sum of Squares
Mean Square
0.449792
0.762552
Term
Intercept
SDATE
F Ratio
0.5899
Prob > F
0.4853
Mean Square F Ratio
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1
DF Sum of Squares
1 0.4792167
13 7.9207833
14 8.4000000
Parameter Estimates
Term E
Intercept
SDATE
stimate
3.0585626
-0.003922
Std Error
0.35443
0.004422
t Ratio Prob>t
8.63 <.0001
-0.89 0.3913
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Source
Model
Error
C. Total
Mean Square
0.479217
0.609291
F Ratio
0.7865
Prob > F
0.3913
Regression Analysis 22: "Length of Follow-up Period in Pivotal Trials" as an Indicator of
Complexity over Time
Linear Fit - Route of Administration=="Oral"
FOLTM* = 51.753* + 1.966 SDATE*
Summary of Fit
RSquare 0.40344
RSquare Adj 0.304014
Root Mean Square Error 124.3748
Mean of Response 146.875
Observations (or Sum Wgts) 8
Analysis of Variance
Source DF Sum of Squares Mean Square F Ratio
Model 1 62768.39 62768.4 4.0577
Error 6 92814.49 15469.1 Prob > F
C. Total 7 155582.88 0.0906
Parameter Estimates
Term Estimate Std Error t Ratio Prob>|t|
Intercept 51.753132 64.52542 0.80 0.4531
SDATE 1.9663435 0.97616 2.01 0.0906
Linear Fit - Route of Administration=="Subcutaneous"
FOLTM = -54.439 + 1.091 SDATE
Summary of Fit
RSquare 0.290266
RSquare Adj 0.112832
Root Mean Square Error 69.98399
Mean of Response 30.33333
Observations (or Sum Wgts) 6
Analysis of Variance
Source DF Sum of Squares Mean Square F Ratio
Model 1 8012.300 8012.30 1.6359
Error 4 19591.034 4897.76 Prob > F
C. Total 5 27603.333 0.2700
Parameter Estimates
Term Estimate Std Error t Ratio Prob>|t|
Intercept -54.43943 72.17485 -0.75 0.4927
SDATE 1.0914948 0.853379 1.28 0.2700
Linear Fit - Route of Administration=="Pooled"
FOLTM = 46.527 + 0.666 SDATE
Summary of Fit
RSquare 0.058021
RSquare Adj -0.01444
Root Mean Square Error 131.4658
Mean of Response 90.46667
Observations (or Sum Wgts) 15
Analysis of Variance
Source DF Sum of Squares Mean Square F Ratio
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Source DF Sum of Squares Mean Square F Ratio
Model 1 13839.32 13839.3 0.8007
Error 13 224682.41 17283.3 Prob > F
C. Total 14 238521.73 0.3871
Parameter Estimates
Term Estimate Std Error t Ratio Prob>|t
Intercept 46.526957 59.694 0.78 0.4497
SDATE 0.6664263 0.744745 0.89 0.3871
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Regression Analysis 23: "Number of Primary Endpoints in Pivotal Trials" as an Indicator
of Complexity over Time
Linear Fit - Route of Administration=="Oral"
NPEND = 1.725 - 0.005 SDATE
Summary of Fit
RSquare 0.058522
RSquare Adj -0.09839
Root Mean Square Error 0.970298
Mean of Response 1.5
Observations (or Sum Wgts) 8
Analysis of Variance
Source DF Sum of Squares Mean Square F Ratio
Model 1 0.3511330 0.351133 0.3730
Error 6 5.6488670 0.941478 Prob > F
C. Total 7 6.0000000 0.5638
Parameter Estimates
Term Estimate Std Error t Ratio Prob>t|
Intercept 1.7249809 0.503389 3.43 0.0140
SDATE -0.004651 0.007615 -0.61 0.5638
Linear Fit - Route of Administration=="Subcutaneous"
NPEND* = 3.533* - 0.026 SDATE*
Summary of Fit
RSquare 0.614116
RSquare Adj 0.517645
Root Mean Square Error 0.850607
Mean of Response 1.5
Observations (or Sum Wgts) 6
Analysis of Variance
Source DF Sum of Squares Mean Square F Ratio
Model 1 4.6058684 4.60587 6.3658
Error 4 2.8941316 0.72353 Prob > F
C. Total 5 7.5000000 0.0651
Parameter Estimates
Term Estimate Std Error t Ratio Prob>t|
Intercept 3.5325139 0.877236 4.03 0.0158
SDATE -0.02617 0.010372 -2.52 0.0651
Linear Fit - Route of Administration=="Pooled"
NPEND* = 2.073* - 0.009 SDATE*
Summary of Fit
RSquare 0.191851
RSquare Adj 0.129686
Root Mean Square Error 0.923979
Mean of Response 1.466667
Observations (or Sum Wgts) 15
Analysis of Variance
Source DF Sum of Squares Mean Square F Ratio
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Source DF Sum of Squares Mean Square F Ratio
Model 1 2.634753 2.63475 3.0861
Error 13 11.098581 0.85374 Prob > F
C. Total 14 13.733333 0.1025
Parameter Estimates
Term Estimate Std Error t Ratio Prob>jt
Intercept 2.0729418 0.419546 4.94 0.0003
SDATE -0.009195 0.005234 -1.76 0.1025
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Regression Analysis 24: "Number of Secondary Endpoints in Pivotal Trials" as an
Indicator of Complexity over Time
Linear Fit - Route of Administration=="Oral"
NSEND = 4.674 - 0.022 SDATE
Summary of Fit
RSquare 0.141569
RSquare Adj -0.0015
Root Mean Square Error 2.776328
Mean of Response 3.625
Observations (or Sum Wgts) 8
Analysis of Variance
Source DF Sum of Squares Mean Square F Ratio
Model 1 7.627015 7.62702 0.9895
Error 6 46.247985 7.70800 Prob > F
C. Total 7 53.875000 0.3583
Parameter Estimates
Term Estimate Std Error t Ratio Prob>|t|
Intercept 4.6735453 1.440354 3.24 0.0176
SDATE -0.021675 0.02179 -0.99 0.3583
Linear Fit - Route of Administration=="Subcutaneous"
NSEND = 4.369 - 0.028 SDATE
Summary of Fit
RSquare 0.498969
RSquare Adj 0.373711
Root Mean Square Error 1.164886
Mean of Response 2.166667
Observations (or Sum Wgts) 6
Analysis of Variance
Source DF Sum of Squares Mean Square F Ratio
Model 1 5.405498 5.40550 3.9835
Error 4 5.427835 1.35696 Prob > F
C. Total 5 10.833333 0.1167
Parameter Estimates
Term Estimate Std Error t Ratio Prob>t|
Intercept 4.3685567 1.201353 3.64 0.0220
SDATE -0.028351 0.014205 -2.00 0.1167
Linear Fit - Route of Administration=="Pooled"
NSEND = 4.295 - 0.018 SDATE
Summary of Fit
RSquare 0.127655
RSquare Adj 0.060551
Root Mean Square Error 2.254323
Mean of Response 3.133333
Observations (or Sum Wgts) 15
Analysis of Variance
Source DF Sum of Squares Mean Square F Ratio
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Source DF Sum of Squares Mean Square F Ratio
Model 1 9.667702 9.66770 1.9024
Error 13 66.065631 5.08197 Prob > F
C. Total 14 75.733333 0.1911
Parameter Estimates
Term Estimate Std Error t Ratio Prob>|t|
Intercept 4.2946788 1.023609 4.20 0.0010
SDATE -0.017614 0.012771 -1.38 0.1911
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Regression Analysis 24: "Number of Secondary Endpoints in Pivotal Trials" as an
Indicator of Complexity over Time
Linear Fit Route of Administration=="Oral"
DOSDUR = 137.21015 + 0.0318316 SDATE
Summary of Fit
RSquare 0.000378
RSquare Adj -0.16623
Root Mean Square Error 85.19492
Mean of Response 138.75
Observations (or Sum Wgts) 8
Analysis of Variance
Source DF Sum of Squares Mean Square F Ratio
Model 1 16.449 16.45 0.0023
Error 6 43549.051 7258.18 Prob > F
C. Total 7 43565.500 0.9636
Parameter Estimates
Term Estimate Std Error t Ratio Prob>|t
Intercept 137.21015 44.19898 3.10 0.0210
SDATE 0.0318316 0.668656 0.05 0.9636
Linear Fit Route of Administration=="Subcutaneous"
DOSDUR = 305.04039 - 1.1636102 SDATE
Summary of Fit
RSquare 0.326482
RSquare Adj 0.158103
Root Mean Square Error 68.52975
Mean of Response 214.6667
Observations (or Sum Wgts) 6
Analysis of Variance
Source DF Sum of Squares Mean Square F Ratio
Model 1 9106.026 9106.03 1.9390
Error 4 18785.308 4696.33 Prob > F
C. Total 5 27891.333 0.2362
Parameter Estimates
Term Estimate Std Error t Ratio Prob>t|
Intercept 305.04039 70.67509 4.32 0.0125
SDATE -1.16361 0.835646 -1.39 0.2362
Linear Fit=="Pooled"
DOSDUR = 172.84477 - 0.0512351 SDATE
Summary of Fit
RSquare 0.00089
RSquare Adj -0.07596
Root Mean Square Error 84.04666
Mean of Response 169.4667
Observations (or Sum Wgts) 15
Analysis of Variance
Source DF Sum of Squares Mean Square F Ratio
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Source DF Sum of Squares Mean Square F Ratio
Model 1 81.799 81.80 0.0116
Error 13 91829.935 7063.84 Prob > F
C. Total 14 91911.733 0.9159
Parameter Estimates
Term Estimate Std Error t Ratio Prob>|t
Intercept 172.84477 38.16263 4.53 0.0006
SDATE -0.051235 0.476119 -0.11 0.9159
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Appendix D Prescription Drug User Fees Act
Prescription Drug User Fees Act (PDUFA)
The Prescription Drug User Fees Act (The Act), PDUFA, was first passed in 1992
(PDUFA I) for five years by the Congress as to supplement Congressional appropriations
for strengthening the functions and capabilities of the CDER (Center for Drug Evaluation
and Research) offices in FDA, who are responsible for drug review; in other words,
expediting CDER's drug approval process. The Act was renewed and revised in 1997
(PDUFA II, Title I of the Food and Drug and Administration Modernization Act) for
another five years and 2002 (PDUFA III, Title V of the Public Health Security and
Bioterrorism Preparedness and Response Act) for another five years, and is under
consideration for reauthorization in 2007.
Under this Act, FDA can collect three types of user fees-application fees,
establishment fees, and product fees from the applicant drug company. The application
fee is paid to FDA upon submission of a New Drug Application. The product fees are
paid annually for products that have previously received marketing approval. The
establishment fees are charged annually on approved manufacturing facilities, yet
multiple products manufactured in the same facility can share on establishment fee.
Congressional Findings
The congressional findings that introduced PDUFA include: ... the prompt
approval of safe and effective new drugs is critical to the improvement of the public
health.. .the user fee revenue were to supplement the FDA's review activity
resources.. .the fees authorized.. .will be dedicated toward expediting the review of
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human drug applications as set forth in the goals identified in the [September 14 Letters
and [September 21 Letter]...
Evaluation of the Implementation of PDUFA
According to Philipson et al.'s findings, 2 even though there was a decline in
review times of 2% a year prior to PDUFA, passage and implementation of PDUFA I and
II accelerated the decline by 6-7% and 3-4% a year respectively.
PDUFA as a Solution to Correct Market Failure of Externalities
The goal of PDUFA is to correct the market failure of external costs including the
delay in access of new treatment for patients leading to loss in social welfare and delay in
product launch for the industry leading to higher R&D cost.
According Philipson's same study mentioned above, the researchers have found
that PDUFA raised the combined social surplus between $18 to $31 billions, which
consisted of the producer surplus and the consumer surplus. PDUFA raised the private
surplus of producers, as well as innovative returns as consequence by about $11 to $13
billion. PDUFA raised the consumer surplus between $5 to $19 billion-dependent on the
market power of the producers while having patent protection. In this research, the
authors converted these economic gains into equivalent health benefits, the more rapid
access of drugs on the market enabled by PDUFA saved equivalent of 180 to 310
thousand life-years.
1. Economic Rationale-Internalizing Externalities
The economic rationale behind the user fee mechanism suggests that those who
benefit from a government service should also pay for it. Hence, a well-defined and
2 Tomas Philipson, Ernst R. Berndt, Adrian H. B. Gottschalk, and Matthew W. Strobeck, Assessing the
Safety and Efficacy of the FDA: the Case of the Prescription Drug User Fee Acts
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identifiable group of beneficiaries, who require the service, should exist. In this case, we
can consider the industry and the consumers both as the beneficiaries. Collection of user
fees can also be considered as internalizing the external cost of acquiring more resources
to facilitate the drug review by asking the beneficiaries to pay for the cost. In the
PDUFA's case, due to the strong market power the industry has, the industry captures all
the welfare gains before the expiration of the patent-which might be at the expense of
product liability in the worst scenario.
2. Increase on the Producers' Surplus
PDUFA has increased the incentives in R&D innovation for the pharmaceutical
industry. On average, it takes 14 years for a drug from discovery to product launch.
From the moment the drug company files the patent for the new molecular entity (NME),
the patent expiration typically takes place about 12 years after product launch, a.k.a.
effective patent life. Another factor affecting the innovation return is that the Hatch-
Waxman Act, which gives a drug 14 years as a maximum amount of time to enjoy market
exclusivity (with possible 6-month extensions for sponsors providing efficacy in the
pediatric population). Thus, given the fact that PDUFA decreased the drug approval time,
PDUFA has effectively increased the innovative returns for the industry.
3. Increase on the Consumers' Surplus
On the social welfare side, through PDUFA, it may be possible to internalize the
external cost of expediting the drug review process by collecting the user fees. However,
due to the market power of the producers, no evidence has shown any decrease in the
drug price though the profitability for the drug company gets improved after PDUFA.
The consumers still benefit from the PDUFA with a faster access to drugs.
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Appendix E System Dynamics Models for Diabetes Management
(1) Figure 1 shows the basic stocks and flows structure in the diabetes management.
Obesity, Poor Diet, Treatment
Sedentary Lifestyle Screening
People w/ People
Healthy People Undiagnosed Urdiagnosed W/
Population Onset Diabees Diagnosis Diabetes Death of
Increase Diagnosed
Death of Healthy Death of
People Undiagnosed
Figure 1 Stocks and Flows Structure in Diabetes Management
(2) Figure 2 shows policy of the Center for Disease Control (CDC) on the diabetes
management, National Diabetes Prevention and Control Program (NDPCP), which
focuses on the downstream management of the system: (a) improving quality, availability
and accessibility of treatment; and (b) earlier and broader screening.
Dennd for
Downstream Resources
RI + Treatment
Obesity Poor Diet, + Downstream Pressure
Sedentary Lifestyle Screenints Priority 
Dos Treatment
People w/ People
Qr ' g Healthy People ==o Undiagnosed Diagnosed w/
Population Onset Diabetes Diagnosis Diabetes Death of
Increase Diagnosed
Death ofHealthy Death of
People Undiagnosed
Figure 2 CDC's National Diabetes Prevention and Control Program (NDPCP)
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(3) Figure 3 demonstrates the side effect from the policy of NDPCP. Because the policy
focuses on the downstream management (e.g. screening and treatment), the downstream
management competes for the resources with the upstream management (e.g. prevention
by changing people's lifestyle). This results in more prevalence of diabetes.
Available
Resources
Resources for
Needs for B2 Prevention Demalnd forZ B2 Downstream Resources
+ Proention C
Prevalenc of R2
Diabetes + Treatment
Obesity, Poor Diet, ~ + DoTtnstream Pressure
Sedentary Lifestyle Screeninets PriorGt Downstream e
++ People w/ People
Healthy People ==m Undiagnosed 4-a Diagniosed w/ ~
Population Onset Diabetes Diagnosis Diabetes Death of
Increase Diagnosed
Death of Healthy Death of
People Undiagnosed
Figure 3 Side Effect of NDPCP
(Source: Based on Sterman J., Dynamics of the Diabetes Epidemic; Jones A.P. et al., Understanding Diabetes
Population Dynamics through Simulation Modeling and Experimentation; Homer J.B. et al., System Dynamics
Modeling for Public Health: Background and Opportunities)
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